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Abstract 
Background 
Intensity-modulated radiotherapy (IMRT) for gynaecological malignancies aims to reduce 
toxicity and improve tumour control. However, there are several barriers to its uptake in 
clinical practice. Amongst these are that of pelvic organ motion, whereby due to motion of 
the target organs on treatment there is a risk of geographical miss with IMRT. Secondly, 
although new IMRT techniques may improve bowel toxicity, there is limited knowledge 
about dose-volume constraints for bowel, making it difficult to assess whether new 
techniques are likely to translate into clinical improvements. The purpose of this thesis is to 
address these problems.  
Methods 
Dose-volume constraints for late bowel toxicity are investigated initially through systematic 
review, followed by a dose-volume study based on toxicity data from pelvic radiotherapy 
patients. Pelvic organ motion is assessed in a systematic review examining organ motion 
patterns and potential strategies to account for this. Population-based and adaptive margin 
strategies are investigated in modelling studies for both definitive cervical cancer patients 
and post-hysterectomy patients.  
Results 
Initial systematic review of the literature, followed by the analysis of the toxicity and dose-
volume data of 203 pelvic radiotherapy patients highlighted anal canal, bowel loops, bowel 
bag, sigmoid and large bowel as important organs at risk (OARs) for bowel toxicity. Dose-
volume constraints were derived for these organs.  
Pelvic organ motion was found to be a significant problem for gynaecological IMRT. 
Adaptive margin strategies, such as plan-of-the-day, were demonstrated to achieve both 
CTV coverage whilst reducing dose to the OARs compared to standard margins and 
population-based margins. 
Conclusions 
Dose-volume constraints derived for late bowel toxicity, if validated with independent data, 
may be used to reduce bowel toxicity in future patients, and as a benchmark to assess the 
efficacy of new IMRT techniques. Adaptive strategies for gynaecological cancers appear a 
promising solution for organ motion management.  
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1. Chapter I: Introduction 
1.1. Introduction to Gynaecological Malignancies 
Gynaecological malignancies account for 19% of all malignancies worldwide (1) and 
include cancers of the cervix, endometrium, ovary, vulva and vagina. The work of this 
thesis focuses on cervical and endometrial cancers.  
1.1.1. Cervical Cancer 
Cervical cancer is the fourth most common cancer worldwide in women with an estimated 
528,000 new cases being diagnosed in 2012. Globally it accounted for 266,000 deaths in 
2012, 7.5% of all female cancer deaths (2). There is significant geographic variation in the 
incidence seen worldwide, with a higher incidence noted in developing countries.  
In the UK, cervical cancer is the 12th most common cancer, with 3064 new cases 
diagnosed in 2011 (3). Approximately 920 women die from cervical cancer annually in the 
UK, with more than 50% of these women being between 25 and 64 years old.   
Cervical cancer has two age peaks of presentation, the first being age 30-34 years (20 in 
100,000), and the second at 80-84 years (13 in 100,000). The key risk factor for the 
development of cervical cancer is exposure to human papilloma virus (HPV), found in 
99.7% of cases (4). In the UK, the incidence of cervical cancer has decreased in the last 4 
decades due to the introduction of the cervical cancer screening programme in 1988, and 
a further decrease in incidence is predicted 15-20 years from now, due to the introduction 
of HPV vaccination in the UK in 2008. Over 90% of cervical cancers are squamous cell 
carcinomas, with 7-10% being classified as adenocarcinomas, and rarer histologies being 
small cell, basaloid, sarcoma, adenosquamous and verrucocus carcinomas (5).  
1.1.2. The role of radiotherapy in cervical cancer management  
Cervical cancer is staged using the International Federation of Gynaecology and 
Obstetrics (FIGO) classification (table 1.1-1), and management is dependent on stage as 
well as the patient’s performance score and co-morbidities.  
Early stage disease (stage 1A or IB1 disease) is predominantly managed surgically with 
radical hysterectomy; however, cone biopsy may be offered to patients with stage IA 
disease, and radical trachlectomy to those wishing to preserve fertility. Post-operative 
radiotherapy after radical hysterectomy is recommended where high-risk features, such as 
positive surgical resection margins, lymph node involvement, lymphovascular space 
invasion and microscopic parametrial involvement are present. Radiotherapy alone post-
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hysterectomy improves local disease control (6), and the addition of chemotherapy has 
been demonstrated to improve both overall and progression-free survival (7).  
Table 1.1-1: FIGO staging of cervical cancer 
FIGO 
stage 
Definition 5 yr 
survival 
(%) (8) 
IA1 Microscopic disease, stromal invasion≤3mm in depth and 
≤7mm in horizontal spread 
97.5 
IA2 Microscopic disease, stromal invasion>3mm and <5mm in 
depth and >7mm in horizontal spread 
94.8 
IB1 Clinically visible lesion <4cm  89.1 
IB2 Clinically visible lesion >4cm 75.7 
IIA Tumour without parametrial invasion or involvement of the 
lower third of vagina 
73.4 
IIB Tumour with parametrial invasion 65.8 
IIIA Tumour involves lower third of vagina (no pelvic side wall 
invasion) 
39.7 
IIIB Tumour extends to the pelvic wall and/or causes 
hydronephrosis or non-functionitng kidney 
41.5 
IVA Tumour invades mucosa of bladder or rectum &/or extends 
beyond true pelvis 
22.0 
IVB Distant metastasis (including peritoneal spread, 
involvement of supraclavicular, mediastinal or paraaortic 
lymph nodes, lung, liver or bone) 
9.3 
 
For stage IB2 to IVA disease, defined as ‘locally advanced’ disease, the mainstay of 
treatment is chemo-radiotherapy followed by intra-cavitary brachytherapy. Surgery alone is 
likely to leave residual disease, mandating the need for adjuvant radiotherapy. Together 
these modalities are considered to have an increased risk of toxicity compared to chemo-
radiotherapy alone, with equivalent survival outcomes (9), hence surgery is not advocated 
for locally advanced disease.  
The addition of concurrent chemotherapy adds a 6-10% survival advantage to 
radiotherapy alone and has become an international standard (10). Intra-cavitary 
brachytherapy after chemo-radiation has also been shown to improve survival outcomes 
(11) and has become an essential component of the treatment paradigm for locally 
advanced cervical cancer.   
For those patients with stage IVB (metastatic) disease, the aim of treatment is symptom 
control and this may be in the form of radiotherapy, chemotherapy and/or palliative care.  
Radiotherapy therefore forms a vital component of cervical cancer management, being 
used as a treatment modality in radical, adjuvant and palliative settings. It is indicated for 
60% of cervical cancer patients (12), and advances in radiotherapy may therefore have a 
significant impact on outcomes for these patients.   
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1.1.3. Endometrial Cancer 
Endometrial cancer is the sixth most common female cancer worldwide, with 320,000 new 
diagnoses made worldwide in 2012 (13). In the UK, it is the fourth most common cancer, 
with 8,500 new cases diagnosed annually and a 5-year survival of 80% (14). 
Endometrial cancer occurs mainly in post-menopausal women (in 75% of cases). The 
main risk factors include excessive oestrogen exposure, which may arise endogenously 
through obesity, or exogenously with the use of hormone replacement therapy with 
oestrogens alone. Endometrioid carcinoma is the most common histological subtype, 
followed by serous and clear cell carcinomas. Endometrial cancer is also staged using 
FIGO staging (table 1.1-2). 
 
Table 1.1-2: FIGO staging of endometrial cancer 
 
1.1.4. The Role of Radiotherapy in Endometrial Cancer Management 
Management of endometrial cancer is determined by both staging and other pathological 
findings, which categorise women into low, intermediate or high-risk groups. The majority 
of women present with post-menopausal vaginal bleeding and are managed surgically with 
total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAHBSO). Adjuvant 
treatment may include radiotherapy, chemotherapy or a combination of both. 
The management pathways are illustrated in figure 1.1-1. For low and low-intermediate 
risk disease no adjuvant treatment is required post-hysterectomy.  
 
FIGO 
stage 
Definition 5 yr 
survival 
(%)(15) 
IA Tumour limited to endometrium or invades less than one-
half of the myometrium 
90 
IB Tumour invades one-half or more of the myometrium 78 
II Tumour invades stromal connective tissue of the cervix but 
does not extend beyond the uterus 
74 
IIIA Tumour involves serosa and/or adnexa (direct extension or 
metastasis) 
56 
IIIB Vaginal involvement (direct extension or metastasis) or 
parametrial involvement 
36 
IIIC1 Pelvic node involvement 57 
IIIC2 Para-aortic node involvement 49 
IVA Tumour invades bladder mucosa and/or bowel mucosa 22 
IVB Distant metastasis (includes metastasis to inguinal nodes, 
intraperitoneal disease, or lung, liver or bone.  
21 
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Figure 1.1-1: Overview of Endometrial Cancer Management 
In patients with high-intermediate risk disease, adjuvant radiotherapy is recommended. 
This improves local control rates, although has no impact on overall survival (16). Intra-
vaginal brachytherapy may be used alternatively with comparable outcomes (17).   
 
There is no uniform management paradigm for Stage III/IV disease. If operable, then 
TAHBSO will usually be undertaken, with adjuvant chemotherapy recommended post-
operatively (18). Adjuvant radiotherapy may be given, although no survival advantage has 
been determined.  
For inoperable stage III disease, primary radical radiotherapy (with or without concurrent 
chemotherapy) can be considered, with survival rates of 49% at 5 years (19). The 
combination of external beam radiotherapy with low-dose rate (LDR) or high-dose rate 
(HDR) brachytherapy has also been considered (20). 
For patients with stage IV disease, treatment is palliative and may be in the form of 
chemotherapy, radiotherapy (for symptom control) and/or palliative care. 
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total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAHBSO). Adjuvant 
treatment may include radiotherapy, chemotherapy or a combination of both. 
The management pathways are illustrated in figure 1.1. For low and low-intermediate risk 
disease no adjuvant treatment is required post hysterectomy.  
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This improves local control rates, although has no impact on overall survival (16). 
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There is no uniform management paradigm for Stage III/IV disease. If operable, then  
TAHBSO will usually be undertaken, with adjuvant chemotherapy recommended post-
operatively (18). Adjuvant radiotherapy may be given, although no survival advantage has 
been determined.  
For inoperable stage III disease, primary radical radiotherapy (with or without concurrent 
chemotherapy) can be considered, with survival rates of 49% at 5 years (19). The 
	
	
	
Low	risk	disease:	
stage	IA,	grade	1-2,	
endometrioid	
histology	
Radical	
hysterectomy	
No	adjuvant	
treatment	
Intermediate	risk	
disease:	stage	IB	or	
II,	endometrioid	
histology	
Radical	
hysterectomy	
Low	intermediate	
risk	(stage	IB	without	
LVSI,	grade	1-2)	
No	adjuvant	
treatment	
High	intermediate	
risk	(stage	II	or	stage	
IB	with	LVSI,	grade	3)	
Adjuvant	
radiotherapy	+/or	
brachytherapy		
High	risk	disease:	
Stage	III/IV,		
or	serous	or	clear	
cell	
Operable		High	Risk	
Radical	
Hysterectomy	
Adjuvant	
chemotherapy	+/-	
Adjuvant	
radiotherapy	
Inoperable	High	Risk	
Radical	
radiotherapy		
Stage	IVB	disease	
Radiotherapy		
(symptom	control)	
PalliaNve	
Chemotherapy	or	
best	supporNve	care	
22 
 
As with cervical cancer, radiotherapy forms a key therapeutic component in managing 
endometrial cancers, and is indicated in up to 45% of patients (21).  Advances in 
radiotherapy could therefore impact the outcomes of affected patients.  
1.2. Limitations of current radiotherapy treatment: treatment 
failure 
Despite the development of agreed treatment pathways and improved outcomes for 
patients with cervical and endometrial cancer over the last 30-40 years, improvements 
have been somewhat static in the last decade.  
1.2.1. Survival Data 
Worldwide, 5-year survival data for cervical cancer patients treated with radical 
radiotherapy (with or without chemotherapy) ranges from 68.3% to 19.2% (stages 1B2-
IVA) (8). From national UK data, the use of chemo-radiotherapy results in overall 5-year 
survival of 65% for stage IB through to 44% for stage IIIB disease (22).  
For endometrial cancer, early stage disease generally has a good prognosis (80-90% 5-
year survival) (table 1.1-2), but for patients with stage III and IV disease, survival rates 
drop significantly, with estimates of 57% and 19% 5-year survival respectively (15). 
1.2.2. Recurrences 
Cervical and endometrial cancers recurrences occur locally (at the vaginal apex), 
regionally (within the pelvis), or distantly. Twenty-two per cent of patients treated with 
chemo-radiotherapy for cervical cancer develop local/regional recurrence and 27% 
develop distant metastases (22); 69-89% of recurrences occur within the first 2 years of 
completing treatment (23). The most common sites of distant metastases are the para-
aortic lymph nodes (81%), lungs (21%) and supraclavicular nodes (7%) (24). 
 
After radical treatment for endometrial cancer, recurrences occur in 2-15% of early stage 
disease (25), and in 50% of patients with advanced disease or non-endometrioid 
histologies (16, 26). Data from the PORTEC-1 trial found that although vaginal recurrences 
were low (2%) after adjuvant radiotherapy, those who did recur within the radiotherapy 
field had a lower overall survival rate (43% compared with 65% 5-year survival) (27).  
 
Recurrences after radiotherapy frequently occur within the previously treated radiation field 
(in-field recurrence) or just beyond (marginal recurrence). In a study of 198 cervical cancer 
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patients who had a regional recurrence after definitive radiotherapy, 58% had a 
component of in-field recurrence, and 66% had a component of marginal recurrence (28). 
Marginal recurrences mainly occurred above the upper border of the treatment field (L4/5 
vertebral body) in this study. A further study examining recurrences after chemo-
radiotherapy found 55% occurred between L4/5 and the aortic bifurcation, and 45% in the 
para-aortic region (29).  
 
For patients with a regional recurrence in a previously irradiated field, unless confined to 
the vaginal apex, the only established curative option is pelvic exenteration surgery. This is 
a highly radical surgery with significant physical and psychological consequences for 
patients. Long-term morbidity rates of 48% are reported (30), and older patients are often 
precluded from this procedure due to co-morbidity.  
 
For distant recurrences, the treatment aim is palliative and chemotherapy may be an 
option.  Recurrence within a previously irradiated site has been reported as a poor 
predictor of response to palliative chemotherapy, with a 5.3% response compared with 
25.2% outside of the radiation field, and subsequent poorer survival (31). Those who had 
chemo-radiation as primary treatment show a poorer response to chemotherapy after 
recurrence (32).  
 
This data highlights the importance of optimising radiotherapy for both cervical and 
endometrial cancers. Given the in-field and marginal recurrences demonstrated after 
radical radiotherapy, it is possible that dose escalation or volume extension might improve 
outcomes. 
1.3. Limitations of current radiotherapy treatment: late toxicity 
The other significant limitation of current gynaecological radiotherapy treatment is late 
toxicity. Toxicity occurs after pelvic radiotherapy due to radiation being delivered to the 
organs at risk (OARs), which surround the target organs, such as bowel, rectum, bladder, 
bone as well as reproductive organs. 
Most patients experience acute toxicities during radiotherapy, which resolve within the first 
three months after treatment. A substantial number of patients also suffer late toxicity, 
which can be long-term or even permanent. The spectrum of late toxicity seen is common 
to other malignancies treated within the pelvis, including prostate, bladder, rectal and anal 
cancer.    
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1.3.1. Late bowel toxicity 
The most common toxicity seen after pelvic radiation is bowel toxicity. Acute radiotherapy 
reactions are thought to occur due to an inflammatory reaction involving the mucosa, and 
then submucosa. Following this either mucosal repair can occur, whereby the patient 
recovers, or there is a severe inflammatory process which produces fibrosis (33). This 
fibrosis is further perpetuated by a cytokine cascade, which manifests as late toxicity.  
A wide range of symptoms can occur under the umbrella of late toxicity, including 
diarrhoea, rectal bleeding, constipation, faecal incontinence, flatulence, mucus, pain, 
tenesmus and urgency (33). Severe (grade 3-4) toxicity can present as bowel obstruction, 
malabsorption, fistulae (recto-vaginal, vesicovaginal), which can require surgical 
intervention and may be life-threatening. 
 
The incidence of late bowel toxicity described in the literature varies significantly 
depending on the source of the data. Clinical trial data report severe late bowel toxicity 
rates of 6-23% in gynaecological studies (34), 1.9% in bladder cancer studies (35) and 1% 
in prostate cancer studies involving pelvic radiotherapy (36).  
 
Most clinical trials report late toxicity with the use of clinician-reported scores such as 
Radiation Therapy Oncology Group (RTOG) (37) or Common Terminology Criteria for 
Adverse Events (CTCAE) scores (38). The RTOG score has been used traditionally for 
two decades when reporting toxicity, although in the context of bowel toxicity includes only 
a small number of symptoms (rectal bleeding, cramp, diarrhoea and proctitis), and does 
not cover the entire spectrum of late toxicity symptoms. CTCAE scoring has been used 
more recently and is considered to be the ‘gold standard’ of reporting. It is more 
comprehensive than the RTOG score, however used in its entirety may be cumbersome 
with over 40 symptoms within the GI toxicity section. Often only grade 3 toxicity is 
reported, where lower grades may also be important. Currently CTCAE version 4.0 is used 
internationally. 
 
It is now appreciated that although the clinician-reported scores are helpful in objectively 
determining serious or life-threatening toxicity, they can underestimate the extent of the 
problem from a patient’s perspective. Patient-reported outcome (PRO) questionnaires are 
therefore being used, such as the patient questionnaire from the Late-Effects Normal 
Tissue-Subjective Objective Management Analytic (LENT-SOMA) score (39), and other 
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questionnaires originally developed in gastroenterology such as the inflammatory bowel 
disease questionnaire (IBD-Q) (40).  
In cervical cancer survivors a comparison of clinician-reported (RTOG) and patient-
reported (subjective LENT-SOMA) scoring found that severe bowel toxicity (grade 3-4) 
was 45% with patient-reporting though only 15% with clinician-reporting in the same 
patients (41). 
Patient-reported toxicity studies for gynaecological cancer patients have shown high rates 
of faecal urgency (79%), and faecal incontinence (24%) reported at 1-year post 
radiotherapy. At 3-years the most common symptoms experienced were urgency (33%), 
defecation pain (13%), diarrhoea 2-4 times a day (10%), and weekly faecal incontinence 
(7%) (42).   
1.3.2. Late genitourinary, sexual and bone toxicity 
Survivors of pelvic malignancies may also experience late genitourinary (GU) toxicity. It is 
hypothesised that this is due damage to vascular endothelial cells within the bladder (43).  
After definitive radiotherapy for cervical cancer late GU toxicity, defined in one study as 
frequency, urgency and incontinence, has a reported incidence of 26% (44), with rates of 
11-16% reported in the post-operative setting (16). More severe late complications such as 
haemorrhagic cystitis, urethral strictures and fistulae occur less commonly, in 1.3% of 
patients. Studies of patient-reported late urinary toxicity have found higher toxicity rates 
overall, with urinary urgency and incontinence reported in 27% and 45% respectively, 3 
years after treatment (42). 
 
Sexual and reproductive toxicity is also an important concern for survivors of pelvic 
radiotherapy. In pre-menopausal women pelvic radiation can cause ovarian failure. This 
not only impacts fertility, but also can increase the risk of cardiovascular disease and 
osteoporosis.  Following pelvic radiotherapy female patients often experience vaginal 
stenosis (particularly after brachytherapy), vaginal dryness and dyspareunia.  
In men, pelvic radiation can result in erectile dysfunction in up to 77% of cases. Both men 
and women report that treatment has an effect on their ability to have a sexual relationship 
in 23.8% (women) and 53.3% (men) (45).   
 
Pelvic radiotherapy also has a late effect on pelvic bones: 9.7% of women who have 
radiotherapy for gynaecological cancers have reports of pelvic fractures within two years, 
the most common sites being the sacrum, pubis, iliac crest and acetabulum. Almost half of 
these patients present with bone pain (46).  
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1.3.3. Impact of late toxicity on quality of life 
These late complications can have a serious impact of quality of life for survivors of pelvic 
malignancies. Retrospective studies reveal that 90% of patients report a permanent 
alteration in their bowel habit, with 50% reporting that this affects their quality of life, and 
20-30% stating the effect on quality of life is moderate or severe. The most common bowel 
symptoms to affect quality of life are faecal incontinence (25-89%), defaecation urgency 
(14-79%), diarrhoea (25-67%), change in bowel habit (16-79%), pain (10-77%) and rectal 
bleeding (10-31%) (33). 
Questionnaires examining which pelvic radiation symptoms cause most “distress” have 
found that “much distress” is caused by dyspareunia (24%), reduced orgasm (23%), bowel 
urgency (22%) and loose stool (19%) (47). 
Pelvic radiation has also been shown to have an impact more globally on quality of life. For 
example in endometrial cancer patients, as well as higher rates of urinary incontinence, 
diarrhoea, and faecal leakage, radiation was associated with lower “physical functioning” 
and “role function” scores 13 years after radiotherapy in the PORTEC-1 trial (48).  
1.4. Advances in radiotherapy treatment 
The two issues described above of treatment failure and late toxicity highlight the need for 
improved pelvic radiotherapy treatments. Improvements that reduce the volume of normal 
tissues irradiated to critical levels may both improve toxicity and quality of life. Furthermore 
they may allow safe dose or volume escalation, hopefully improving tumour control and 
survival. 
The last 20 years have seen the development of radiotherapy techniques with the aim of 
improving patient outcomes. Radiotherapy evolved from using conventional techniques, to 
conformal radiotherapy in the 1990s, and more recently to using intensity modulated 
radiotherapy (IMRT) techniques. 
1.4.1. Conventional radiotherapy and 3D-Conformal radiotherapy 
Conventional radiotherapy, which was used for several decades, is generally delivered 
with 2-dimensional beams. There was little anatomical basis for treatment planning, with a 
conventional simulator used to determine bony landmarks. The pelvis was often treated 
with large anterior and posterior beams, which although covering the tumour would also be 
treating large amounts of OARs.  
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3D-Conformal radiotherapy (3DCRT), which came into widespread use in the 1990s, aims 
to conform radiation delivery to tissues as accurately as possible. With the use of 3D 
planning CT scans target volumes are delineated by the clinician. International 
Commission on Radiation Units (ICRU) defined the volumes that are to be delineated as: 
gross tumour volume (GTV), representing gross disease; clinical target volume (CTV), to 
include microscopic disease; and planning target volume (PTV) to account for geometric 
errors (49). Radiotherapy planning of 3DCRT generally uses ‘forward planning’ 
techniques, a trial and error process, in which the planner decides initial beam parameters 
(such as number of beams, angle and energy), and then modifies these parameters to 
achieve acceptable clinical solutions. Multi-leaf collimators (MLCs) can be used to shape 
the beams to improve precision. 
 
3DCRT in the pelvis traditionally uses 3 (posterior and two lateral) or 4 (anterior, posterior 
and two lateral) beams (illustrated in figure 1.4-1). This can deliver satisfactory coverage of 
the target volumes; though can still include significant volumes of the surrounding rectum, 
bladder and bowel.   
1.4.2. Intensity modulated radiotherapy 
Intensity modulated radiotherapy (IMRT) is a highly conformal type of radiotherapy which 
uses multiple beamlets to conform dose to the target volume or tumour. This is illustrated 
in figure 1.4-1. Although target volumes (GTV, CTV and PTV) are defined in the same way 
as 3DCRT, the planning process differs, and is known as ‘inverse planning’.  For inverse 
planning, specified dosimetric requirements for target volume coverage and OAR sparing 
are prioritised prior to planning. In the planning process (‘optimisation’) the treatment 
planning software performs multiple computer iterations until a mathematical solution is 
found which satisfies the specified requirements.  
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Figure 1.4-1: 3DCRT and VMAT pelvic plans 
 
Rather than using beams of uniform intensity as with 3DCRT, IMRT uses multiple 
beamlets of non-uniform intensity. When individual contributions from each beamlet are 
Figure 1.4-1: The first image shows a 3D-CRT pelvic plan with 4-field brick. The second image 
is a volumetric arc therapy (VMAT) plan. The PTV is in blue and 95% isodose in green. 
Increased conformality with VMAT is noted 
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combined, a complex ‘dose cloud’ is generated with steep dose gradients around the PTV. 
The result is a highly conformal treatment to the PTV, and minimisation of dose to OARs 
potentially resulting in reduced toxicity for patients.  
IMRT may also allow dose escalation to the tumour, often with simultaneous delivery of 
different dose levels to different targets, known as simultaneous integrated boost (SIB) 
technique, with the potential of improving tumour control. 
 
IMRT can be delivered by three main methods: step and shoot IMRT, dynamic arc therapy 
or tomotherapy. The step-and-shoot technique involves moving the leaves of the MLC only 
when the radiation beam is turned off, and they remain in their predefined positions while 
the required radiation is being delivered. In contrast, dynamic arc treatments (such as 
volumetric arc therapy (VMAT)) involve the MLCs moving continuously shaping the beam 
while the radiation is being delivered (figure 1.4-1). In tomotherapy, treatment is delivered 
with a narrow beam from a rotating gantry, which continuously revolves around the patient 
as the patient moves through the bore. 
IMRT successes 
IMRT, regardless of treatment delivery method, has been demonstrated to be successful 
in many clinical scenarios. In head and neck radiotherapy, IMRT can allow sparing of 
OARs such as the parotid gland, brainstem and spinal cord and there is randomised trial 
evidence demonstrating that IMRT can reduce late toxicity in patients (50, 51). IMRT is 
now the standard of care for head and neck cancer patients.  
There has also been a widespread uptake of IMRT in prostate cancer, replacing conformal 
techniques. Although no randomised trials were performed, there were large comparative 
studies demonstrating significant reductions in acute and late GI and GU toxicity (52). As a 
result in 2014 78% of UK centres were treating more than 80% of their prostate cancer 
patients with IMRT (53). Furthermore dose escalation with the use of IMRT has been 
made possible.  
Limitations of IMRT 
IMRT does however have some limitations, dosimetrically, practically and in terms of 
resources or ‘cost’.  
With the steep dose gradient produced by IMRT planning, there is little margin for error in 
terms of anatomical change. The success of IMRT is dependent on the position of the 
tumour (and OARs) at planning being comparable to the position for the entirety of the 
course of a treatment. This can be unrealistic, as inter- and intra-fractional motion of 
organs is likely, tumours may shrink during the course of treatment changing the anatomy, 
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and patients may lose weight during the course of treatment, changing their anatomy from 
the time of planning. These changes may lead to OAR overdosage and/or target 
underdosage.    
IMRT generally uses an increased number of beams compared to 3DCRT, and arc 
therapy delivers radiation from multiple directions in a continuous beam. Although high 
dose is concentrated to the tumour, IMRT and arc therapy result in a ‘low dose bath’ 
whereby a much higher volume of normal tissue is treated to a low dose. Although this 
may not result in measurable increases in toxicity, it may theoretically lead to an increased 
risk of radiation-induced secondary malignancies. Predictive studies have suggested due 
to the increased number of monitor units the risk of secondary cancers compared with 
conventional radiotherapy is increased from 1% to 1.75% for patients surviving 10 years 
(54), although there is no clinical evidence for this as yet. 
 
In practical terms, IMRT techniques impact on resources at all stages of treatment 
planning. Although the same target volumes (GTV, CTV and PTV) are outlined, more 
precision is required to ensure accurate delineation. This may necessitate the use of 
additional radiological modalities such as fluoroxydeoxyglucose positron emission 
tomography (FDG-PET) scans.  
IMRT treatment planning, especially in the implementation stages is time consuming, with 
more time per patient required than a simple 3DCRT plan. In the case of squamous cell 
cervical cancer, a relatively fast growing tumour (category I), where timing of the 
radiotherapy has an important influence on outcome, it would be crucial to commence 
treatment in a timely fashion.  
 
Whilst having treatment with radiotherapy, patients need to be positioned with a high 
degree of accuracy every day to ensure precise dose delivery, and additional on-treatment 
imaging may be required to verify patient and target position when IMRT is used. All these 
components add to the overall ‘cost’ of the treatment, which has limited the use of IMRT in 
some centres.  
Cost-effectiveness is also an important consideration and there must be clear evidence of 
clinical benefit to patients to balance the costs. In the case of prostate cancer, this is 
deemed to be cost-effective. Reports from USA suggest that prostate IMRT costs $47,931 
compared with 3D-CRT costing $21,865. These costs are justified on the assumptions of 
IMRT resulting in improved biochemical disease-free survival and reduced late toxicity 
(55). 
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1.5. The evidence for IMRT in Gynaecological cancers 
With the success of IMRT demonstrated in other tumour sites, the benefits in 
gynaecological cancers have also been investigated.  
1.5.1. Dosimetric Evidence for IMRT use 
In the last decade, studies comparing IMRT with 3DRCT have demonstrated IMRT to be 
dosimetrically advantageous. Initial planning studies by Roeske et al and Heron et al (56-
58), looking mostly at post-hysterectomy patients found that IMRT plans reduced dose to 
small bowel, bladder and rectum compared with 3DCRT.  Roeske et al found that the 
small bowel, rectum and bladder volumes receiving 100% dose (V100%) were reduced by 
50%, 23% and 23% respectively (57).  
 
Furthermore, bone marrow of the pelvis can be relatively spared by IMRT. Much of the 
bone marrow reserve of the body lies in the lumbo-sacral spine and pelvic girdle. Bone-
marrow sparing IMRT (BMS-IMRT), where bone marrow constraints are used, is shown to 
reduce the volume of bone marrow irradiated to >50% dose from 87.4% to 60%, whilst 
maintaining the benefits of sparing dose to bowel, rectum and bladder (59, 60). 
 
A systematic review and meta-analysis including 13 dosimetric studies (61), pooling data 
from 455 gynaecological patients, concluded that IMRT significantly reduced the average 
percentage volumes of rectum and small bowel irradiated, although the reductions to 
bladder or bone marrow were not statistically significant.    
 
Chan et al (62) investigated the use of IMRT for an external beam boost of 20-30Gy in the 
scenario of patients being unable to have intracavitary brachytherapy, either due to 
medical reasons or location of the tumour. Compared with 3DCRT, IMRT improved rectal 
and bladder dose distributions.  
1.5.2. Clinical evidence for IMRT use in gynaecological cancer 
Following the dosimetric studies, evidence for the clinical benefits of gynaecological IMRT 
have been published. The key studies are summarized in table 1.5-1, with prospective 
studies detailed first. 
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Table 1.5-1: Evidence for Gynaecological IMRT 
Abbreviations: CC= cervical cancer; EC= endometrial cancer; LACC=Locally advanced cervical cancer; PO 
EC=Post-operative endometrial cancer; Gr2=grade 2; Gr3=grade 3; GI= gastrointestinal; GU=genitourinary; 
WCC=white cell count; HM=haematological. 
 
Author Type of 
study 
Pt no Clinical 
scenario 
Techniques 
Compared 
Dose Acute 
toxicity 
Late 
Toxicity 
Gandhi, 
2007 (63) 
Prospective 
randomized 
study 
44 LACC IMRT vs 
3DCRT 
50.4Gy 
/28# 
Gr 2 GI 
31.8% 
IMRT; 
63.6% CRT 
Gr 3 GI 
4.5% IMRT; 
27.3% CRT 
Gr 2 GI 
4.5% IMRT; 
13.6% CRT 
Gr 3 GI 0% 
IMRT; 9.1% 
CRT 
(med F/U 21 
months) 
Kidd, 2010 
(64) 
Prospective 
study 
452 
(135 
IMRT) 
LACC IMRT vs 
3DCRT 
50Gy NR Gr 3 6% 
IMRT; 17% 
CRT  
(med F/U 22 
months) 
Jhingran, 
2013 (65) 
Prospective 
Phase II 
multi-centre 
study 
43 PO EC IMRT (no 
comparison) 
50.4Gy/ 
28# 
Gr 2 GI 
21%; 
Gr3 GI 7% 
NR 
Mundt, 
2002 (66) 
Retrospective 
cohort 
75 
(40 
IMRT) 
Mixed 
CC+ EC  
IMRT (vs 
3DCRT 
retrospective 
cohort) 
45Gy 
/25# 
Gr 2 GI 
53.4% 
IMRT; 96% 
3DCRT 
NR 
Mundt, 
2003 (67) 
Retrospective 
cohort 
66 (36 
IMRT) 
Mixed 
CC+ EC 
IMRT (vs 
retrospective 
3DCRT 
cohort) 
45Gy 
/25# 
NR Gr 2 GI 
2.8% IMRT; 
16.7% CRT  
Gr 3 GI 0% 
IMRT; 3.3% 
CRT 
(med F/U 20 
months) 
Hasselle, 
2011 (68) 
Retrospective 111 Mixed 
CC+ EC  
IMRT (no 
comparison) 
45Gy 
/25# 
Gr3 GI 2%  
 
Gr3 GI 
3.6%; Gr 3 
GU 4.5% 
 (med F/U 
26mnths) 
Beriwal, 
2006 (69) 
Retrospective 47 PO EC IMRT (no 
comparison) 
45-
50.4Gy 
Gr2 GI 72% 
Gr3 GI 0% 
Gr 2 GI 0% 
Gr3 GI 2% 
(med F/U 20 
months) 
Shih, 2013 
(70) 
Retrospective 46 PO EC IMRT (no 
comparison) 
50.4Gy/ 
28# 
Gr 2 GI 11% 
Gr 3 GI 2% 
Gr 2 GI 0%  
Gr3 GI 2% 
(med F/U 52 
months) 
Brixey, 
2002 (71) 
Retrospective 
cohort 
124 
(36 
IMRT) 
Mixed EC 
+ CC 
IMRT vs 
3DCRT 
45Gy/ 
25# 
Gr2+ WCC 
31.2% 
IMRT; 60% 
3DCRT 
NR 
Chen, 
2011 (72) 
Retrospective 109 LACC IMRT (no 
comparison) 
 Gr 3 GI: 
2.7% 
Gr 3 HM: 
23.9% 
Gr 3 GI 
4.6%;  
Gr 3 GU 
6.4% 
(med f/U 32 
months) 
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1.5.2.1. Randomised evidence 
Only one randomised study (63) comparing IMRT with 3DCRT is published which included 
44 stage IIB-IIIB squamous cell cervical cancer patients. Significant improvements were 
seen in both acute and late GI toxicity, with late GI toxicity rates being 13.6% in the IMRT 
arm and 50% in the 3DCRT arm. No significant differences were seen in survival 
outcomes. Further clinical trials are in progress to gather randomised evidence for the use 
of IMRT for gynaecological malignancies, with 3 endometrial cancer phase III trials, and 1 
cervical cancer phase III trial currently recruiting patients (74). 
1.5.2.2. Non-randomised evidence 
The majority of clinical evidence for IMRT use for endometrial and cervical cancer is based 
on single centre retrospective studies, with or without comparison with historical cohorts, 
rather than prospective or randomised evidence.  
The first reports for clinical benefit of IMRT were provided by Mundt et al (67, 75) in a 
mixed groups of cervical and endometrial cancer patients. Compared with retrospective 
cohorts of 3DCRT-treated patients, improvements in both acute and late toxicity outcomes 
with IMRT were reported.   
1.5.2.2.1. Post-operative cervical and endometrial studies 
Particular to the post-operative setting Jhingran et al (65) report data from a phase II study 
(RTOG 0418) of post-operative endometrial cancer patients. As well as toxicity outcomes 
(table 1.5-1), they aimed to assess whether pelvic IMRT was feasible across multiple 
institutions with the use of a detailed protocol and quality assurance. They found that IMRT 
was feasible across 25 centres with a consensus protocol and centralised quality 
assurance. They reported an overall survival of 92% at 3 years, and acute GI toxicity of 
grade≥2 as 28%. A subset analysis of haematological toxicity (76) reported low toxicity 
rates overall, and high compliance with dose intensity for weekly cisplatin, despite not 
specifically planning to bone marrow constraints. Details of other post-operative studies 
are detailed in table 1.5-1 (69, 71, 77).  
1.5.2.2.2. Radical chemo-radiotherapy studies 
Only three studies focused purely on chemo-radiotherapy for locally advanced cervical 
cancer (63, 64, 72). Kidd et al. (64), in their relatively large prospective series of 452 
patients, compared outcomes for 135 FDG-PET-guided IMRT with 317 non-IMRT patient 
treated for locally advanced cervical cancer. Grade 3 late toxicity was improved in the 
IMRT group (6% vs 17%). Unexpectedly the IMRT group showed better overall cause 
specific survival and overall survival compared with the 3DCRT cohort, although follow up 
was much shorter in the IMRT group. The authors comment that they are unsure if this 
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was due to difference in radiotherapy treatment alone, and may be due to the slightly 
higher percentages of patients in the IMRT group that had no lymph nodes involvement or 
received concurrent chemotherapy.  
1.5.3. Extended field studies 
As well as for post-operative and radical treatments, IMRT may have potential application 
for extended-field radiotherapy to include the para-aortic nodes (PAN). Treatment of PAN 
usually involves treating the pelvic nodal chain higher in the abdomen, with an upper 
border of T12/L1 used.  Treatment is typically with a conformal anterior-posterior field 
arrangement. This is potentially disadvantageous as significant dose is likely to be 
received by kidneys and small bowel. 
  
In cervical cancer, macroscopic involvement of PAN is associated with poor prognosis. 
The GOG-116 study (78) found in these patients with PAN conformal treatment of 45Gy, a 
3 year overall survival rates of 39%. However grade 3 late toxicity rates of 19% were 
reported. A more recent study investigating optimal dose to the PAN using PET scanning 
to assess response suggested that a minimum total dose of 54Gy is recommended for 
involved PAN (79). With the use of conformal radiotherapy this is likely to further increase 
toxicity.  
 
Prophylactic PAN irradiation has a potential benefit in patients without gross PAN disease 
with a high risk of microscopic PAN involvement. Patients with stage III disease have a 
25% risk (80) and positive pelvic node patients have a 50% risk of microscopic PAN 
disease (81). Early studies (82) have shown that prophylactic extended field irradiation in 
such high-risk patients can improve survival. This however was prior to the adoption of 
chemoradiotherapy, so the question of whether prophylactic irradiation is necessary with 
modern chemoradiotherapy is unanswered. Given the rates of toxicity involved with 
extended field conformal radiotherapy few centres would advocate this treatment 
prophylactically. 
 
IMRT techniques may be a solution in this scenario, and a few studies have examined this.  
A dosimetric planning study for extended field radiotherapy demonstrated that IMRT 
significantly reduced volume receiving 45Gy (V45) of the small bowel, rectum and bladder 
compared with 3DCRT (83).  
Du et al (2010) (84) in their study of 60 patients with positive PAN, after neoadjuvant 
chemotherapy, randomised patients into IMRT or 3DCRT groups. With IMRT a median 
35 
 
dose of 63.5Gy was delivered, with 3DCRT the dose was 45-50Gy. 3-year survival was 
higher in the IMRT group (36.4% vs 15.6%) and acute grade 3-4 toxicity was 3.6% in the 
IMRT group, compared with 19% in the 3DCRT group. Other smaller studies looking at 
extended field IMRT have found tolerable toxicity levels with IMRT (85, 86) and low in-field 
recurrence rates.  
1.5.4. Dose-escalation studies 
Dose escalation is one of the prime aims of IMRT techniques, with the basis that most 
radiosensitive tumours, including cervical cancer, have a dose-response relationship. In 
prostate cancer, for example, dose escalation with modern radiotherapy techniques has 
been proven to be feasible and improve disease outcomes such as progression-free 
survival (87). 
 
In gynaecological malignancies, standard external beam doses include 45Gy in 25 
fractions, or 50.4Gy in 28 fractions. These doses tend not to be escalated with 3DCRT due 
to the risk of bowel toxicity.  Rather than external beam treatment much investigation has 
gone into dose escalation to the primary tumour with intracavitary brachytherapy, and 
many centres now use higher doses of HDR brachytherapy. This reduces the risk of local 
recurrence, but does not benefit pelvic or para-aortic nodal relapse. Brachytherapy cannot 
always deliver dose to bulky tumours or parametrial extension (88), in which case an 
external beam boost is desirable. 
 
Dose escalation with IMRT to both the primary tumour and to lymph node metastases 
could be considered, but to date only single centre series have been conducted in the form 
of treatment boosts. These boosts are either simultaneous (SIB) or ‘sequential’ where the 
boost treatment is delivered after completing the rest of treatment. 
 
Boyle et al 2014 (89), examined the use of dose escalation with SIB in 39 patients with 
locally advanced disease (cervical, endometrial and vaginal cancers).  Patients were 
treated with doses of up to 65Gy to areas of gross disease, such as pelvic nodes, para-
aortic nodes, pelvic sidewall extension or residual primary disease. At 1 year post 
treatment no grade 3 or 4 toxicities were found, although 24.5% of patients had grade 1-2 
late toxicities. Local control rate at 18 months was 77.2%, although longer follow-up is 
needed. A UK based phase I/II multicentre dose escalation trial in locally advanced 
cervical cancer (“DEPICT”) using SIB is currently underway. 
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In the post-operative setting the use of SIB with IMRT up to 60.2Gy has been investigated 
to the vaginal cuff in 80 high-risk cervical cancer patients (90) and in 50 high-risk 
endometrial cancer patients with doses of 66Gy being delivered to the vaginal cuff (91). 
Acceptable toxicity, disease control and survival rates were reported in both studies, 
though no comparison was made with non-escalated patients. 
1.5.5. Uptake of IMRT for gynaecological malignancies 
Given the mostly favourable growing body of evidence for IMRT in gynaecological 
malignancies, it has been increasingly adopted into clinical practice in the last decade. In 
the USA for example, it has been rapidly accepted, and rates of IMRT for endometrial 
cancer had risen from 3.3% in 2002 to 23.2% in 2007 (92).   
A national survey addressing the uptake of IMRT in England between December 2013 and 
February 2014 (53) found that within the 50 radiotherapy centres in England, 33% of all 
radical gynaecological patients were treated with IMRT. However there was significant 
variation between centres. The national target for 2009 was 20% of all gynaecological 
patients and although 27 centres reached this target and 6 centres treated 100% of their 
patients with IMRT, 13 centres did not treat any of their patients with IMRT.    
1.6. Reluctance towards adoption of gynaecological IMRT 
Although there are many advocates of the use of IMRT in gynaecological patients, some 
clinicians have reservations. The first concern is the quality of evidence available. It must 
be noted that much of the above body of evidence is retrospectively reported data, in 
single centre studies, without any prospective or direct comparison to 3DCRT. Many 
studies report only early outcomes in terms of progression free survival and toxicity 
outcomes and effects on late toxicity are unknown.  
 
International guidance has suggested that IMRT for the reduction of toxicity “may be 
considered” over 3DCRT, however there is insufficient data to recommend IMRT for 
disease related outcomes (93). 
 
For the widespread adoption of any new treatment, it needs to be deemed cost-effective. 
Gynaecological IMRT has not as yet been demonstrated to be cost-effective, given the 
lack of definite evidence of its benefit over 3DCRT. Data from the USA examining this 
issue has suggested the planning cost for IMRT treatment is $2088.19 (compared with 
$564.69 for 4-field 3D-CRT), with treatment costs of $519.84 (compared with $262.30) 
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(94). This balanced against equivalent survival outcomes, likely reduced acute toxicity and 
unclear impact on late toxicity, resulted in IMRT not proving to be cost effective. More 
concrete evidence of the benefits of gynaecological IMRT is warranted, especially for late 
toxicity, to improve the cost-effectiveness balance.  
 
Further to this several technical problems exist with the use of gynaecological IMRT, which 
must be considered before it can be used safely and efficiently. Authors of the consensus 
guidelines for cervical cancer IMRT outlining suggest that application of IMRT to 
gynaecological treatments must be done with “greater caution” (95), with other authors 
suggesting IMRT should not be used without consideration of the “pitfalls, hazards and 
cautions” (96). 
National Comprehensive Cancer Network guidelines suggest that IMRT in cervical cancer 
should be applied with “very careful attention to detail and reproducibility, including 
consideration of target and normal tissue definitions, patient and internal organ motion, 
and rigorous dosimetric and physics quality assurance”(97). These concerns and 
considerations are summarised below. 
1.6.1. Problems with volume definition  
Given the precision of IMRT planning, accurate target volume definition is of paramount 
important to ensure adequate treatment. ‘Consensus guidelines’ for both definitive cervical 
cancer IMRT and post-operative endometrial/cervical cancer have been defined by the 
RTOG and Japanese consensus groups (95, 98-100). Despite efforts with several 
international gynae-oncology experts (RTOG, European Society for Radiotherapy and 
Oncology (ESTRO), Japanese, Canadian) there are still many uncertainties about target 
volume definition in relation to gynaecological tumour sites, and within the guidelines 
consensus was not achieved for several points regarding volume definition.  
 
For definitive cervical cancer radiotherapy, traditionally the GTV includes gross tumour in 
the cervix and lymph nodes. There are two CTVs; the primary CTV, which comprises the 
cervix, uterus, upper vagina, and parametrium; and the nodal CTV, which comprises 
involved lymph nodes as well as uninvolved nodes, which are at risk of microscopic 
spread.  
With definitive cervical IMRT in there is on going debate on whether the whole uterus 
should be included within the CTV. The whole uterus has traditionally been included in the 
primary CTV for definitive cervical treatments, given that there is no anatomical boundary 
between the cervix and uterus. However there is little pathological evidence to indicate the 
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importance of including the whole uterus.  Most of the histological studies that define 
patterns of cervical cancer spread are from early-stage cervical cancers, post-
hysterectomy, where uterine involvement is unlikely. For locally advanced cancers there is 
no histological data to evidence the uterus as a common site of spread as these patients 
are normally treated with radical radiotherapy rather than surgery. At the time the RTOG 
guidelines were developed, 42% of survey respondents felt it was not always necessary to 
include the whole uterus (95), however, as the majority of the group did so in practice, 
inclusion of the whole uterus was recommended.   
 
The definition of the borders of the parametrium is also debated (95, 100), in particular the 
superior border. While the RTOG recommend starting to outline the parametrium at the 
superior border of the fallopian tube, the Japanese consensus used the upper border of 
the cervix, resulting in significantly different volumes depending on which definition is 
used.  The length of uninvolved vagina to include is also disputed, with some suggesting 
1.5cm below tumour, and others use bony landmarks such as the bottom of the pubic 
symphysis, which can be up to 4cm below tumour.  
 
The RTOG consensus guidelines based their atlas on Magnetic Resonance Imaging 
(MRI)-based planning (MRI in the treatment position), with the use of structures that are 
visible on MRI (such as mesorectum and utero-sacral ligaments), which are not clearly 
visible on CT. This was despite most of their respondents (91%) using CT as the primary 
imaging modality. This makes application of the guidelines difficult, unless widespread 
uptake of MRI planning scans occurs.  
 
The prophylactic nodal CTV in both radical cervical treatment and post-operative 
gynaecological treatments has also some controversy. Based on key papers by Taylor et 
al, consensus is present with regards defining the nodal CTV with a 7mm margin around 
the iliac vessels (101).  
However where to commence the nodal volume based is not concluded.  For endometrial 
cancer it is recommended to treat the external and internal iliac and the obturator nodes. 
For cervix cancer or endometrial cancers involving cervix, or where there are positive 
nodes involved the common iliac nodes are also included (102).  
The RTOG recommend starting the nodal CTV based on bony landmark (7mm below the 
L4-L5 interspace), whereas others (99) recommend the use of CT anatomy, such as the 
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the common iliac bifurcation as the start of the nodal CTV. Bony landmarks are not truly 
representative of pelvic vessel anatomy and vary between patients (103).  
For the lower aspect of the obturator region, which forms the inferior aspect of the nodal 
CTV there again is discrepancy within the available guidelines (98, 99, 102).   
 
In summary many aspects of target volume definition in gynaecological IMRT lack clarity. 
With this being such a key aspect of IMRT planning this may well have impact on 
treatment outcome. 
1.6.2. Problems with organ motion and CTV-PTV margins 
Organ motion is a known phenomenon and is a problem with pelvic radiotherapy. With 
highly conformal treatments such as IMRT, it is important that the target organs and OARs 
are in the same anatomical position on treatment as they are at the time of planning. 
Motion of target organs outside of the PTV may result in geographical miss and potential 
underdosage of the target. Motion of the OARs into to PTV may increase dose to these 
organs, which may result in increased toxicity. This was demonstrated in a retrospective 
study looking at SIB use in cervical cancer patients where 2 of 10 patients received less 
than 95% of the prescribed dose, and much higher doses to OARs were reported as a 
result of organ motion (104). 
 
Within the pelvis many organs, including uterus/prostate, bladder, rectum, and bowel, are 
prone to motion during a radiotherapy treatment course. Motion in between fractions is 
termed inter-fractional motion, and that during a fraction is termed intra-fractional motion. 
Knowledge of both of these aspects is important when implementing IMRT to ensure 
adequate treatment margins are used, and geographical miss is minimised.  
 
For definitive cervical treatment organ motion is a particular concern. Many studies have 
tried to evaluate the motion of different components of the primary CTV, though with 
widely variable results. 
For cervical motion some studies used fiducial markers inserted into the cervix to assess 
motion (105, 106), and have found maximal motion of 23mm (anterior-posterior (AP)), 
36mm (superior-inferior (SI)) and 23mm (left-right (LR)). Others using volumetric imaging 
such as Cone Beam Computed Tomography (CBCT), MRI and Megavoltage (MV) imaging 
(107-110) have found maximal motion of 29mm anterior, 63mm posterior, 35mm superior 
and 30mm inferior.  
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Uterine motion occurs in the anterior-posterior, superior-inferior directions with the addition 
of rotational motion. Margins of up to 4cm have been suggested to account for uterine 
motion (108).  
Cervical and uterine motion may also be determined by the volume/position of 
neighbouring organs, such as bladder (111) or rectum (108). An example of the 
relationship between bladder volume and uterine position is illustrated in figure 1.6-1. 
There is also significant intra-patient variation in the relationship between bladder filling 
and uterine motion, having a major impact in some patients but hardly any in others (111). 
 
Figure 1.6-1: Uterine motion with bladder filling 
 
With pelvic organ motion being such a potential problem, adequate CTV-PTV margins 
around the CTV are vital to ensure no geographical miss. The CTV-PTV margin consists 
of an internal margin (IM), which accounts for organ motion of the CTV, and a set-up 
margin. Set-up margins are determined within institutions depending on their 
immobilisation techniques and imaging protocols. The IM however must be determined 
depending on the estimated organ motion pattern of the CTV components. 
 
For gynaecological IMRT appropriate CTV-PTV margins are unclear for both the primary 
CTV and the nodal CTV.  
 
For the nodal CTV the RTOG recommend a 1.0-1.5cm CTV-PTV margin (98), and there is 
no mention of CTV-PTV margins by other published guidelines (99, 102). Guidelines from 
other pelvic tumours and from trial protocols recommend much smaller CTV-PTV margins 
23	
	
Cervical and uterine motion occur partly as a result of bladder filling (114) and rectal filling 
(111). The relationship between bladder volume and uterine position is illustrated in figure 
1.3. There is also significant intra-patient variation in the relationship between bladder 
filling and uterine motion, having a ajor impact in some patients but hardly any in others 
(114).  
 
 
Fi 	 3:	Uterine	motion	with	bladder	filling	
With the large amount of motion seen, large population-based CTV-PTV margins are 
required to ensure safe coverage of the CTV. Suggested CTV-PTV margins within the 
RTOG consensus document are 1.5cm-2cm around the CTV “if good quality daily soft 
tissue verification was available during treatment.” They also recommend that if bone 
matching alone was being used “more generous margins would be necessary”, though 
these margins were not quantified (94).  
 
The concern with the use of large population based margins is that they are likely to take 
in a larg  pr portion of the neighbouring OARs into the PTV, for example bowel and 
rectum. T is may then negate any potential benefits of IMRT in these patients. For those 
patients with large organ motion, these margins will be appropriate, however for those 
patients who have little organ m tion, these margins will be excessive and m y lead to 
unnecessary toxicity. 
         
	
	
Uterine motion with bladder filling 
The initial figure shows uterine position at 
the time of radiotherapy planning with a 
bladder volume of 550ml.  
The second figure shows an on-treatment 
CBCT of the same patient with a bladder 
volume of 75mls, with which the uterine 
position has rotated inferiorly and 
anteriorly. 
(uterus in red; bladder in blue)  
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(5mm (112), and 7-8mm (113)). No studies are found in the literature for the basis of these 
margins. 
 
For the primary CTV in definitive cervical cancer, with the large amount of motion seen 
especially of the uterus, large CTV-PTV margins may be required to ensure safe coverage 
of the CTV. Suggested CTV-PTV margins within the RTOG consensus document are 
1.5cm-2cm around the CTV “if good quality daily soft tissue verification was available 
during treatment.” They also recommend that if bone matching alone was being used 
“more generous margins would be necessary”, although this was not quantified further 
(95).  
 
The concern with the use of large margins is that although they will reduce the risk of 
geographical miss, they are likely to increasingly include the volume of OARs into the PTV, 
for example bowel and rectum. This may then negate any potential benefits of IMRT in 
these patients. Large margins that are population-based, may also be excessive for some 
patients who have very little organ motion.  
 
In post-hysterectomy radiotherapy, the primary CTV comprises the post-hysterectomy 
vagina with a margin to form the ‘paravaginal CTV’. Motion of this CTV has been studied in 
less detail than the definitive cervical cancer CTV. The vagina has been demonstrated to 
move 1.46cm AP, 1.2cm SI and 0.59cm LR, potentially influenced by bladder and rectal 
filling (114). 
For this scenario the RTOG did not determine any consensus CTV-PTV margins, although 
suggested that a 1.0cm-1.5cm margin is “commonly advocated.” They also suggested use 
of a vaginal ITV (internal target volume), where patients undergo planning simulation 
initially with a full bladder and then with an empty bladder. An ITV is constructed using the 
vaginal position on both scans, to account for the change that can be seen with bladder 
volume changes. Although this has been recommended by RTOG, no clear evidence of 
benefit is reported in the literature. No rectal preparation guidance is given in any of the 
consensus documents.  
1.6.3. Problems with tumour regression 
A further issue is that of tumour regression during treatment. It is known that squamous 
cell cervical cancer is a radiosensitive tumour, and tumours have been shown to reduce 
during the course of a radiotherapy treatment, with mean cervical volumes reducing from 
97cc to 31.9cc after a course of 45Gy (110).  
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This again makes IMRT challenging, as the anatomy within the pelvis is likely to change 
with shrinking of the GTV. With the GTV being smaller, the CTV may be considered to be 
smaller also. With OARs such as bladder and rectum being in close proximity, the relative 
positions of these OARs may also change, and they may end up receiving a higher dose 
than planned.  
IMRT, with its precise nature, is unable to accommodate this anatomical change. Re-
planning of the patient during treatment is one solution, which needs to be examined. 
 
1.6.4. Problems with choice of IGRT technique 
Following on from the above issues with organ motion, regression and lack of clear CTV-
PTV margins, it becomes apparent that IMRT for gynaecological cancer cannot be 
delivered safely without appropriate image-guided radiotherapy (IGRT).  
 
IGRT is a broad term which uses imaging to localise tumours initially for radiotherapy 
planning, and then to monitor, update and adjust treatment delivery to improve its 
accuracy (115). IGRT is complementary to IMRT in achieving the goals ensuring target 
coverage and reducing OAR doses. However the majority of the studies demonstrating 
evidence of the benefits of gynaecological IMRT do not even mention the IGRT techniques 
used for their patients. 
 
For on-treatment imaging, the type of imaging, frequency of imaging and choice of offline 
versus online protocols are important considerations. Offline imaging protocols compare 
on-treatment imaging to a reference image offline; there is no action until the following 
treatment. The aim of this is to correct ‘systematic errors’ which are reproducible errors 
occurring in the same direction and in a similar magnitude.  
Online imaging protocols compare the reference image to on-treatment imaging that is 
acquired and checked prior to each fraction of treatment. If a significant discrepancy is 
noted a correction is applied. The aim of this is to correct both ‘random errors’ and 
systematic errors. Random errors arise from changes in target position and shape 
between and during fractions of treatment and cannot be predicted.  
 
In the case of gynaecological IMRT, UK (116) and international guidelines (95) 
recommend the use of soft tissue imaging to be used with IMRT techniques for both 
definitive and post-operative IMRT is necessary. This is due to the independence of pelvic 
organ motion to bony anatomy.  
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Many centres use imaging protocols which include day 1, 2, 3 and then weekly offline 
review, as standard for conformal pelvic treatments. However for gynaecological IMRT, 
use of online imaging is recommended (95, 116), which appears logical, given that organ 
filling and target volume position on one day is unlikely to be representative of the next 
day. This is likely to lead to random error rather than systematic error, though there is little 
documented in the literature to evidence this.  
 
Even with daily online imaging, further complexity is added when using IMRT in the pelvis 
due to the differential motion of the nodal CTV and primary CTV. The nodal CTV is thought 
to have little motion compared with the primary CTV. As a result, with online imaging, if 
isocentre shifts are made to accommodate for the movement of the primary CTV, this may 
compromise coverage of nodal CTV which is unlikely to have moved in the same direction 
with the same magnitude.  
An IGRT solution is therefore required that can accommodate the complexity of differential 
CTV motion.  
Adaptive Radiotherapy  
Adaptive radiotherapy may offer solutions to the issues of tumour regression and organ 
motion described above. This is defined as a “process intended to improve radiation 
treatment by systematically monitoring patient/treatment positional and volumetric 
variations and incorporating them to re-optimise the treatment plan at appropriate intervals 
during the course of treatment” (117).  
 
Adaptive treatments may be used in the context of tumour regression, where the GTV has 
changed during treatment, as well as the position of the OARs; a re-plan part way through 
treatment would then be appropriate. Adaptive re-planning has been used in head and 
neck cancers, as with tumour shrinkage and weight loss, there is often anatomical change 
during treatment with the potential for OARs to be included within the PTV. Studies have 
shown adaptive re-planning to be beneficial in terms of sparing dose to spinal cord and 
parotids in selected groups of patients (118).  
 
Adaptive radiotherapy may also be used to account for an individual’s organ motion 
pattern, for example, with use of a ‘composite strategy’. With this strategy a composite 
CTV is generated combining the CTV on a number of offline images for an individual 
patient. The composite strategy has been modelled in prostate cancer (119), where each 
patient’s composite CTV was determined from the CTVs on imaging from the first six 
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fractions of treatment. A 7mm PTV margin was used around the composite, and the 
strategy was compared to use of a standard 10mm CTV-PTV margin. Use of the 
composite reduced the PTV volume by 29% and subsequently reduced dose>65Gy to the 
rectum by 19%.  
An alternative adaptive solution is the ‘plan of the day’ strategy, where a library of plans is 
created prior to treatment and then daily online imaging is used with each fraction of 
treatment to select which plan best covers the CTV that day. This has been modelled in 
bladder cancer, with each patient having a library of plans with “small”, “medium” or “large” 
margins used to account for inter-fraction variation in bladder filling. This has shown some 
promise in single centre studies for significantly reducing the volume of normal tissue 
irradiated whilst maintaining CTV coverage (120, 121), and is now being tested in a UK 
Phase II multicentre trial (122).  
 
In gynaecological cancer IMRT, no studies have reported modelling or use of composite 
strategy. Plan of the day modelling for definitive cervical cancer has been initiated in the 
Netherlands (123) with some early clinical data to show potential feasibility (124). Its 
potential for organ-sparing however has not been quantified and further work is required to 
establish how best to form a plan library for these patients.  
In post-operative gynaecological radiotherapy, no adaptive strategies have been modelled 
to date. 
1.6.5. Problems with lack of dose constraints: “how much bowel sparing is 
enough?” 
For pelvic radiotherapy, bowel irradiation and the subsequent bowel toxicity is a critical 
concern. This applies not only to gynaecological malignancies, but also for rectal, prostate 
and bladder cancer radiotherapy. In prostate cancer, high-risk patients have their pelvic 
nodes treated and may suffer toxicity resulting from high radiotherapy doses to the rectum, 
and moderate radiotherapy doses to the bowel. In bladder cancer, though the pelvic nodes 
are not routinely treated, large margins tend to be needed to accommodate organ motion 
of the bladder and this may result in additional irradiation of bowel. 
 
In gynaecological malignancies, there are therefore significant parallels with other pelvic 
tumours. However, differences also exist - in comparison to prostate, bladder and rectal 
cancer radiotherapy, gynaecological radiotherapy typically involves treatment of an 
increased length of the pelvic nodal chain. Depending on the clinical scenario, the nodal 
volume may be treated up to L4/L5, the level of the aortic bifurcation, or may also include 
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all the para-aortic nodes (up to T12). This is significantly higher than in prostate cancer 
where the pelvis is treated up to L5/S1, or in rectal cancer where nodes are treated to 
S2/S3. This increase in PTV length significantly increases the amount of bowel that is 
irradiated and may increase toxicity. 
 
The problem is compounded in the post-hysterectomy setting, when the uterus has been 
removed, and consequentially more bowel falls into the pelvis. Bowel is therefore more 
likely to be irradiated, and toxicity increased for survivors of post-hysterectomy cervical 
and endometrial cancer. 
   
Much of the evidence for the use of gynaecological IMRT is based on dosimetric and small 
clinical studies. Dosimetric studies show IMRT can reduce bowel doses to various extents. 
However, there is little to suggest whether the reductions of bowel doses seen in these 
studies will translate into clinically meaningful reductions in bowel toxicity. As for the 
clinical studies, although some demonstrate reduced bowel toxicity with IMRT, again it is 
not clear what degree of bowel sparing with IMRT may have resulted in this toxicity 
reduction.  
  
The bowel is a sizeable organ with many different components including the small bowel 
(duodenum, jejunum and ileum) and large bowel (caecum, colon, sigmoid and rectum and 
anal canal). These components, with their differing anatomy and physiology, are likely to 
have different radio-sensitivities, and different ‘dose-volume relationships’ with radiation.  
 
The dose-volume relationship of a particular tissue quantifies the relationship between 
toxicity and the volume of a tissue irradiated to a specific dose level. From this, “dose-
volume predictors” and “dose-volume constraints” are derived for clinical use in 
radiotherapy planning. Dose-volume predictors indicate which dose-volume parameters 
(for example, maximal dose (Dmax), or Volume receiving x Gy (VxGy)) are related to the 
risk of toxicity. Dose-volume constraints are the cut-offs of these dose-volume predictors; 
above the constraints there is higher risk of toxicity, and below the constraints there may 
be relative safety of avoiding toxicity. 
 
In the early 1990s, a key paper by Emami et al (125), defined dose-volume limits for many 
tissues within the body. These were largely based on 2-dimensional planning data and 
“expert opinion.” For bowel limits, quantification of bowel volumes was based on 
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“expert opinion.” For bowel limits, quantification of bowel volumes was based on 
orthogonal films using barium contrast, which now may be considered out of date. More 
recently the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) 
initiative updated this data with the use of 3-dimensional data and summarised their 
findings in a number of reviews in 2009 (126).  
 
With relevance to late bowel toxicity, two QUANTEC summaries are found, firstly that 
describing rectal toxicity (127), and the second describing small bowel toxicity (128). For 
rectal toxicity, there is a significant amount of high quality data, mainly from prostate 
cancer trials, and specific dose-volume constraints are clearly recommended to reduce 
toxicity. 
In the case of small bowel, the QUANTEC report was much less definitive. Variation in the 
methods of defining small bowel was identified; some papers used bowel loops with others 
using the concept of ‘bowel bag’. Bowel bag is the potential space for bowel within the 
intestinal cavity allowing for its motion during the course of radiotherapy. QUANTEC 
mainly reviewed acute bowel toxicity studies, and constraints were suggested for bowel 
loops and bowel bag to reduce acute toxicity.  
For late bowel toxicity however the paucity of data was highlighted. No clear guidance on 
the dose-volume predictors for late bowel toxicity was provided. 
 
With the lack of clear dose-volume constraints for late bowel toxicity, it is currently difficult 
to make any clear assessment on gynaecological (or other pelvic) IMRT techniques as to 
whether the amount of bowel spared is sufficient to reduce toxicity for patients. If sufficient 
bowel is not spared, it is questionable whether the implementation of new IMRT 
techniques, along with IGRT and potentially adaptive strategies is a worthwhile goal in this 
scenario. 
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1.7. Thesis Aims  
The aims of this thesis are to investigate and offer solutions to two problems associated 
with the implementation of pelvic IMRT for gynaecological malignancies.  
 
1. Determination of dose-volume constraints for late bowel toxicity: sparing of the 
bowel is identified as a key objective for pelvic IMRT, however it is not yet known what is 
the critical component, volume and dose level for determining the risk of late toxicity for 
patients. In this thesis, the dose-volume constraints that are predictive of late bowel toxicity 
will be determined. 
 
2. Assessment and management of organ motion for gynaecological IMRT: Organ 
motion makes gynaecological IMRT particularly challenging. In this thesis literature on 
organ motion in the definitive cervical cancer setting will be systematically reviewed, and 
appropriate population-based and adaptive strategies to account for organ motion will be 
modelled.  
Further, in the post-operative setting, organ motion will be quantified, and population-
based strategies modelled, with an assessment of the need for adaptive strategies. 
1.8. Structure of the thesis 
Section A of the thesis will focus on dose-volume predictors of late bowel toxicity after 
pelvic radiotherapy. Chapter 2 is a systematic review of the available scientific literature to 
assess already known dose-volume predictors of late bowel toxicity. Chapter 3 is a study 
collecting patient-reported late bowel toxicity data, assessing the dosimetric predictors of 
this toxicity and deriving dose-volume constraints. 
 
Section B examines the issue of organ motion specific to gynaecological malignancies and 
potential solutions for this. Chapter 4 and 5 investigate organ motion and potential 
solutions to overcome this in patients undergoing definitive radiotherapy for cervical 
cancer. Chapter 4 is a systematic review of organ motion and IGRT studies and Chapter 5 
is a modelling study of adaptive and population-based IMRT strategies for definitive 
cervical cancer patients. Chapter 6 investigates organ motion in patients undergoing post-
operative radiotherapy for cervical and endometrial cancer, and assesses the need for 
adaptive strategies in this setting. Chapter 7 is my discussion and conclusions. 
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Section A: Determination of Dose Volume Constraints for Bowel 
Toxicity 
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2. Chapter 2: A Systematic Review 
of Dose-Volume Predictors for Late 
Bowel Toxicity 
2.1. Introduction 
Late bowel toxicity is a significant problem after pelvic radiotherapy regardless of tumour 
site. Serious life-threatening toxicity such as bowel obstruction, fistulae and bleeding 
requiring transfusion occur in 4-10% of patients 5-10 years from treatment (129). Also 
long-term bowel symptoms, which adversely affect quality of life, can occur. 50% of pelvic 
radiotherapy patients report long-term bowel symptoms after radiotherapy that affect 
quality of life, with 2 out of 3 patients stating this effect on quality of life is “moderate” or 
“severe”.  
 
A prime aim of modern radiotherapy techniques such as IMRT is to spare normal tissue to 
reduce both acute and late toxicity. In particular minimising late toxicity with its influence 
on quality of life is a key objective.  
Late bowel toxicity is generally attributed to radiation both to the rectum and bowel and it is 
difficult to differentiate toxicity symptomatically from these two OARs. The rectum is often 
directly adjacent to the target organ in the pelvis, such as the prostate or cervix, and is 
therefore susceptible to high doses. Other parts of bowel may either be close to high dose 
areas, or in close proximity to prophylactic pelvic nodal volumes, which tend to be treated 
with more moderate doses.   
 
New radiotherapy techniques to minimize late bowel toxicity by sparing these OARs are 
being introduced. In gynaecological radiotherapy there is some published evidence that 
IMRT techniques may reduce bowel doses. However whether these reductions in bowel 
doses will equate to reduced toxicity can only be predicted if the dose-volume relationship 
of rectum or bowel is precisely understood.  
 
Dose-volume constraints are used in radiotherapy planning to limit the risk of toxicity. 
Initially retrospective studies are used to identify potential dose-volume parameters (such 
as maximum dose, or volume of OAR receiving x amount of dose, Vx) that are associated 
with a specific toxicity endpoint. From this dose-volume constraints that split patients into 
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high or low risk of endpoint are determined. The assumption is that prospective use of 
such constraints will limit future cohorts of patients developing toxicity. They can also be 
used as a benchmark for modelling studies of novel radiotherapeutic techniques to predict 
their likely benefit. 
 
Dose-volume constraints for bowel toxicity were first examined in the 1980s. A key study 
by Gallagher et al. (130) included 150 patients with pelvic malignancies (urological, 
gastrointestinal and gynaecological). Orthogonal films with the use of barium contrast were 
used to quantify the volume of small bowel irradiated. The volumes of small bowel 
irradiated to specific doses were related to late toxicities.  This study showed the average 
volume receiving radiation to be significantly higher in those manifesting chronic diarrhoea 
or small bowel obstruction. The incidence of these effects increased with dose received; 
with the incidence of late complications being 4.3% at 45Gy, 5.9% at 50Gy and 30% at 
55Gy.  
 
In 1991 this study combined with ‘expert opinion’ of a panel formed the basis of the 
‘Emami’ tolerances to OARs which have been used in clinical practice for several years 
(125). Probabilities of 5% and 50% complication rates within five years are reported as 
TD5/5 and TD50/5, respectively. Emami et al recommended normal tissue tolerance of the 
bowel as a TD5/5 to 1/3 of small bowel as 50Gy and 40Gy to the whole bowel. For TD50/5 
constraints suggested were for 60Gy for 1/3 small bowel irradiation and 55Gy for whole 
bowel. They also recommend a colon TD5/5 of 55Gy and TD50/5 of 65Gy. For rectum, no 
volume effect was noted, though TD5/5 of 60Gy and TD50/5 of 80Gy for whole rectum 
were suggested.  
 
Following this, also with the use of 2-dimensional data, Letschert et al (131) studied the 
relationship of small bowel volumes and late diarrhoea in patients treated to 50Gy, finding 
that above 328cc the risk of toxicity increased to 42%, and below 77cc this reduced to 
<31%.  
Data from these early studies have formed an important basis of the dose-volume 
constraints used in clinical practice, however these are based on 2-dimensional data and 
both imaging and radiotherapy planning techniques have significantly changed since then.  
 
Almost twenty years later in 2010, the Quantitative Analysis of Normal Tissue Effects in 
the Clinic (QUANTEC) initiative produced a series of reviews using 3D data to update on 
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the Emami recommendations. Guidance from these reviews provides dose-volume 
constraints for various OARs based on dose-volume data that is derived from modern 
radiotherapy planning techniques. QUANTEC also provided recommendations for 
reporting and gathering data on dose-volume dependencies on treatment outcomes (132).   
For bowel toxicity two QUANTEC reviews are reported, the first for rectal constraints (127) 
and the second for small bowel constraints (128).  
2.1.1. Dose-volume predictors of the rectum 
Regarding rectal toxicity QUANTEC found a number of high quality studies, mainly 
involving prostate cancer patients included in clinical trials. The main endpoints that were 
considered were rectal bleeding and grade 2 RTOG toxicity. Most studies examined the 
relationship between higher doses (>60Gy) and toxicity, and there was clear concordance 
between studies, allowing validation of the findings. Dose-volume constraints 
recommended were V50<50%, V60<35%, V65<25%, V70<20%, and V75<15%. Use of 
these constraints are predicted to limit ³ grade 2 rectal toxicity to <15% and ³grade 3 
rectal toxicity to <10%. 
Outside of QUANTEC, studies have examined constraints for lower/intermediate doses to 
the rectum as adhering to these may also reduce toxicity. Gulliford et al (133) addressed 
the use of intermediate dose constraints in 388 patients treated in a prostate cancer trial 
(RT-01), examining not only rectal bleeding, but other toxicity such as proctitis, subjective 
sphincter control, loose stool and urgency. They applied a number of dose constraints 
retrospectively to the plans of patients treated within the trial, and concluded that dose 
constraints of V30≤80%, V40≤65% and V50≤55% decreased the risk of moderate or 
severe toxicity. In agreement, Fiorini et al in their studies found that faecal incontinence 
was more predictive by V40<65-70% (134). 
2.1.2. Dose-volume predictors of bowel 
The QUANTEC review of small bowel data (128) identified six key papers that examined 
the dose-volume relationship of bowel toxicity; however these studies examined acute 
toxicity only. Recommended constraints from these papers were that the absolute volume 
of small bowel loops to receive ≥15Gy should be <120cc; if the entire volume of peritoneal 
space is considered the volume receiving >45 Gy should be <195 cc.  
 
For late bowel toxicity there was no detailed dose-volume relationship analysis described. 
The review mentioned dose-fractionations used within certain trials and the associated late 
toxicity rates, though no specific dose-volume predictors can be derived from this 
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information. The QUANTEC reviewers suggest that the constraints identified for acute 
bowel toxicity may be applied for late bowel toxicity; however “this correlation is not 
established”.  
It must be noted also that although small bowel was assessed by QUANTEC, there was 
no mention of the other components of bowel such as colon, and sigmoid, which may also 
be contributing to late bowel toxicity. 
 
2.1.3. Lack of clear dose-volume constraints for late bowel toxicity 
Despite late bowel toxicity being an important clinical problem, dose-volume constraints for 
bowel are not well established. QUANTEC guidance (132) highlighted issues which may 
hinder the development of clear and clinically useful dose-volume constraints, and have 
made recommendations for future studies. These issues broadly including endpoint 
definition, statistical standards, and standardized definition of OARs which may all be 
applicable in the context of late bowel toxicity.  
In the last few years the paucity of dose-volume data for late bowel toxicity has been 
acknowledged and more studies have been reported to address this. Review of the 
published data is therefore important to clarify dose-volume constraints for late bowel 
toxicity, and be able to use these to predict the likely benefits of advanced bowel-sparing 
radiotherapy treatments.  
2.2. Aims 
The aims of the work in this chapter were to: 
- Systematically review published studies investigating the dose-volume relationship of 
bowel with development of late bowel toxicity, and assess the quality of these studies 
using criteria derived from QUANTEC recommendations.  
- To seek dose-volume constraints from these studies which can be applied to assess the 
potential ability of new gynaecological radiotherapy techniques to reduce late bowel 
toxicity. 
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2.3. Methods 
2.3.1. Inclusion criteria 
The inclusion criteria were as follows: 
1. English language studies 
2. Human studies only  
3. Studies involving adults  
4. Studies with patients treated with external beam radiotherapy (EBRT) 
5. Studies with patients treated for tumour sites including:  Any gastrointestinal (upper 
or lower), Urological or Gynaecological  
6. Studies describing the dose-volume relationship of any component of bowel from 
duodenum to anal canal (excluding the rectum*) 
7. Studies where toxicity after 3 months of completion of radiotherapy is reported 
8. Studies aiming to correlate the dose-volume relationship of bowel/bowel 
components to late bowel toxicity outcome data (not simply quoting toxicity rates 
with a specific radiotherapy regime) 
*dose-volume studies for the rectum were excluded given the already well 
established knowledge on dose-volume constraints 
2.3.2. Exclusion Criteria  
1. Review articles and letters 
2. Studies using brachytherapy only 
3. Studies using stereotactic body radiotherapy (SBRT) – as the radiobiology is 
considered different with extreme hypofractionation 
4. Studies searching for dose-volume constraints of the rectum, or anorectum (where 
anal canal was not distinguished from rectum) 
5. Studies with insufficient methodological detail to be able to repeat the method on 
an independent sample of patients 
2.3.3. Searches 
A systematic search was carried out using Medline, Premedline, Embase, Pubmed and ISI 
Web of Science on 15th October 2013. Updated searches were performed on 10th 
November 2014 and 3rd September 2015 to ensure all new literature was included.  
Searches were performed by Mrs Bernadette Coles (Cancer Research Wales Library). 
The search strategy used is found in Appendix D.  
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Search terms around “radiotherapy, radiotherapy injuries, side effects, toxicity, intestines 
bowel, dose, dose fractionation, dose response relationship” were used. Duplicates of 
references were removed.  
2.3.4. Study Selection 
Two reviewers (myself and Dr Emma Higgins) independently assessed the abstracts for 
inclusion in the review. For those abstracts meeting the eligibility criteria, full papers were 
acquired and assessed further for suitability against the eligibility criteria. The reference 
lists of all the included papers were searched for any additional relevant references not 
included in the original database search.  
2.3.5. Data extraction and synthesis of results 
Data was extracted from each of the included papers and collected on Microsoft Excel.  
Bowel can be defined in several different ways and for the purpose of this work papers 
were divided into studies looking at the ‘whole bowel’ (including bowel loops and ‘bowel 
bag’), small bowel (and its components) and large bowel (and its components).  
Basic information was gathered and tabulated: Number of patients, Number of patients 
with the toxicity endpoint studied, tumour site, OAR studied, key findings. Further analysis 
of the papers was performed looking at OAR and toxicity definition. 
Furthermore, the recommendations from QUANTEC (132) on quality of dose-volume 
studies were reviewed, and those statistical and toxicity endpoint criteria that can be 
applied to this subject were selected (table 2.3-1). Each study was compared to these 
criteria as a quality assessment.   
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Table 2.3-1: Quality Assessment Considerations 
 
  
Statistical considerations  
1. Basic statistical data provided on incidence of toxicity 
      - Both number of subjects and number of events should be reported 
      - If an estimate of incidence is given the standard error should be supplied 
2. Numerical labeling of response histogram – if into groups eg. quartiles must state 
number of patients in each quartile 
3. When predictive models are correlated with complications parameter estimates must 
be stated with their standard error 
4. Complication rates associated with constraints must be reported 
5. “Goodness of fit” to be reported such as Chi-squared 
6. Discriminator statistics reported such as receiver operating characteristic curves 
7. Full organ volumes (rather than partial) should be used 
- If this is not possible absolute volumes should be used or a standard method of 
normalization 
- A clear statement of organ volume definition should be given 
Toxicity Endpoint considerations 
1. Symptom-specific information rather than a portmanteau endpoint (eg. RTOG gr 2) 
should be used 
2. Consideration that symptoms may be attributed to pre-radiotherapy co-morbidities 
3. Patient-reporting of symptoms may be important 
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2.4. Results 
The results of the systematic search are shown in figure 2.4.1. 25 studies were included in 
the review (see table 2.4-1). Of these studies, 17 included patients with prostate cancer, 2 
with bladder cancer, 5 with gynaecological cancers (cervical and endometrial), and 2 with 
pancreatic cancer.   
 
Figure 2.4-1: Systematic Search Results 
  
The majority of studies (n=17) had less than 100 patients included, with 9 studies having 
less than 50 patients included. A variety of toxicity scores were used including RTOG 
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(n=9), CTCAE (n=6), LENT-SOMA (n=2), Radiotherapy Induced Late Intestinal Toxicity 
score (RILIT) (n=2), or author-defined scores (n=5). 11 studies were reported based on the 
use of 3DCRT, 8 studies used IMRT, and 6 used a combination of both.   
The 25 studies are divided into three categories: whole bowel studies (n=7), small bowel 
studies (n=10) and large bowel studies (n=15) depending on the OAR studied. There was 
some overlap between the papers so some are featured in more than one section. 
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Table 2.4-1: Studies included in systematic review  
Author Year Cancer site No 
of 
pts 
Pts with 
tox 
OAR studied Toxicity score 
used 
RT Type Primary RT 
Dose (Gy/#) 
Pelvic RT 
dose (Gy/#) 
Concurrent 
chemo use 
Adkison 
(135)  
2012 Prostate 53 20 small bowel CTCAE v3.0 IMRT 70/28 56/28 no 
al-Abany 
(136) 
2005 Prostate 65 9 anal sphincter 
region 
Own questionnaire 3D 70.2/39 NS no 
Alsadius 
(137) 
2012 Prostate or 
prostatic bed 
403 51 anal sphincter 
region 
Own questionnaire  3D 470/35 NS no 
Buettner 
(138) 
2012 Prostate  388 57  anal canal Common grading 
scheme 
3D 64/32 or 74/37 NS no 
Chopra (139) 2014 Cervix (post-
op) 
71 9 small bowel, large 
bowel 
CTCAE v3.0 IG-MRT (46); 
3D (25) 
50/25 50/25  63/71 
cisplatin 
Deville(140)  2010 Prostate 30 2 intestinal cavity RTOG IMRT 79.2/44 45/25 no 
Deville(141) 2012 Prostatic bed 36 5 intestinal cavity RTOG IMRT 70.2/39 45/25 no 
Fokdal (142) 2005 Prostate or 
bladder 
71 Symptom 
specific 
small bowel LENT-SOMA Conformal 60/30 
(bladder) 
69.6/35 
(prostate) 
48-60Gy 
bladder; NS 
for prostate) 
no 
Fonteyne 
(143) 
2007 Prostate 241 Symptom 
specific 
small bowel, 
sigmoid 
RTOG and “RILIT” IMRT 74/37-80/40 NS no 
Guerrero-  
Urbano (112) 
2010 Prostate & 
Pelvic nodes 
79 21 bowel loops RTOG diarrhoea & 
LENT SOMA 
diarrhoea 
IMRT 70/35 50/35 or 
55/35 
no 
Huang (144) 2011 Pancreas 46 8 duodenum CTCAE v4.0 Conformal & 
IMRT 
42/15 42/15; 
36/15; 38/19 
Gemc; 18 pts 
erlotinib in 
addition  
Isohashi 
(145)  
2013 Cervix (post-
op) 
97 16 peritoneal cavity, 
small & large bowel 
RTOG/EORTC 2D or 3D 50/25 50/25 All nedaplatin 
Kelly (146) 2013 Pancreas 106 20 duodenum CTCAE v4.0 3D or IMRT 50.4/28 
(78pts); 57.5-
75.4 in 28-39# 
(28pts) 
50.4/28 
(78pts); 
57.5-75.4 in 
28-39# 
(28pts) 
Gemc (19) 
5-FU (15)/ 
capec (72) +/- 
cetuximab 
(21) or 
erlotinib (6) 
Koper (147) 2004 Prostate 266 141 anal canal RTOG (simplified) 
Symptom 
questionnaire 
 
3D or 2D  66/33 NS no 
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Abbreviations: NS: not stated; IMRT: intensity modulated radiotherapy; RTOG: Radiation Therapy Oncology Group; CTCAE: Common Toxicity Criteria for Adverse Events; RILIT: Radiotherapy 
Induced Late Intestinal Toxicity;  FACT-P: Functional Assessment of Cancer Therapy=Prostate; EORTC: European Organisation for Research and Treatment of Cancer; PAN: Para-aortic 
nodes; MMC: Mitomycin-C ; Gemc: Gembcitabine; Capec: Capecitabine 
Author Year Cancer site No 
of 
pts 
Pts with 
tox 
OAR studied Toxicity score 
used 
RT Type RT Dose 
(Gy/#) 
Pelvic RT 
dose (Gy/#) 
Concurrent 
chemo use 
Mavroidis 
(148) 
2005 Prostate 65 Symptom 
specific 
anal sphincter Own questionnaire 3D 70.2/39 NS no 
Mcdonald 
(149) 
2015 Bladder 47 10 bowel loops RTOG 3D 64/32 64/32 21 received 5-
FU/MMC 
Mouttet-
Audouard 
(150) 
2015 Cervical  37 8  
 
Small bowel, 
sigmoid 
CTCAE v4.0 IMRT 
(tomotherapy) 
60/28 50/28 Yes, cisplatin 
Peeters 
(151) 
2006 Prostate 641 146 Anal wall RTOG/EORTC plus 
5 symptoms 
3D (41 pts 
IMRT boost) 
68/34 or 78/39 NS no 
Peeters 
(152) 
2006 Prostate 368 32 Anal wall Incontinence (no 
specific 
questionnaire) 
3D (22 pts 
had IMRT 
boost) 
68/34 or 78/39 NS no 
Poorvu (153) 2013 Cervix & 
Endometrium 
(+ PA nodes) 
46 3 peritoneal cavity, 
small bowel, 
duodenal segments 
CTCAE v4.0 IMRT 45/25 (22pts);  
PAN boost 
50-65 (33pts) 
45/25 (22pt) 
plus PAN 
boost 50-65 
(33pts) 
yes, 24 pts 
cisplatin 
Smeenk 
(154) 
2012 Prostate 48 21 Anal sphincter 
muscles 
Presence or 
absence of 
frequency, urgency 
and incontinence 
3D (n=43,  
IMRT (n=5) 
67.5/27 or 
70/28 
NS no 
Smeenk 
(155) 
2012 Prostate 36 23 Anal wall Late RILIT score: 
urgency, 
incontinence, 
frequency 
3D 67.5/27 or 
70/28 
NS no 
Taussky 
(156) 
2003 Prostate 73 unclear anal canal Prostate specific 
QoL scores: UCLA, 
FACT-P and 
EORTC QLQ-PR25 
3D 66.6-72/ 37-
40 
NS no 
Verma (157) 2014 Cervix & 
Endometrium 
105 9 duodenum RTOG and 
endoscopic findings 
IMRT 45-50 with 
boost 60-
66Gy 
45-50 with 
boost 60-
66Gy  
58 pts 
platinum 
agents 
Vordermark 
(158) 
2003 Prostate and 
prostatic bed 
44 14% severe 
incontinence 
anal canal 10 question 
continence  
questionnaire  
3D 58-72/29-36 NS No 
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2.4.1. Whole bowel 
Seven papers (including 372 patients) examined the dose-volume relationship of whole 
bowel either using bowel loops or intestinal/peritoneal cavity. The findings are detailed in 
table 2.4-2, with studies with positive findings detailed first. The last two columns indicate 
the quality assessments that were met (as defined in table 2.3-1). If the consideration is 
met the number of the consideration is noted.   
2.4.1.1. Whole bowel: Peritoneal cavity/bowel bag 
Of the 5 peritoneal cavity papers, 3 papers (140, 145, 153) found no dose-volume 
parameters of the peritoneal cavity related to late bowel toxicity. Deville et al (141) found 
an association of RTOG Grade≥1 late bowel toxicity with both volume and V20 of 
peritoneal cavity, though no constraints were derived. Mouttett-Audouard et al (150) 
defined their “small bowel” OAR as “the entire abdominal cavity including all possible 
locations to the top of iliac crests or to D12-L1 in para-aortic radiation cases,” hence this is 
included in the whole bowel section. They found that their endpoint of “whole late digestive 
toxicity” was associated with small bowel dose D20%, D40%, D50%, D80% and D95%. 
Bowel receiving 10-30Gy was significantly associated with toxicity, though no constraints 
were derived.     
2.4.1.2. Whole bowel: Bowel loops 
Two studies (112, 149) examined the dose-volume relationship using bowel loops, defined 
as from the rectosigmoid junction up to 2cm above the PTV, which included sigmoid, large 
and small bowel. Guerrero-urbano et al (112) found a clear relationship between bowel 
volume above 450cc and increased risk of late diarrhoea (by both RTOG and LENT SOMA 
definitions) in patients who have prostate and pelvic nodal IMRT. Dose-volume 
relationships were found with RTOG scoring of diarrhoea, though not LENT SOMA. 
Constraints suggested were V40<124cc, V45<71cc and V60<0.5cc to reduce grade 2 
toxicity in IMRT patients. No complication rates associated with these constraints are 
mentioned. 
McDonald et al (149) in their study of 47 bladder cancer patients suggest threshold 
constraints for 25% risk of grade 1 RTOG toxicity as V30<178cc; V35<163cc; V40<151cc; 
V45<139cc; V50<127cc; V55<115cc; V60<98cc and V65<40cc. With these constraints the 
authors suggest grade 2 toxicity will be 0%.  
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Table 2.4-2: Whole bowel studies – significant findings and quality assessment 
Abbreviations: n/a: not applicable; Gr: Grade 
 
      Quality Assessment 
Author OAR studied OAR defined Toxicity 
definition 
Pts with 
toxicity  
Significant findings Statistical 
considerat-
ions met (1-7) 
Endpoint 
considerat-
ions met (1-
3) 
Deville (141)  Intestinal cavity Intestinal cavity 
below L4-5  
RTOG Gr≥1 5/36 
(14%)  
Toxicity associated with volume & V20. No 
constraint specified. 
1,7 
(n/a: 2-6) 
None 
 
Mouttet-
Audouard 
(150) 
“Small bowel” 
though outlined 
as abdominal 
cavity 
Entire abdominal 
cavity including all 
possible organ 
locations to iliac 
crests or D12/L1 
CTCAE v4.0 
Gr1-3 –diarrhoea 
or “whole 
digestive toxicity” 
8/37 
(21.6%) 
17/37 
(46%) 
 ‘Larger volumes’ receiving 10-30Gy 
associated with diarrhoea & ‘whole late 
digestive toxicity’  
 
1,6,7  
(n/a 2-5) 
1, 2 
 
Deville (140) Intestinal cavity Intestinal cavity: 
large & small bowel 
below L4-5  
RTOG Gr≥2 2/30 (6%)   No dose-volume relationship found 1,7 
(n/a: 2-6) 
None 
Isohashi (145) Peritoneal cavity Volume surrounding 
small bowel loops to 
edge of  peritoneum 
RTOG/EORTC 
Gr2+ 
16/97 
(16.5%) 
No dose-volume relationship found 1,4,6,7 
(n/a 2,3) 
 
2 
 
Poorvu (153) 1. Peritoneum 
2. Peritoneum 
+ Colon 
1. Possible location 
of small bowel exc 
solid organs & RP 
structures.  
2. Peritoneum (as 
above) plus asc & 
desc colon  
CTCAE v4.0 
Gr3+ 
3/46 
(6.5%) 
No dose-volume relationship found 1,6,7 
(n/a 2-3) 
2 
 
        
Guerrero-
Urbano (112) 
Bowel loops Loops from recto-
sigmoid junction to 
2cm above PTV 2 
RTOG diarrhoea; 
LENTSOMA 
consistency & 
frequency- worst 
grade 
21/79 
(26%) 
RTOG; 
≥gr2 6/79 
(7.6%) 
Bowel volume of >450cc had both higher 
RTOG & LENTSOMA diarrhoea.  
Constraints: V40<124cc, V45 <71cc, V60 
<0.5cc for RTOG<gr 2 (for IMRT) 
1,7 
(n/a 2-3) 
 
1 
 
Mcdonald 
(149) 
Bowel loops  Loops from recto-
sigmoid junction to 
2cm above PTV 
RTOG Gr≥1 7/47 gr1; 
3/47 gr2 
(6.4%) 
Constraints for <25% ≥ gr2 toxicity: 
V30<178cc;V35<163cc;V40<151cc;V45<139c
; V50<127cc; V55<115cc; V60<98cc 
V65<40cc 
1,4,7 
(n/a 2-3) 
2 
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2.4.2. Small Bowel and its components  
Ten papers (including 836 patients) examined dose-volume relationships of the small 
bowel or its components. The findings are detailed in table 2.4-3. Six studied small bowel 
as a whole, and 4 more specifically the duodenum. No papers examining ileum or jejunum 
were found.  
Small bowel  
Of the 6 studies, 4 found no correlation with late bowel toxicity and dose-volume 
parameters of small bowel. Isohashi et al (145) found in their study of 97 cervical cancer 
patients that a V40 to 340cc small bowel was the best predictor of toxicity. This constraint 
split patients into cohorts, with 46.2% having toxicity above the constraint and 8.7% having 
toxicity below the constraint. Chopra et al (139) in a similar group of patients found on 
multivariate analysis that reducing V15 to below 275cc dichotomised patients into 20% 
toxicity above the constraint and 5% below the constraint (p=0.02). V40 was significant on 
univariate analysis only. 
Duodenal Papers 
Out of 4 papers 3 papers found a relationship between dose-volume parameters and 
duodenal toxicity.  Huang et al (144) found the V25 to be the significant predictor for 
pancreatic cancer patients treated with concurrent gemcitabine – V25 below 45% of 
duodenal volume was associated with toxicity of 8%, above this toxicity was 48%. With 
exclusion of 18 patients who had both gemcitabine and erlotinib group V35Gy was the 
best predictor with a V35% of <20% splitting patients into cohorts with 41% above the 
constraint and 0% below the constraint.  
Kelly et al (146) found (also in pancreatic cancer patients treated with a variety of 
concurrent agents) that a V55 more than 1cc was the most important predictor on 
multivariate analysis: higher than 1cc resulted in toxicity of 47%, compared with 9%.  
Verma et al (157) and Poorvu et al (153) both examined duodenal dose-volume data in 
gynaecological patients. Whilst Poorvu found no dose-volume relationship, Verma also 
found that V55 was a significant dose-volume predictor. With a constraint of V55 of <15cc 
49.6% of patients had toxicity above this constraint, and 7.4% had toxicity below this 
constrain
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Table 2.4-3: Small bowel studies: significant findings and quality assessment  
 
      Quality Assessment 
Author OAR 
studied 
OAR defined Toxicity 
definition 
Pts with this 
toxicity  
Significant findings Statistical 
considera-
tions met 
(1-7) 
Endpoint 
considerat-
ions met  
(1-3) 
Chopra 
(139) 
Small bowel 2cm above target, individual small 
bowel loops (differentiated from 
large bowel – unclear how) 
CTCAE v3.0 
Gr3+ 
9/71 (12.6%) V15<275cc, V30<190cc, V40<150cc 
reduces gr3 from 20% to <5%. V15 
significant on multivariate analysis 
1, 4, 6 
(n/a 2,3) 
2 
 
Isohashi 
(145) 
Small bowel Bowel loops remaining after 
exclusion of large bowel loops 
RTOG/EORTC 
Gr≥2 
16/97 (16.5%) V40 best predictor of late toxicity; 
Recommend V40<340ml to reduce 
toxicity from 46.2% to 8.7% 
1,4,6,7 
(n/a 2,3) 
 
2 
 
Adkison 
(135)  
Small bowel Not clearly defined CTCAE v3.0 
Gr1 & 2 
Gr1 16/53 
(30%); Gr2 4/53 
(8%)  
No dose-volume relationship with V30-
V60 small bowel 
1 
(n/a 2-6) 
None 
 
Fokdal 
(142) 
Small bowel Opacified & unopacified small 
intestine loops (outer contour & 
contents) from 1st slice to minor 
pelvis 
LENT-SOMA 
Gr1-4 
Symptom 
specific  
No dose-volume relationship found 
with small bowel 
1,2,4,5,7 
(n/a 3) 
 
1,2,3 
 
Fonteyn
e (143) 
Small bowel Not clearly defined RTOG and 
“RILIT” Gr1 & 
Gr2 
Gr1 112/241 
(46%), Gr 2 
32/241(13%)  
No dose-volume relationship found 
with small bowel 
1, 4, 5  
(n/a 3) 
1,2  
 
 
Poorvu 
(153) 
Small bowel Opacified & Non-opacified small 
bowel loops  
CTCAE v4.0 
Gr3+ 
3/46 (6.5%) No dose-volume relationship found 
with small bowel 
1,6,7 
(n/a 2-3) 
2 
 
        
Huang 
(144) 
Duodenum Duodenal bulb to ligament of Treitz CTCAE v4.0 
Gr≥3 
8/46 (17.4%) V25>45% increases toxicity from 8% to 
48%  Excluding patients having 
erlotinib the V35Gy>20% increases tox 
from 0% to 41% 
1,4,6,7 
(n/a 2,3) 
 
2 
Kelly 
(146) 
Duodenum Gastric pylorus until end of 
duodenum  
CTCAE v4.0 
Gr≥2 
20/106 (18.9%)  V55>1cc increases toxicity risk from 
9% to 47% 
1,4,6,7 
(n/a 2,3) 
2 
Poorvu 
(153) 
Duodenal 
segments 
D1 segment: bulblike shape & 
origin beyond gastric pylorus. 
Transitions between 2nd & 3rd was 
lateral border of IVC; Between 3rd & 
4th was medial border of aorta 
CTCAE v4.0 
Gr≥3 
3/46 (6.5%) No dose-volume relationship found 
with duodenum 
1,6,7 
(n/a 2-3) 
2 
 
Verma 
(157) 
Duodenum From gastric outlet through 
transverse portion of duodenum 
(ascending portion excluded) 
RTOG, all 
grades 
9 / 105 (8.6%) V55>15cc toxicity increased from 7.4% 
to >48.6% 
1,4,6,7 
(n/a 2,3) 
 
2 
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2.4.3. Large Bowel and its components 
Sixteen studies (including 2518 patients) were included in this section (see table 2.4-4). 11 
studies examined dose to the anal canal/anorectal region. 2 papers looked at ‘large bowel’ 
and 2 at sigmoid colon.  
2.4.3.1. Large bowel 
“Large bowel” was examined in post-operative gynaecological patients. Chopra et al (139) 
found on multivariate analysis that V15 was associated with gr 3 CTCAE defined toxicity. 
Their recommendation was that reducing V15 <250cc, V30 to <100cc and V40 <90 cc 
could reduce grade 3 toxicity from 20% to 5%. Isohashi et al (145) however found no 
correlation with RTOG toxicity and large bowel.  
2.4.3.2. Sigmoid colon 
2 studies looked at the sigmoid as an OAR. Fonteyne et al (143) examined the dose-
volume relationship of sigmoid colon and toxicity. Gr 1 RILIT was inversely related to the 
volume of the sigmoid colon with a smaller volume being associated with an increased 
toxicity risk. V40 was associated on multivariate analysis to grade 1 diarrhoea and grade 1 
blood loss. Recommendations were that V40 must be<10% and V30 <16% to avoid grade 
1-2 diarrhoea. Mouttet-Aldouard et al (150) found that “digestive toxicity” significantly 
correlated with sigmoid doses. They also found doses of 30-40Gy were most significant, 
and that D40%, D50% and D80% significantly correlated. No specific cut-offs were 
identified. 
2.4.3.3. Anal canal  
12 papers were found examining the dose-volume relationship of the anal canal and bowel 
toxicity. Many of the studies looked at both rectal and anal parameters, though only those 
related to the anal canal are discussed in this review.  
2.4.3.4. Dose-volume parameters 
2.4.3.4.1. Anal canal / anal sphincter region 
Of the 12 papers, 11 had positive findings for relating toxicity to the anal canal/sphincter to 
dose-volume parameters or NTCP models. Different anatomical definitions were used 
though most defined the anal canal as the distal 3cm of rectum. In 5 studies (136-138, 
151, 155) Dmean to the anal canal/sphincter region was considered to be most predictive, 
though others including Dmin (158), V65 (151) and V90% (=V>59.4Gy) (147), Dmax (142) 
and Dmedian were found to be important in individual studies.  
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Table 2.4-4: Large bowel papers: significant findings and quality assessment 
      Quality Assessment 
Author OAR 
studied 
OAR defined Toxicity 
definition 
Pts with 
toxicity  
Significant findings Statistical 
consideratio
ns met (1-7) 
Endpoint 
consideratio
ns met (1-3) 
Chopra 
(139) 
Large 
bowel 
2cm above target, 
individual loops of large 
bowel  
CTCAE v3.0 ≥Gr3 9/71 (12.6%) Multivariate analysis: V15 related to 
gr 3 toxicity.  
Constraints: V15<250cc, V30<100cc, 
V40<90cc reduces toxicity 20% to 5%   
1, 4, 6 
(n/a 2,3) 
2 
 
Isohashi 
(145) 
Large 
bowel  
Single loop continuing from 
end of sigmoid to 
ascending colon 
RTOG/EORTC, 
Gr≥2 
16/97 (16.5%) No constraint found for large bowel 1,4,6,7 
(n/a 2,3) 
 
2 
 
        
Fonteyne 
(143) 
Sigmoid 
colon 
Where rectum swerves 
anteriorly to one slice 
above aortic bifurcation 
RTOG and 
“RILIT”, Gr 1 and 
2 
Gr 1 112/241 
(46%), gr 2 
32/241 (13%).  
V40 associated with gr1 diarrhoea & 
blood loss.  
Constraints: V40<10%, V30<16% to 
avoid gr1-2 diarrhoea 
1, 4, 5  
(n/a 3) 
1,2  
 
 
Mouttet-
Audouar
d (150) 
Sigmoid 
colon 
Anterior curvature of 
sigmoid colon to anterior 
abdominal wall 
CTCAE v4.0 Gr 1-
3 –“Whole 
digestive toxicity” 
8/37 (21.6%); 
17/37 
(46%) (whole 
tox) 
 ‘Whole late digestive toxicity’ 
associated with V10-40. No specific 
constraints.  
1,6,7  
(n/a 2-5) 
1,2 
 
        
al-Abany 
(136) 
Anal 
sphincter 
region 
Caudal 3cm of the rectum 
from anal verge (inc filling) 
Own 
questionnaire;  
Faecal leakage 
>2X/week 
9/65 (13.8%) 
faecal leakage  
Constraints: V35<60%, V40<40% 
associated with no risk of faecal 
leakage. 
Increased risk with mean dose of 45-
55Gy  
1,4,6,7 
(n/a 2,3) 
1,2,3 
 
Alsadius 
(137)  
Anal 
sphincter 
region 
Caudal part of large bowel, 
from end of rectal ampulla 
where bowel no longer had 
visible content or air.  
Own 
questionnaire;  
Faecal leakage 
>once per month 
51/403 
(12.7%) faecal 
leakage 
Dmean<40Gy reduces risk from 17% 
to 4%.  
1,2,4,5,7 
(n/a 3) 
 
1,2,3 
Fokdal 
(142) 
Anal canal Outer contour of the 
structure extending from 
anal verge 2 cm cranially 
LENT SOMA 
score 
 
Urge: 27/71 
(38%); 
Incontinence: 
21/71 (30%) 
Urgency related to Dmed>33.8: 
increases toxicity 31% to 47%  
Incontinence related to Dmax> 53.8 
increases 14% to 44% 
1,2,4,5,7 
(n/a 3) 
 
1,2,3 
 
Vorderm
ark (158) 
Anal canal  Anal verge to the section 
below visible rectal lumen, 
corresponding to the upper 
border of the 
levator ani muscle 
 “Solid soiling” 
(Severe 
incontinence) 
Own continence 
questionnaire 
6/44 (14%) Severe incontinence  
- ass with Dmin (23.1Gy) 
- related to portals extending 2 mm 
below ischial tuberosities (compared 
with 5mm above) 
 
1, 7 
(n/a 2-3) 
 
1,2,3 
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Koper 
(147) 
Anal canal Caudal 3cm of the intestine RTOG gr1 +2;  
Plus symptom 
questionnaire.  
141/248 (57%) D90% (=54.9Gy) to associated with ≥ 
Gr1 rectal toxicity 
 
1,6,7 
(n/a 2-3)  
2,3  
  
 
Taussky 
(156)  
Anal canal  Most distal 2-3cm of 
rectum 
10 questions from 
UCLA-PCI, FACT-
P  & EORTC QLQ 
-PR25  
Unclear no relation with anal canal DVH found  7 
(N/a: 2-3) 
3 
 
Buettner 
(138) 
Anal canal Caudal 3cm of rectum Common grading 
scheme; 
subjective 
sphincter control 
at highest grade  
57/388 
(14.7%) 
DSH data: Toxicity correlated with 
dose to anal surface: lateral extent 
53Gy>56%.  
DVH data: Dmean 47Gy to anal 
sphincter volume correlated with 
sphincter toxicity.  
Constraints: Dmean of >30Gy. 
NTCP modeling to LKB model 
(parameters defined) 
1,3,6,7 
(n/a 2) 
1,2,3 
 
Peeters 
(151) 
Anal wall Wall of caudal 3cm of 
anorectum (method 
described)  
RTOG/EORTC ≥ 
Gr 2 and ≥Gr 3 
Plus incontinence 
pad use>2x/wk  
Gr≥ 2 165/641 
(25.7%)  
Gr≥ 3 27/641 
(4.2%)  
Dmean increase from 19Gy to 52Gy 
increased Gr2 toxicity: 16% to 31%.  
V65 & Dmean most sig for 
incontinence. Dmean increase by 
33Gy increased incontinence by 12% 
1,2,4,6,7 
(n/a 3) 
1,2  
  
Mavroidis 
(148) 
Anal 
sphincter 
region 
Musculaure layer around 
the rectal aperture, 3cm 
caudal from anal verge 
Own 
questionnaire 
faecal leakage 
19/65 (29%); 
blood/mucus 
22/65 (34%) 
Relative seriality NTCP model of anal 
sphincter for incontinence, 
blood/mucus. Parameters defined 
(see text)  
1, 3, 5, 6, 7 
(n/a 2) 
1,3  
 
Peeters 
(152) 
Anal canal 
wall 
Wall of caudal 3cm of 
anorectum (method 
described)  
Incontinence 
requiring pad  
use>2x/wk; 
32 (7%) NTCP LKB model of incontinence 
with anal wall dose parameters (see 
text)  
1,3,4,5,6,7 
(n/a: 2) 
1,3 
 
Smeenk  
(154) 
Anal 
sphincter 
muscles 
Individual muscles defined 
(Internal anal sphincter 
(IAS), external anal 
sphincter (EAS), 
puborectalis and levator 
ani) 
Frequency, 
Urgency, 
Incontinence 
21/48 (44%) For complication <5% Dmean<30Gy 
to IAS; <10Gy to EAS, <50Gy to 
puborectalis, <40Gy to levator ani  
1, 4,5  
(n/a 2) 
1.2.3 
Smeenk 
(155) 
Anal wall Continuation of rectal wall 
from anal verge to slice 
below lowest slice with a 
rectal balloon 
Frequency, 
urgency, 
incontinence 
39% 
frequency, 
31% urgency, 
31% 
incontinence 
For urgency:  
Anal wall Dmean<38Gy risk <15%, 
>38Gy risk is 62% 
1,4,7 
(n/a 2,3,5,6) 
1,3 
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Dmean 
5 studies (see table 2.4-5) found Dmean anal canal/sphincter region to be predictive of 
toxicity, 4 of faecal incontinence and 1 of faecal urgency. The Dmean was converted to an 
equivalent dose in 2Gy fractions. As it can be seen there is relative consistency in the 
recommended Dmean constraints between 40-47Gy, despite the OARs being defined 
slightly differently. Though Buettner et al found a Dmean of 47Gy to be most statistically 
significant, they recommend an optimal constraint of <30Gy. Peeters et al, despite their 
large study did not suggest a specific constraint though noted an increase Dmean above 
52Gy results in toxicity of 31%.  
 
Table 2.4-5: Anal canal Dmean findings 
 
Other DVH parameters 
Koper et al (147) found that a V>90% dose (in their study 59.4Gy) to the anal canal was 
significantly associated with toxicity. Vordemark et al (158) found the parameter Dmin to 
be significantly different in patients with complete continence (Dmin 15.1Gy) and severe 
incontinence (Dmin 23.1Gy) (p=0.04). A threshold of Dmin<20 was suggested, however 1 
patient with severe incontinence (of 6) had a Dmin much lower than this. They also 
compared the 2 groups in terms of the lower border of the treatment fields – those with 
severe incontinence ended 2mm below ischial tuberosities versus 5mm above ischial 
tuberosities.  
Fokdal et al found a relationship between urgency and Dmedian, and incontinence and 
Dmax (159). Their cut-offs suggest above a Dmedian of 33.8Gy risk of urgency is 47% 
below is 31%. Incontinence was related to maximal anal canal dose: above a Dmax of 
Study  No 
of 
pts 
OAR Endpoint Dmean (in 
EQD2) 
constraint 
Risk of 
endpoint 
below this 
constraint 
Risk of 
endpoint 
above 
this 
constraint 
Al-
albany 
65 Anal 
sphincter 
region 
Incontinence 
>2X/week 
43.2 8% 52% 
Alsadius 403 Anal canal Incontinence 
>1x/month 
40 5.2% 21% 
Buettner 388 Anal 
sphincter 
region 
Incontinence : 
moderate/severe 
(gr2) 
47, though 
<30Gy 
ideal 
5% (approx; 
read from 
graph) 
 
Smeenk 36 Anal canal 
wall 
Urgency present 41.8 15% 62% 
Peeters 641 Anal canal 
wall 
Incontinence 
requiring pad 
>2x/week 
No 
constraint 
specified 
16% at 19Gy 31% at 
52Gy 
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53.8Gy risk is 44%, below is 14%. V65 anal canal wall was also strongly associated with 
incontinence (151).  
 Anal sphincter muscles 
Smeenk et al (154) also approached the anal canal region by relating dose to individual 
sphincter muscles for the presence or absence of three symptoms: urgency, frequency 
and incontinence. Their suggestion to keep urgency and incontinence below 5% was for 
Dmean to be <30Gy to the internal anal sphincter, <10Gy to the external sphincter, <50Gy 
to puborectalis, <40 to the levator ani muscles.  
Dose surface parameters 
Buettner et al (138) examined incontinence in prostate patients. As well as DVH data, 
dose surface maps (DSM) for the anal canal were used. These give more spatial 
information compared with a traditional DVH. They found that to the lateral extent a dose 
of 53Gy of 56% was most correlated with subjective sphincter toxicity. They recommend 
45Gy (ideally 27Gy) for surface-based mean-dose to the anal canal to reduce toxicity. 
NTCP modeling 
Three studies used NTCP models to relate late toxicity data with dosimetric parameters. 
Buettner et al (138) fitted mean-dose anal canal data to a Lyman-Kutcher-Burman (LKB) 
model, identified parameters related to grade 2 RTOG toxicity: TD50 of 120, m of 0.42. 
Peeters et al also fitted data to an LKB model (152) – with the parameters of anal wall 
dose to incontinence requiring pads >x2/week of n=7.48; TD50=105; m=0.46. They further 
modified their model to incorporate a previous history of abdominal surgery and found this 
improved the model fit, suggesting a decreased radiation tolerance for patients with this 
risk factor.  
Mavroidis et al (148) modelled dose to the anal sphincter region for ‘faecal leakage’ and 
‘blood or phlegm’ in stools using the relative seriality NTCP model. They found parameters 
of D50 = 70.2 Gy, γ = 1.22, s = 0.35 for incontinence and D50 = 74.0 Gy, γ = 0.75, s ≈ 0 
for blood or mucus with a recommendation that reducing the biologically effective uniform 
dose (EUD) to anal sphincter < 40–45 Gy may significantly reduce toxicity. 
 
2.4.4. Quality Assessment 
Quality assessment considerations for each paper are detailed in tables 2.4-2, 2.4-3 and 
2.4-4. If, for example considerations 1 and 3 (from table 2.3-1) was met a ‘1,3’ was noted 
in the column. 
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Statistical criteria 
The majority of papers provided adequate information on basic statistical data (24/25), and 
clear definition of OARs (22/25). Constraints were derived in 15 papers, with associate 
complication rates stated in 13 papers. Of the 15 papers goodness of fit was reported in 7 
papers, with discriminator statistics reported in 14 papers. For the 3 papers with NTCP 
models all provided parameter estimates with standard error.  
Endpoint criteria 
Overall toxicity grades rather than individual symptoms were assessed in 12 of 25 studies, 
with patient-reporting found in 10 studies (9 of which were studies of the anal canal). 16 of 
the studies looked at co-morbidity to assess its contribution to late toxicity and this was 
taken into account in multivariate analyses if thought to be associated.   
2.5. Discussion  
Late bowel toxicity is a common occurrence, and reduction of bowel toxicity is a key goal 
of modern radiotherapy techniques. Dose-volume predictors and constraints for late bowel 
toxicity after pelvic radiotherapy are not well established and it is difficult to determine the 
likely efficacy of new radiotherapy techniques without this knowledge.   
 
This systematic review aimed to examine the currently published literature for dose-
volume predictors and constraints to reduce the risk of late bowel toxicity. 25 studies 
including 3718 patients were found after systematic searching and matching of studies to 
specified inclusion criteria. Key findings were relatively consistent dose-volume constraints 
for anal canal as an OAR in five of the studies. Constraints were also suggested in 
individual studies for bowel loops, small bowel, duodenum and large bowel though these 
findings were not corroborated with other studies.   
 
Although the focus of this thesis is gynaecological malignancies, within this review all 
pelvic malignancy diagnoses were included, with the rationale that the dose-volume 
response to bowel should be the same regardless of primary tumour. This approach has 
been used both in historic papers (125, 130) and more recently QUANTEC guidelines. 
Though it is known that other patient- and treatment-related factors associated with 
specific diagnoses, such as previous surgery, concurrent treatments and co-morbidities, 
may influence late toxicity, these factors should be accounted for in the statistical analysis 
of the individual studies and were not reason for exclusion from this review. 
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2.5.1. Whole bowel studies  
Delineation of bowel traditionally is defined with individual loops visible on the planning CT. 
This however does not take into account inter- and intra-fractional variation of the bowel 
over the course of treatment. It has been suggested that only 19.2% of the bowel occupies 
the same space over time (160). To account for this motion the ‘potential space’ where 
bowel may lie is outlined, and denoted as ‘bowel bag’, ‘intestinal cavity’ or ‘peritoneal 
cavity’.  
 
For acute toxicity QUANTEC recommend the peritoneal cavity constraint of V45<195cc 
based on a study by Roeske et al (56) in 50 patients with cervical cancer. They suggest 
that such a limit may also be applied in late toxicity, though this “correlation is not yet 
established.” Dose-volume parameters of bowel bag have been found to be more 
predictive than those of bowel loops (161) for acute bowel toxicity.    
 
In this systematic review, 2 of 5 studies found a correlation with dose-volume parameters 
of the peritoneal cavity and late toxicity. There was some concordance between the two 
studies with one study finding V20 peritoneal cavity to be important (141), and the other 
suggesting V10-V30 (150). However no volume cut-offs or constraints were defined by 
either study.  
There was no concordance demonstrated in the studies with the V45 constraint 
recommended by QUANTEC for acute toxicity. Poorvu et al (153) found no toxicity 
constraints using two definitions of peritoneum. In addition they applied the QUANTEC 
dose constraints to bowel bag (V45<195cc) and found this to have limited sensitivity 0 of 3 
cases (0%) though a specificity in 32 of 39 cases (82%). For peritoneal cavity, therefore, 
no specific constraints for late toxicity can be concluded from this review.  
 
Guerrero-Urbano et al (112) and McDonald et al (149) both suggest dose-volume 
constraints for RTOG defined toxicity, with Guerrero-Urbano finding constraints specifically 
for diarrhoea. Both studies defined bowel loops with the same method, though despite this 
their suggested constraints are significantly different, for example V60 (equivalent dose of 
58.5Gy) of <98cc compared with a V60 (equivalent dose of 56.6Gy) of <0.5cc. McDonald 
et al defined their model for grade≥2 toxicity, with only 3 patients in their study having 
grade ≥2 toxicity. With this lack of concordance in the findings it is again difficult to 
recommend any specific bowel loop constraints.  
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2.5.2. Small bowel studies  
For small bowel QUANTEC recommend constraints of V15<120cc for acute toxicity. This 
is based on initial modelling studies in rectal cancer by Baglan et al (162), which has 
subsequently been validated by Robertson et al (163). The studies were found to have 
concordant results with three other studies (164-166) including rectal and cervix cancer 
patients.  
 
In this chapter only 2 of 6 small bowel papers found a dose-volume relationship of the 
small bowel with late toxicity. Both Isohashi et al (145) and Chopra et al (139) studied in 
similar groups of patients, treated with similar dose-fractionations. Isohashi et al found V40 
was most significant parameter, though in contrast Chopra et al found V15 to be significant 
on multivariate analysis. V40 was significant on univariate analysis by Chopra et al too, 
however when comparing the findings, one suggests a V40<150cc and the other 
V40<340cc.  Reasons for the lack of concordant results between papers could be due to 
different toxicity scoring systems and Isohashi et al only considering grade 3 toxicity.  
Although V15 was found to be significant by Chopra et al, their suggestion of V15<275cc 
was dissimilar to that recommended by QUANTEC.  
 
Five of the six small bowel studies used an overall grade score (either CTCAE or RTOG) 
rather than individual symptom analysis, which may account for the lack of consistent 
constraints found. Patient numbers in all these studies were relatively small, many with 
<100 patients (and small numbers of patients with defined toxicity endpoint).  
 
For the duodenum two studies (146, 157) found the V55 to be a predictive parameter of 
toxicity, though one with a constraint of 1cc and another with 15cc. Again this could be due 
to different clinical scenarios and different scoring system used (RTOG versus CTCAE). In 
all four duodenal papers different dose-fractionations were used, and the full detail of the 
dose-fractionation data was not available making it is impossible to directly compare their 
findings with conversion of dose using BED calculations.  
 
As for whole bowel, it is difficult to choose constraints for small bowel and duodenum from 
the results of single studies. Each of the above studies did consider some of the statistical 
and endpoint considerations as recommended by QUANTEC, and their findings could be 
important, however further validation is needed with additional data. 
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2.5.3. Large bowel studies 
For “large bowel” Chopra et al defined constraints (V15<250cc, V30<100cc, V40<90cc) to 
reduce toxicity from 20% to 5%. However there was no concordance with the second 
study (145) where no correlation was found.  
Fonteyne et al (143) examined the sigmoid colon and made recommendations (V40<10%, 
V30<16%) to avoid grade 1-2 diarrhoea. There was some correlation with a second paper 
(150) which also found V30 and V40 to be of importance, though this was not quantified. 
This may well be useful clinically though again further validation is needed. 
2.5.4. Anal canal studies 
Of all the components of bowel studied, most data was available in studies regarding the 
anal canal/anal sphincter region. This was due to large studies of prostate patients, often 
from clinical trials, where both high quality late toxicity data and dosimetric data are found.  
10 of the studies used individual symptoms reported by patients rather than an overall 
toxicity score, an important consideration recommended by QUANTEC. The main 
symptom studied was faecal incontinence (‘faecal loss’ or ‘faecal leakage’), though 
urgency and frequency were also addressed. Statistical and endpoint measures were met 
much more frequently in these studies suggesting a higher quality. Some were still limited 
by the lack of baseline data and information on co-morbidities.  
 
From the available data it is clear that there is a definite relationship between dose-volume 
parameters to the anal canal and incontinence. Dmean was found to be the most 
significant parameter in 5 different studies (see table 2.4-5), most with relatively large 
populations of patients, allowing for its conclusive use. There were different definitions in 
the endpoint and OAR definitions, however, relatively consistent constraints for Dmean of 
40-47Gy were found.  
From the available data it may be concluded, that the constraint Dmean of <40Gy (in 2Gy 
fractions) to the anal canal is likely to improve patient toxicity. 
2.5.5. Quality assessment measures 
QUANTEC provided guidance on quality assessment of papers when considering different 
dose-volume studies together for clinical use or meta-analysis. Statistical criteria were 
considered with varying degrees between studies, generally with the larger studies looking 
at anal canal focusing more on these statistics, and the smaller studies looking at small 
bowel for example not addressing these concepts. Clear definition of the OAR was found 
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in all but three studies. However in between studies definitions varied significantly, making 
pooling of results/conclusions difficult. 
 
Normal tissue complication probability (NTCP) modelling is considered a more robust 
method to test the relationship of a dose-volume parameter with a toxicity endpoint 
compared with simple correlation alone. The main NTCP models within the literature are 
Lyman-Kutcher-Burman, and Relative Seriality models, and these were investigated within 
this review with regards the anal canal in three studies.   
 
In terms of toxicity endpoint QUANTEC recommended that individual symptoms are used 
in place of “portmanteau” endpoints such as “RTOG grade 2”, which could mean a variety 
of different toxicities. Only 13 studies used individual symptoms rather than an overall 
score, and with ten of these studies producing more conclusive results. QUANTEC also 
suggest that patient-reporting of toxicity may be of benefit, and this was noted to be used 
in the majority of papers reporting dose-volume constraints to the anal canal, where 
conclusive results were found.  
2.5.6. Strengths and Limitations  
This review has many strengths, including that the literature search was performed 
systematically with potential studies being assessed by two separate investigators. A 
heterogeneous group of studies were compared and contrasted with different primary 
tumour sites, based on the assumption that the dose-volume response to bowel should be 
similar for all pelvic radiotherapy treatments.  
The importance of the anal canal as an OAR was highlighted in this review, which has not 
been such a prominent OAR in the literature and is rarely considered in clinical or trial 
protocols.  
Limitations of this chapter include the exclusions made at the onset which may have 
prevented additional information from being gathered. A “cut-off” definition of late toxicity, 
as “after 3 months of radiotherapy” to distinguish between acute and late toxicity was 
used. There is some evidence to suggest that acute and late toxicity should not be entirely 
distinguished as late toxicity may be a continuum of acute toxicity (a “consequential late 
effect”) (167). The time-point when acute becomes late may not be 3 months for all 
patients developing bowel toxicity and there is a potential that studies where toxicity 
developed earlier may have contributed to the information gathered.  
By excluding studies that focussed on the rectum, studies examining the ‘anorectum’ may 
have been excluded. Similarly some studies looking at the ‘gastro-duodenum’ were not 
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included as they included dose-volume parameters for the stomach which is beyond the 
scope of this review.  
Studies using SBRT were also excluded as with the large fraction sizes used in these 
studies whether the results would be directly comparable radiobiologically to standard 
fractionation is not known, and a simple BED conversion may not be enough, as the 
validity of the linear quadratic model is questioned with extreme hypofractionation (168). 
  
Although all pelvic tumour sites were included assuming that bowel would have the same 
dose-volume response, other contributing factors may influence late toxicity such as 
concurrent chemotherapy or brachytherapy, or specific patient-related factors. Though it is 
expected that individual authors may account for these factors statistically this may not 
always be possible and may result in the inconsistent results found.  
 
Furthermore many of the studies found no correlation with OAR dose parameters and late 
bowel toxicity, and this is assumed to be because of methodological reasons. The 
alternative reason could be that in fact the particular OARs may genuinely not have any 
influence on late toxicity, and rather than dose-volume predictors, other considerations 
such as inherent radiosensitivity of individual patients, may be the main predictors of 
toxicity.  
2.6. Conclusions 
This systematic review aimed to seek dose-volume constraints for late bowel toxicity from 
the published literature which can be applied to assess the usefulness of advanced 
radiotherapy techniques in gynaecological malignancies. 
To reduce late bowel toxicity such as incontinence and urgency, reduction of the anal 
canal mean dose to <40Gy is an important constraint.  
For other components of bowel, though some dose-volume constraints are found, 
individual studies do not correlate with each other, and reliable constraints cannot be 
found in the published data. 
2.7. Future Work 
Future studies should aim to derive bowel dose-volume constraints for late toxicity with 
quality considerations as recommended by QUANTEC. Validation of constraints found 
75 
 
within this systematic review with additional data in future studies may be a good starting 
point, potentially enabling the constraints to be used clinically. 
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3. Chapter III: Definition of dose-volume 
constraints for patient-reported late 
bowel toxicity 
3.1. Introduction 
Late bowel toxicity is a significant problem for survivors of pelvic malignancies. During 
radiotherapy planning dose-volume constraints are used to limit the development of 
toxicity. Reliable dose-volume constraints for bowel toxicity may be useful to assess the 
toxicity-reducing ability of IMRT techniques in gynaecological malignancies.  
 
The previous chapter of this thesis systematically reviewed the available literature on 
dose-volume constraints for late bowel toxicity. The anal canal was found to be an 
important OAR with dose-volume constraints available from the literature, which aim to 
reduce faecal incontinence.  
Other components of bowel, including bowel loops, small bowel, duodenum and sigmoid 
were identified as potential OARs for late bowel toxicity. Dose-volume relationships for 
these OARs were described, and some constraints suggested, however there was little 
corroborative evidence in other studies to validate these findings.  
The systematic review also highlighted the need for further studies to carefully consider 
toxicity endpoints, the OAR being studied and the statistical methods used to assess the 
data. This chapter aims to further knowledge and corroborate data from published studies 
on dose-volume constraints for patient-reported late bowel toxicity whilst taking these 
considerations into account. 
3.1.1. Toxicity considerations 
Late bowel toxicity includes a multitude of symptoms, which can be graded by different 
scoring systems and at different time-points, and these factors must be clearly defined in 
dose-volume studies. 
Symptoms 
Prioritising which individual symptoms within the umbrella of bowel toxicity to study is an 
important question.  One possible avenue is to examine symptoms perceived by patients 
as influencing their quality of life. Andreyev et al (33) reported in their review of patient 
reported studies after pelvic radiotherapy that symptoms affecting quality of life include 
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faecal incontinence (25-89%), change in bowel habit (18-79%), faecal urgency (10-79%), 
and rectal bleeding (11-31%). Another study found that diarrhoea, bleeding, urgency and 
pain caused most distress (169).  After review of the literature the following four symptoms 
were selected for this work: faecal urgency, faecal incontinence, diarrhoea and rectal 
bleeding. 
Scoring system 
Radiation toxicity has traditionally been graded with the Radiation Therapy Oncology 
Group (RTOG) score. The RTOG bowel toxicity score comprises only a small number of 
symptoms, including bleeding, proctitis and diarrhoea (37). Other bowel symptoms that 
may impact quality of life, such as faecal incontinence and urgency, are not included. 
Scores from individual symptoms tend to be grouped together to form an overall RTOG 
score from 0-4, with grade 3-4 considered clinically most important.  
The Common Terminology Criteria for Adverse Events (CTCAE) grading has been used 
preferentially in recent years, especially in clinical trials, as it is more comprehensive in 
terms of symptom inclusion (38).  
The LENT-SOMA (Late Effects of Normal Tissues-Subjective, Objective, Management and 
Analytic Measure) score was developed in the 1990s (39). It comprises a subjective (‘S’) 
component, which was converted into a patient-reported questionnaire in 2003, and has 
been validated in the literature (170, 171). It also includes three other components: 
objective, management and analysis, and there is flexibility whether one or all components 
are used.  
 
RTOG and CTCAE are clinician-reported scores, which potentially underestimate toxicity 
compared with patient-reported scores. A comparison of RTOG and subjective LENT-
SOMA scoring in survivors of cervical cancer found that severe bowel toxicity (grade 3-4) 
was 45% with patient-reporting though only 15% with clinician-reporting (41). The 
importance of patient-reporting is being acknowledged and a patient-reported CTCAE 
(PRO-CTCAE) is being developed to be used alongside the CTCAE score (172).   
  
The UCLA prostate cancer index is a subjective quality of life (QoL) score used in prostate 
cancer, where patients report “bowel bother” symptoms on a linear scale from 0-100. 
Though this is demonstrated to be useful, it was also found to be limited in terms of 
symptoms compared to the LENT SOMA score (173). Further the Inflammatory Bowel 
Disease Questionnaire (IBDQ) questionnaire has been also been applied in the 
radiotherapy setting and found to be reliable for assessing toxicity symptoms (40). Other 
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scores, such as the EORTC-CLC-30, are used to assess patient-reported toxicity though 
with the focus being on Qol (174).		
 
When considering a toxicity score for dose-volume studies QUANTEC recommend the 
outcomes to be “clinically relevant” scores of individual symptoms (rather than a collective 
overall score) and suggest the use of patient-reported outcomes (PROs) (132).  
After a review of the literature on available toxicity scoring LENT-SOMA was chosen 
because it has a comprehensive coverage of bowel symptoms, is validated and can be 
used in a variety of ways (including clinician and patient reporting) hence best fitting the 
QUANTEC recommended criteria. 
 
With respect to toxicity grade many of the studies in the systematic review considered 
endpoints of grade 3 and above as important, and grade 2 or below as being “low grade” 
or mild. However, when the definitions of individual bowel symptoms are examined it is 
clear that lower grades of toxicity may be impactful on daily life. Grade 2 diarrhoea, for 
example by RTOG is defined as “bowel movement more than 5 times a day” (37), by 
CTCAE v4.0 as an “increase of 4-6 stools per day over baseline” (38), and by LENT 
SOMA as “bowel movement 5-8 times a day” (39). To qualify these grades of toxicity as 
low grade may underrate the impact of these symptoms on an individual, especially if 
these symptoms are life-long. In view of this, all grades of toxicity were considered as 
important to include in this work. 
Choice of toxicity time-point  
Late bowel toxicity can occur at any time, some studies suggest that most patients develop 
toxicity within the first two years after treatment (175); others report a median onset at 9 
months after radiotherapy (176). Prostate cancer studies have reported a maximal toxicity 
at around 18 months post-radiotherapy (177). From this, collection of toxicity data after 9 
months though within the first 2 years of radiotherapy completion was deemed appropriate 
for capture of late bowel toxicity. The two time-points selected for this work were 12 
months and 24 months after radiotherapy completion.  
3.1.2.  Choice of OAR 
Bowel toxicity symptoms may be caused by radiation to all or any part of the bowel from 
duodenum to anal canal. Diarrhoea, for example, may be caused by small bowel injury 
(resulting from bacterial overgrowth, bile sale malabsorption, or changes in small bowel 
transit) (33); large bowel injury may result in strictures which can diarrhoea and rectal 
injury may also present with diarrhoea. As discussed in chapter II, bowel itself can be 
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defined and divided in a number of ways: bowel loops, bowel bag, small bowel, large 
bowel, sigmoid colon and anal canal all have been studied as OARs for late toxicity with 
varying degrees of positive findings. All of these have potential to be important OARs 
without clear evidence of the importance of one over the other. Therefore an inclusive, 
exploratory approach of all potential OARs was chosen in this work.  
Statistical Considerations 
QUANTEC have made recommendations on the statistical requirements for studies 
addressing dose-volume dependence (132). These include clear statistical data on 
patients included and patients with toxicity, and for complication rates to be stated with any 
constraints. Any suggested models should have an assessment of their “goodness of fit” of 
the model to the data and discriminator statistics should be considered. Cross validation 
with independent data are likely to add to the quality of data. All of these recommendations 
were therefore considered in this work as far as possible. 
3.2. Aims 
The aims of this section of this thesis were to: 
- Correlate late bowel toxicity data with dose-volume parameters of the different 
components of bowel.  
- To seek dose-volume constraints from this analysis 
- To corroborate dose-volume constraints found within the literature (in chapter II) with 
the toxicity data collected in this section.   
3.3. Methods 
3.3.1. Patient selection 
Patients treated with pelvic radiotherapy from September 2012 to January 2014 were 
identified using a hospital database (“CANISC”) at Velindre Cancer Centre, Cardiff. The 
following inclusion and exclusion criteria were used: 
Inclusion criteria: 
1. Patients treated for gynaecological (cervical and endometrial) and urological 
(prostate and bladder) malignancies 
Amongst the prostate cancer patients only patients who had their pelvic nodes 
treated in addition to the prostate were included. 
2. Patients treated with radical or adjuvant intent 
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3. Patients treated with any type of radical radiotherapy – conformal, IMRT or VMAT 
4. Patients who remained alive and recurrence-free at 12 months after completion of 
radiotherapy 
Exclusion criteria: 
1. Patients treated for lower gastro-intestinal malignancies (as it was considered that 
bowel surgery may be a significant confounding factor) 
2. Patients treated with palliative radiotherapy 
3. Patients treated with brachytherapy only 
4. Patients unwell or with dementia who may be unable to return questionnaires 
3.3.2. Toxicity Questionnaires 
Patients were sent toxicity questionnaires via post 12 months post-radiotherapy and 24 
months post-radiotherapy; completed questionnaires were returned via freepost. 
The patient-reported LENT-SOMA questionnaire sent included questions on ten bowel 
symptoms; sexual and genito-urinary questions were not included in view of the fact that 
this focus of the study was late GI toxicity. A copy of the questionnaire used is included in 
Appendix B.  
An additional question was added: “are any of the symptoms you report longstanding, i.e. 
started prior to radiotherapy?” with a free text space. This was added in the absence of 
baseline scores acknowledging that bowel symptoms may be pre-existing or due to other 
co-morbidities.  
3.3.3. Exclusion of returned questionnaires 
Returned questionnaires were excluded from analysis if: 
1. Patients were incorrectly identified as having their prostate and pelvis treated when 
only the prostate was treated.  
2. Patients who reported that all their symptoms were due to another known bowel 
condition, or other causes such as chemotherapy for another malignancy.  
For those who mentioned single symptoms as being longstanding, but other 
symptoms as starting after radiotherapy, the longstanding symptoms were 
excluded though the remainder of the questionnaire was included. 
3. Questionnaires were returned completely blank. Those with some questions 
unanswered remained included. 
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3.3.4. Toxicity data collection 
From the questionnaires reported grades of faecal urgency, faecal incontinence, diarrhoea 
and bleeding were recorded. In addition an “overall” LENT SOMA score was recorded. 
This was defined as the highest grade of any symptom (from the ten symptoms on the 
questionnaire).  
Potential confounding factors 
Patient and treatment-related factors that may be related to toxicity were retrospectively 
collected from the patient’s electronic records as in table 3.3-1.  
Table 3.3-1: Patient, disease and treatment-related factors 
Patient and Disease-Related Factors Treatment-Related Factors 
- Age at commencing 
radiotherapy 
- Gender 
- Disease Site 
- Stage of disease 
- Total dose/Fractionation 
- Pelvic/Nodal dose/fractionation 
- Fraction size 
- Radiotherapy technique (conformal 
versus IMRT/VMAT) 
- Intent (definitive or adjuvant) 
- Concurrent chemotherapy use 
- Brachytherapy use 
- Hormone use 
 
3.3.5. Organs at risk (OARs) definitions 
Each patient’s planning CT was restored onto OncentraMasterplan version 4.3 (OMP). 
The following OARs were contoured: bowel loops, bowel bag, small bowel, large bowel, 
colon, sigmoid, rectum and anal canal.   
OARs were defined with guidance from Dr George Joseph (GJ), consultant radiologist, in 
conjunction with the use of the RTOG consensus document for “Pelvic Normal Tissue 
Contouring Guidelines” (178). All outlining was performed by myself, with the first eight 
cases being checked by GJ.   
The definitions are detailed in table 3.3-2: 
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Table 3.3-2: Definitions of OARs 
Structure Definition Comments 
Bowel 
loops 
Bowel loops (including contents) from the 
recto-sigmoid junction inferiorly to 4.2cm 
above the PTV superiorly.   
4.2cm chosen as it was noted 
on VMAT plans that low dose is 
still found 3cm above the PTV. 
An additional 1cm was added to 
ensure all dose would be 
included to make 4cm. 4.2cm 
had to be used as 3mm slices.  
Bowel 
bag 
The entire abdominal/pelvic contents were 
initially outlined. The inferior slice was the 
most inferior small or large bowel loop 
(regardless of relation to rectum). The 
superior slice was 4.2cm above the PTV.  
Then all non-GI structures (muscle, bone, 
kidney, bladder, prostate, and uterus) were 
excluded. 
As per RTOG guidelines 
Anal 
Canal 
Anal verge identified and 3cm of anal 
canal/distal rectum were outlined caudally, 
inclusive of contents 
 
Rectum Defined inferiorly from the ischial tuberosities 
to the recto-sigmoid junction 
 
Sigmoid Commenced inferiorly at the recto-sigmoid 
junction, followed to the most anterior-lateral 
point where it becomes descending colon 
 
Colon Included caecum, ascending colon, 
transverse colon and descending colon found 
in the slices up to 4.2cm above the PTV.  
Descending colon: commenced proximal to 
sigmoid.  
Ascending colon: continued inferiorly from 
caecum.  
Transverse colon: distinguished from small 
bowel by following the continuation of 
ascending and descending colon on the 
coronal sections. 
 
Large 
Bowel 
Sigmoid and colon were combined Performed using Union function 
on OMP 
Small 
Bowel 
All other bowel loops identified within 4.2cm 
above the PTV which were not large bowel. 
No bowel contrast used 
 
3.3.6. Dose-volume data collection 
Dose-volume data was collected using in-house software “DVHImport”, coded by Phillip 
Parsons (PP), physicist at Velindre Cancer Centre, which allows data to be converted from 
OMP to Microsoft Excel. Data was collected in the format of VxGy, the Volume receiving 
xGy in 0.1Gy dose bins from 0.1Gy to 75Gy.  
  
Patients in this study had been treated with a variety of different fraction sizes from 1.8Gy–
3Gy. To enable comparability between patients, all dose-volume data was converted to 
2Gy/# equivalent doses, using the EQD2 equation (Equation 1), derived from the linear 
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quadratic equation. An α/β ratio of 3 was used, which is commonly used for late reactions 
of the rectum (179). No other specific α/β ratios were found for bowel within the literature. 
Equation 1: EQD2 formula 
 
 
 
 
From the EQD2-converted data Vx dose parameters were recorded: V5, V10, V15 up to 
V75 at 5Gy intervals. For each OAR absolute volume data (in cc) was collected, though for 
sigmoid, rectum and anal canal % volume data was also collected as the entire organs 
were outlined.  Median dose (Dmedian), Minimum dose (Dmin), Maximum dose (D0.1cc), 
and total volume of each OAR were also recorded.  
Brachytherapy doses 
Some of the gynaecological patients within the study had brachytherapy in addition to 
external beam radiotherapy. Methods to combine DVHs of the external beam and 
brachytherapy data were sought, however a robust solution was not found despite seeking 
advice from Professor Roger Dale, Professor of Radiobiology, Imperial College London.  
The main reason is that the CT planning was performed for these treatments at different 
times in different treatment positions. The anatomical position of all structures including 
bowel would be different in the two scans, and this would not be reflected in the DVH data, 
where an area of high dose on one scan may not be representative on the second scan.  
In view of this a pragmatic decision was made to assess the addition of brachytherapy 
statistically as one of the treatment related co-factors, and if found to be associated with 
increased toxicity to take this into account on multivariate analysis. 
  
EQD2 = n*d*(d+α/β) / (2+α/β) 
(n=no of fractions, d=dose per fraction, α/β = alpha beta ratio) 
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3.3.7.  Data analysis 
Statistical analyses were all performed on SPSS 20 in a number of stages as illustrated in 
the diagram below (figure 3.3-1). All analyses were performed on the 12 month toxicity 
data, with the 24 month data only being used for re-exploration of the constraints derived. 
Lajos Katona (LK) and Catharine Porter (CP) at Wales Cancer Trials Unit (WCTU) 
provided statistical advice for the regression analysis and derivation of constraints.  
 
 
Figure 3.3-1: Schematic diagram of data analysis 
Toxicity data analysis 
For the 5 toxicity endpoints (faecal urgency, faecal incontinence, diarrhoea, bleeding and 
overall score) the proportions of each patient with the specific toxicity was assessed.  
Each endpoint was recorded as:  
1) Absent or present (grade 0 vs grade 1-4)  
2) Low grade or high grade (grade 0-2 vs grade 3-4) 
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Statistical analyses were all performed on SPSS 20 in a number of stages as illustrated in 
the diagram below (figure 3.1). All analyses were performed on the 12 month toxicity data, 
with the 24 month data only being used for re-exploration of the constraints derived. Lajos 
Katona (LK) and Catharine Porter (CP) at Wales Cancer Trials Unit (WCTU) provided 
statistical advice for the regression analysis and derivation of constraints.  
Figure 3.1: Schematic diagram of data analysis 
3.3.7.1. Toxicity data analysis 
For the 5 toxicity endpoints (faecal urgency, faecal incontinence, diarrhoea, bleeding and 
overall score) the proportions of each patient with the specific toxicity was assessed.  
Each endpoint was recorded as:  
1) Absent or present (grade 0 vs grade 1-4)  
2) Low grade or high grade (grade 0-2 vs grade 3-4) 
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Association between the recorded patient- and treatment-related factors and each toxicity 
endpoint was assessed with Chi-squared analysis (p<0.05 was considered statistically 
significant). 
Univariate and Multivariate analysis 
Binary logistic regression was used to determine the predictive value of the dose-volume 
parameters for the toxicity endpoints. 
Initially a simple ‘enter’ univariate (UVA) logistic regression was used between each dose-
volume parameter and each toxicity endpoint. A p-value of <0.2 was considered as 
significant at this stage in order not to exclude clinically significant parameters based on 
overly stringent statistical testing. 
For those parameters that were positive on UVA, a multivariate analysis (MVA) was 
performed. Patient and treatment-related co-variates that were statistically associated on 
Chi-squared analysis or considered to be clinically related to late toxicity were included in 
the multivariate model.  
For MVA, a backward-stepwise regression analysis was used (180-182). This automated 
method eliminates variables from the model to include only those that are significant. This 
approach also takes into account multiple hypothesis testing (avoiding the need for 
approaches such as Bonferroni corrections). Significance level for MVA was p<0.05. The 
odds ratio (OR) and confidence interval (CI) for each positive parameter was noted. 
Dose constraint derivation and goodness-of- fit analysis 
Constraints were derived from each dose-volume parameter that was positive on MVA. 
For each dose-volume parameter the predictive probability from the logistic regression was 
obtained from SPSS. This was plotted against the volume of the OAR in question.  
An example is illustrated in figure 3.2, where the OAR volume is on the x-axis and 
predicted probability on the y-axis. At different values of predicted probability constraints 
were determined from the x-axis. For example for a predicted probability of 0.2, the 
suggested constraint is 46cc, and for 0.5 the constraint is 200cc.  
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Figure 3.3-2: Logistic Regression cut-offs 
 
Toxicity rates above and below each constraint were assessed. If the toxicity rates above 
and below the constraint were significantly different (as determined by Pearson’s chi-
squared testing, p<0.05) these were classed as having a “good fit” to the data and were 
included (183) for further assessment.  
Assessment of each constraint: clinical value, accuracy, discriminator testing, and 
re-exploration with 24 month data 
Clinical value 
For each constraint the rate of toxicity above and below the constraint was assessed. If the 
toxicity rate below the constraint was >25% the constraint was disregarded.  
Accuracy testing: sensitivity and specificity 
For the remaining constraints sensitivity and specificity was calculated. Sensitivity is 
defined as the proportion of individuals with the toxicity endpoint who are correctly 
identified as having dose-volume parameters above the constraint. Specificity is defined as 
the proportion of individuals without the toxicity endpoint who are correctly identified as 
having dose-volume parameters below the constraint.  
Discriminator testing: Receiver Operative Characteristic (ROC) analysis 
ROC analysis was performed to determine how well each constraint discriminates those 
with and without toxicity. The ‘Area under curve’ (AUC) statistic from ROC analysis tests 
discriminatory ability, with a value of 1 suggesting perfect discrimination and 0.5 
suggesting discrimination no better than chance. 
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Re-exploration with 24 month results 
Constraints derived using 12 month toxicity data were “re-explored” on the toxicity data 
collected at 24 months with the same “goodness of fit” method as in 3.3.7.3. 
 
3.3.8.  Corroboration of constraints from within the literature  
Toxicity data from the 12 month time point was used to evaluate dose-volume constraints 
for late bowel toxicity from the literature. This included the acute bowel toxicity constraints 
from QUANTEC, and other constraints from the literature found in the systematic review 
(chapter II of this thesis). These are detailed in table 3.3-3.  
Each dose-volume constraint was converted using the EQD2 formula, and the dose level 
nearest to the EQD2 was used. Toxicity rates in patients above and below each 
constraints were assessed, and differences assessed for statistical significance using 
Pearson’s chi squared testing, p<0.05.  
 
Table 3.3-3: Dose-volume constraints from the literature 
Study/Guideline OAR  Constraints 
QUANTEC (Roeske et 
al(56)) (acute toxicity)  
Peritoneal Cavity V45<195cc 
Guerrero-urbano et al 
(112) 
Bowel loops V40<124cc; V45<71cc; V60<0.5cc 
McDonald et al (149) Bowel loops V30<178cc; V35<163cc; V40<151cc; 
V45<139cc 
  V50<127cc; V55<115cc; V60<98cc 
V65<40cc 
QUANTEC (Baglan et al 
(162)) (acute toxicity)  
Small bowel V15<120cc 
Chopra et al (139) Small bowel V15<275cc; V30<190cc; V40<150cc 
Isohashi et al (145) Small bowel V40<340cc 
Fonteyne et al (143) Sigmoid V40<10%; V30<16% 
Chopra et al (139) Large bowel V15<250cc; V30<100cc; V40<90cc 
Multiple studies (136-
138, 155, 184) 
Anal canal Dmean<40Gy 
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3.4. Results 
3.4.1. Questionnaires sent and returned 
Initially 364 patients were identified, including 48 cervical, 67 endometrial, 195 prostate 
and 54 bladder cancer patients. After exclusions (see table 3.4-1) questionnaires were 
sent to 306 patients. The response rates were 74% at 12 months, and 69.5% at 24 
months. 
 
Table 3.4-1: Patient inclusions and exclusions 
 
3.4.2. Patient, disease and treatment characteristics 
Patient, disease and treatment characteristics from the 12 month time-point are 
summarised in table 3.4-2. A median age of 70 years (range 35-92) was found, with a 
male predominance (70%). Disease stage was difficult to compare overall as urological 
  All 
Patients 
Cervical Endomet-
rial 
Prostate Bladder 
Patients 
identified 
 364 48 67 195 54 
Patients 
Excluded at 12 
months 
Died 39 (11%) 6 
(12.5%) 
9 (13%) 4 (2%) 20 (37%) 
Local recurrence 8 (2%) 1 (2%) 4 (6%) 1 (0.5%) 2 (4%) 
Distant 
recurrence 
7 (2%) 0 1 (1.5%) 2 (1%) 4 (7.4%) 
Other 4 (1%) 1 (2%) 2 (3%) 0 1 (2%) 
Questionnaires 
Sent 
 306 
(84%) 
40 (83%) 51 (76%) 188 (96%) 27 (50%) 
Questionnaires 
Returned 
 226 
(74%) 
18 (45%) 39 (77%) 149 (79%) 20 (74%) 
Questionnaires 
excluded from 
analysis 
Prostate only (no 
pelvis) 
19 0 0 19 0 
Symptoms 
predate RT 
1 0 1 0 0 
Other  3 0 0 2 1 
Total no. 
Included in 12 
month analysis 
(%) 
 203 18  
(8.9%) 
38  
(18.7%) 
128  
(63%) 
19 
(9.4%) 
Excluded at 24 
months 
Died 2 (1%) 0 0 1 1 
Local recurrence 3 (1.5%) 0 1 2 0 
Distant 
recurrence 
6 (3%) 0 0 4 2 
Unwell (non-
cancer related) 
3 (1.5%) 0 0 2 1 
2yr point after 
collection ended 
38 
(18.7%) 
3 9 21 5 
Questionnaires 
sent 
 151 15 28 98 10 
No of 
questionnaires 
included in 24 
month analysis 
(%) 
 105 7  
(6.7%) 
18  
(17.1%) 
73  
(69.5%) 
7  
(6.7%) 
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cancers were staged with Tumour, Node, Metastases (TNM) staging, and gynaecological 
cancers with FIGO staging. 
Conformal radiotherapy was used for most (73%), with IMRT/VMAT treatments being used 
27% of the time, reflective of the phasing-in of IMRT within our department.  
 
Table 3.4-2: Patient, Treatment and Disease Characteristics 
 
 
  All patients Cervical Endometrial Prostate Bladder 
 Number  203 18 38 128 19 
Patient characterstics 
Age  
 
Median  70 66.5 68.5 71 76 
Range 35-92 35-92 43-82 54-87 60-87 
Gender 
 
Male 143 (70%) n/a n/a  128(100%) 15 (79%) 
Female 60 (30%) 18 (100%) 38 (100%) n/a 4 (21%) 
Stage 
T-
Category 
T1    2 (1.5%) 0  
T2    26 (20%) 7 (37%) 
T3    92 (72%) 11 (58%) 
T4    6 (5%) 0 
Recurrence    1 (0.8%) 0 
Unknown    1 (0.8%) 0 
Small cell    0 1 (5%)  
N-
Category 
N0    82 (63%) 15 (79%) 
N1    46 (35%) 1 (5%) 
N2    n/a 2 (10.5%) 
FIGO 
stage 
I  3 (17%) 17 (45%)   
II  9 (50%) 7 (18.4%)   
III  3 (17%) 14 (37%)   
IV  2 (11%) 0   
Recurrence  1 (5.5%) 0   
Treatment characteristics 
Treatment 
intent 
Radical 156 (77%) 15 (83%) 0 122 (94%) 19 (100%) 
Adjuvant 47 (23%) 3 (17%) 38 (100%) 6 (5%) 0 
Treatment 
type 
3D-Conformal 149 (73%) 15 (83%) 30 (79%)   
IMRT/VMAT 56 (27%) 3 (17%) 8 (21.5%)   
Concurre
nt 
chemothe
rapy 
Used 23 (11.3%) 13 (72%) 3 (8%) 0 12 (63%) 
Agents  Cisplatin 
(n=11),Carbo
platin (n=2) 
Cisplatin 
(n=3) 
n/a MMC/5FU 
(n=6) 
Cisplatin 
(n=1) 
Brachythe
rapy 
Used 49 (24.1%) 17 (9%) 32 (84%) 0 n/a 
Doses  21.3Gy/3# 
(n=15); 
15Gy/5# (n=2) 
15Gy/5# n/a n/a 
Hormone
s 
Neoadjuvant 127 (63%) n/a n/a 127 (98%) n/a 
Adjuvant 116 (57%) n/a n/a 116 (89%) n/a 
Fraction 
Size (Gy) 
1.8 29 (14%) 18 (100%) 11 (29%) 0 0 
2 83 (41%) 0 27 (71%) 56 (44%) 0 
2.75 30 (15%) 0 0 11 (8.6%) 19 (100%) 
3 61 (30%) 0 0 61 (48%) 0 
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Radiotherapy doses 
15 dose fractionations schedules were used (figure 3.4-1), the most common being 
60Gy/20# and 74Gy/37# (prostate cancer); 45Gy/25# (cervical and high-risk endometrial 
cancer), and 40Gy/20# (endometrial cancer). 
 
Figure 3.4-1: Common dose fractionations 
The dose to the pelvis/nodes varied between 31Gy and 63Gy (in 2Gy fractions), with the 
most common dose ranges being between 40-44Gy (65% of patients), and 45-50Gy (19% 
of patients). 13 patients had a boost to positive nodes ranging from 53.2Gy to 60.3Gy.  
3.4.3. Data analysis 
12 month toxicity data 
Toxicity data for the five endpoints are shown in table 3.4-3. 79.5% of patients reported 
some degree of toxicity at 12 months. There was a high proportion of high-grade toxicity 
(43.4%), and this appeared to reflect the rate of high-grade faecal urgency, which was 
present in 41.3% of patients.  
 
Table 3.4-3: 12 month toxicity data 
 Diarrhoea Faecal 
Urgency 
Faecal 
Incontinence 
Bleeding Overall 
toxicity 
Question 
answered 
196(97%) 197(97%) 177(87%) 201(99%) n/a 
Toxicity 
Present 
37(18.7%) 100(52.3%) 42(23.5%) 28(13.9%) 163(79.5%) 
High grade 
(3-4) 
3(1.5%) 82(41.3%) 6(3.3%) 1(0.5%) 89(43.4%) 
 
 
0% 
5% 
10% 
15% 
20% 
25% 
30% 
35% 
40/20 45/25 52.6/20 55/20 60/20 74/37 Other
Fr
eq
ue
nc
y	(
%
)
Dose	(Gy)/Fractions
Most	Common	Total	Dose	Fractionations	
91 
 
 
 
Details of specific grades for each endpoint are illustrated below in figure 3.4-2: 
 
Figure 3.4-2: Toxicity Grades 
 
Similar patterns of overall toxicity grade were seen regardless of diagnosis (figure 3.4-3): 
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Figure 3.4-3: Overall toxicity grades by diagnosis 
24 month data 
At 24 months 79% reported late toxicity, similar to at 12 months, with the proportion of high 
grade toxicity being 37%. All 4 symptoms showed a trend towards decreasing from 12 
months to 24 months (see figure 3.4-4), though this difference was not statistically 
significant.  
Compared with at 12 months 51% reported the same overall score, 22% a higher score 
and 28% lower score than at 12 months. 
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Figure 3.4-4: Toxicity at 12 and 24 months post-radiotherapy 
 
3.4.4. Associations with patient- and treatment-related factors 
On chi-squared analysis of patient- and treatment-related factors no associations were 
found for urgency, bleeding and overall score. For diarrhoea and incontinence the 
statistically significant results (in bold) are shown in table 3.4-4.  
Table 3.4-4: Chi-squared associations with diarrhoea and incontinence 
Presence of  Diarrhoea Incontinence Comments 
Age 
(<70 vs >70) 
15.0 
(p=0.00) 
8.025 
(p=0.005) 
30.1% of younger patients reported diarrhoea 
compared with 8.6% of older patients. 
33.3% of younger patients reported incontinence 
compared with 15.3% of older patients 
Gender 
(F vs M) 
3.93 
(p=0.047) 
1.19 
(p=0.28) 
27.1% of female patients reported diarrhea 
compared with 15.1% of male patients. 
RT Type 
(conformal vs 
IMRT) 
0.13 
(p=0.91) 
4.29 
(p=0.04) 
 
 
34% of patients treated with IMRT or VMAT 
reported incontinence compared with 19% of 
patients treated with conformal radiotherapy 
3.4.5. Univariate and multivariate analysis 
On UVA 116 dose-volume parameters were related to toxicity (p<0.2). MVA was 
performed on these with co-variates of age, gender, RT type, fraction size and diagnosis.  
On MVA bowel bag, bowel loops, sigmoid, large bowel and rectum had dose-volume 
parameters that were predictive of toxicity (p<0.05). These are shown in Table 3.4-5. 
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Table 3.4-5: Multivariate Analysis 
BOWEL BAG Univariate analysis Multivariate analysis 
Parameter Predictive of p value OR CI p value OR CI 
V5 Diarrhoea present 0.083 1 1-1.001 0.027 1.001 1-1.002 
BOWEL LOOPS   
V45 Urgency present 0.043 1.008 1-1.015 0.027 1.009 1.001-
1.02 
Total 
Volume 
0.055 1.001 1-1.001 0.014 1.002 1.00-
1.003 
V50 Diarrhoea present 0.089 1.011 0.99-
1.03 
0.004 1.067 1.021-
1.12 
V45 Overall 
Score 
high grade 0.124 1.004 0.99-
1.01 
0.047 1.006 1-1.013 
SIGMOID (cc)        
Dmedian Urgency 
present 0.111 1.02 
0.996-
1.04 0.02 1.031 
1.005-
1.058 
V35 Incontin-
ence present 0.048 1.009 1-1.018 
0.049 1.011 1-1.021 
SIGMOID (%)        
V10 Urgency 
high grade 0.06 1.015 
0.999-
1.03 0.016 1.022 
1.004-
1.04 
V15 Urgency 
high grade 0.048 1.015 1-1.03 0.012 1.022 
1.005-
1.04 
V20 Urgency 
high grade 0.074 1.012 
0.999-
1.03 0.019 1.019 
1.003-
1.035 
V25 Urgency 
high grade 0.082 1.011 
0.999-
1.02 0.02 1.017 
1.003-
1.031 
V15 Overall 
score  high grade 0.095 1.012 
0.998-
1.03 0.018 1.019 
1.003-
1.035 
LARGE BOWEL        
Dmedian Urgency  high grade 0.016 1.027 1.005-
1.05 
0.002 1.019 1.016-
1.07 
V15 Diarrhoea present 0.118 1.003 0.99-
1.006 
0.049 1.004 1.00-
1.008 
Dmedian Overall 
score 
high grade 0.097 1.018 0.997-
1.04 
0.01 1.033 1.008-
1.059 
RECTUM         
V70 Overall 
score 
present 0.078 1.202 0.98-
1.48 
0.026 1.301 1.032-
1.64 
 
Small bowel, colon and anal canal had no positive predictors.  For bowel loops V45 and 
total volume were predictive of faecal urgency, and V50 was of diarrhoea.  
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Figure 3.4-5 illustrates three of the dose-volume relationships found, comparing the mean 
DVH for all patients with toxicity (red line) and the mean DVH for all patients without 
toxicity (blue line). The top figure shows the dose-volume relationship for bowel loops with 
the presence of faecal urgency. At all dose levels those with urgency had a larger volume 
of bowel loops irradiated, though this was only significant on MVA at the V45 level. 
The sigmoid had the most number of positive parameters. On MVA V10-V25 were 
predictors for high grade faecal urgency (illustrated in figure 3.7 middle figure), Dmedian 
for the presence of urgency, and V35 for faecal incontinence. 
For large bowel Dmedian large bowel was predictive for both high grade faecal urgency, 
and overall high grade toxicity. V15 large bowel was also positive for the presence of 
diarrhoea. The relationship of large bowel with diarrhoea is illustrated below (figure 3.7 
bottom figure), with V15 being the only level statistically significant on MVA.  
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Figure 3.4-5 Dose-volume Relationships   
 
19 
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3.4.6. Dose-volume constraints 
Twenty seven dose-volume constraints for the dose-volume parameters positive on MVA 
were derived, with the toxicity rates above and below the chosen cut-offs and the 
associated goodness of fit chi-squared results shown in table 3.4-6.  
Table 3.4-6: Dose-volume Constraints 
 
3.4.7. Assessment of constraints 
Clinical Value 
Though being statistically significant many of the constraints would not be valuable in 
clinical practice, as the rate of toxicity below the constraint were too high. All constraints 
below which toxicity was higher than 25% were removed from further analysis (n=18).    
OAR Para-
meter 
Toxicity endpoint Cut-
off 
Value Toxicity 
above 
value 
Toxicity 
below 
value 
Chi-
square
d 
p-
value 
Bowel 
bag 
V5 Diarrhoea Present 0.2 1689cc 27.9% 14.8% 4.67 0.03 
Bowel 
Loops 
V45 Urgency Present 0.6 85.1cc 87% 47% 8.61 0.003 
0.65 122.5cc 90% 48% 6.66 0.01 
0.7 148 cc 100% 48.4% 7.19 0.007 
Total 
volume 
Urgency Present 0.5 665 cc 60% 43.5% 5.07 0.024 
0.6 1229cc 87% 47% 8.611 0.003 
V50 Diarrhoea Present 0.35 80.97cc 50% 17.9% 3.92 0.048 
V45 Overall 
score 
High 
grade 
0.55 127.3cc 85.7% 41.5% 5.38 0.02 
0.65 224.1cc 100% 42.2% 4.03 0.045 
Large 
bowel 
V15 Diarrhoea Present 0.2 154.1cc 30.8% 14.6% 6.536 0.011 
0.3 60.8cc 44.4% 17.6% 4.026 0.045 
Dmedia
n 
Urgency High 
grade 
0.4 15.9Gy 48% 33.7% 4.46 0.035 
0.39 13.4Gy 50% 30.8% 7.48 0.006 
0.38 12.1Gy 49.1% 31.0% 6.54 0.011 
0.35 7.86Gy 46.2% 31.3% 4.006 0.045 
 Dmedia
n 
Overall 
score 
High 
grade 
0.42 
 
13.4Gy 
 
50 
 
35.8% 
 
4.16 0.041 
Sigmoid 
(cc) 
Dmedia
n 
 
Urgency Present 0.4 10.8Gy 52.8% 26.3% 4.82 0.028 
0.41 13.8Gy 53.7% 22.7% 7.506 0.006 
0.43 17.7Gy 53.8% 25% 6.97 0.008 
 V35 Incontinence  Present 0.25 
 
69.7Gy 
 
34% 
 
19.4% 
 
4.378 0.036 
Sigmoid  
(%) 
V10 Urgency High 
grade 
0.3 52.6% 43.8% 19.0% 4.73 0.03 
V15 Urgency High 
grade 
0.3 47.5% 44% 18.2% 5.38 0.02 
V20 Urgency High 
grade 
0.35 55.7% 44.4% 25.7% 4.17 0.041 
V25 Urgency High 
grade 
0.33 36.2% 43.9% 23.1% 4.026 0.045 
V15 Overall 
score 
High 
grade 
0.35 51.9% 46.1% 24% 4.35 0.037 
Rectum 
(cc) 
V70 Overall 
score 
Present 0.8 1.5cc 86.3% 75.4% 3.395 0.065 
0.86 3.56cc 93.9% 76.5% 5.14 0.023 
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Accuracy, Discrimination and Re-exploration at 24 months  
The remaining nine constraints were assessed further as in table 3.4-7   
Table 3.4-7: Sensitivity, specificity, ROC-data and Re-exploration with 24 month data 
Parameter Toxicity 
endpoint 
Cut-off Sensi
-tivity  
Specif
icity 
ROC data Re-exploration with 24 
month data 
  AUC p-
value 
Tox 
above  
Tox 
below  
Chi-
sq 
p-
value 
Bowel 
bag 
V5 Diarrhoea 1689cc 46% 72% 0.6 0.06 25.8% 9.1% 4.8 0.029 
Bowel 
Loops 
V50 Diarrhoea 81cc 8% 98% 0.5 0.996 0% 14.6% 0.17 0.68 
Large 
bowel 
V15 Diarrhoea 154.1cc 43% 77% 0.60
2 
0.05 24% 11% 2.5 0.114 
60.8cc 11% 97% 17.7% 6.9% 1.9 0.168 
Sigm-
oid 
(cc) 
Dme
dian 
Urgency 13.8Gy 95% 17% 0.56 0.215 46.3% 22.2% 1.94 0.164 
17.7Gy 94% 18% 46.8% 20% 2.63 0.105 
V35 Incontine
nce 
69.7cc 43% 74% 0.61 0.035 28% 19.7% 0.73 0.393 
Sigm-
oid 
(%) 
V10 High 
grade 
urgency 
52.6% 95% 15% 0.57 0.099 30.9% 14.3% 0.86 0.353 
V15 High 
grade 
urgency 
47.5% 95% 16% 0.57 0.1 31.3% 12.5% 1.24 0.265 
V25 High 
grade 
urgency 
36.2% 93% 17% 0.57 0.112 31.6% 11.1% 1.65 0.199 
V15 High 
grade  
Overall 
score 
51.9% 93% 17% 0.56 0.161 39.2% 12.5% 2.25 0.133 
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At 24 months 8 out of the 9 constraints dichotomised patients such that a higher toxicity 
rate was found above the constraint and a lower toxicity rate was found below the 
constraint. Of all the constraints, that for bowel bag V5 constraint statistically significantly 
dichotomised patients at 24 months.  
The sigmoid constraints largely had high sensitivities, whereas the V15 large bowel and 
V50 bowel loops had a high specificity. ROC-analysis did not reveal any of the parameters 
to have high discriminatory value, though out of them all large bowel V15 and sigmoid V35 
showed relative promise. 
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3.4.8. Corroboration of constraints from within the literature 
Table 3.4-8 shows the corroboration of constraints from the literature to data from the 
current study. Constraints from 2 of the studies (highlighted in bold) were corroborated by 
the data from patients in this study, both in relation to bowel loops, and significantly 
dichotomised patients with and without toxicity. Applying the other constraints to the 
current study data did not show any corroboration, for example with the QUANTEC 
constraint V45<195cc the rates of toxicity above and below the constraint were 50.6% 
above and 50% below for urgency; 24.5% above and 22.7% below for incontinence; 
14.8% above and 21.7% below for diarrhoea and 13.6% above and 13.6% below for 
bleeding. 
Table 3.4-8: Corroboration of constraints from literature 
Study/Guideline OAR  Constraint EQD2 
equiv 
Corroboration to 
current study data 
p-
value 
QUANTEC acute 
(Roeske (56)) 
Peritoneal 
Cavity 
V45<195cc V43.2 None found  
Guerrero-urbano 
(112)  
Bowel loops V40<124 V33.1 Faecal Incontinence: 
34.2% to 15.2% 
0.003 
  V45<71 V38.6 Faecal urgency: 59.4 to 
41.9% 
Faecal incontinence: 
32.6% to 14.6% 
Diarrhoea: 24.5% to 
13.2% 
0.015 
0.006 
 
0.046 
  V60<0.5 V56.6 None found  
McDonald (149) Bowel loops V30<178cc V23.6 None found  
  V35<163cc V28.6 None found  
  V40<151cc V34 None found  
  V45<139cc V39.66 None found  
  V50<127cc V45.6 Faecal urgency: 100% 
to 48.4% 
Overall toxicity: 85.7% 
to 41.5% 
0.014 
 
0.04 
  V55<115cc V51.9  None found  
  V60<98cc V58.5 None found  
  V65<40cc V65.4 None found  
QUANTEC acute 
(Baglan (162)) 
Small bowel V15<120cc V10.8 None found  
Chopra (139) Small bowel V15<275cc V10.8 None found  
  V30<190cc V25.2 None found  
  V40<150cc V36.8 None found  
Isohashi (145) Small bowel V40<340cc V36.8 None found  
    None found  
Fonteyne(143) Sigmoid V40<10% V32.7 None found  
  V30<16% V22.9 None found  
Chopra (139) Large bowel V15<250cc V10.8 None found  
  V30<100cc V25.2 None found  
  V40<90cc V36.8 None found  
Multiple studies 
(136-138, 155, 
184) 
Anal canal Dmean<40Gy  All patients under this 
constraint, so could not 
be applied 
 
101 
3.5. Discussion  
This section of this thesis assessed patient-reported late bowel toxicity in 203 patients 12 
months after pelvic radiotherapy. 79.5% of patients reported late bowel toxicity, with 43.4% 
reporting high-grade toxicity. Late bowel toxicity was predicted by dose-volume 
parameters to bowel bag, bowel loops, sigmoid and large bowel. Statistically significant 
dose-volume constraints were derived for these four OARs.   
3.5.1. Toxicity Data 
The most frequently reported symptom was faecal urgency, with 41% of patients reporting 
either this as grade 3 (“daily”) or grade 4 (“constantly”). This finding was in concordance 
with published literature, with faecal urgency rates of 45.1% reported in men and 58.7% in 
women after pelvic radiotherapy (45). In this study faecal incontinence was also seen 
commonly, reported by 23%.  Again this had similarity to published patient-reported 
studies where rates of 15-24% (42, 45) are seen.   
Age was found to be an important confounding factor in this chapter, with a lower age 
being associated with higher rates of diarrhoea and incontinence. On regression analysis 
for example being below or above 63 years of age was associated with diarrhoea rates of 
41% compared with 19% above. One explanation for this may be that clinicians may treat 
younger patients with comparatively larger treatment volumes and/or increased doses 
relative to older patients, though further analysis would be needed to confirm this 
hypothesis.  
Assessment of treatment-related factors found that the use of IMRT techniques was 
associated with increased faecal incontinence, not only on initial Chi-squared testing, but 
also on univariate and multivariate analysis. This pattern was seen both in prostate and 
gynaecological cancer patients. No clear dosimetric reason was found for this, and further 
ongoing assessment of late toxicity in IMRT treated patients is warranted. 
It has been suggested in the literature that concurrent chemotherapy may contribute to late 
bowel toxicity(33); however no increased late bowel toxicity was found in patients with the 
use of concurrent chemotherapy compared with those without.  
3.5.2. Dose-volume constraints 
In this section of the thesis, 9 statistically significant and potentially clinically useful dose-
volume constraints were derived for 4 OARS: bowel loops, bowel bag, sigmoid and large 
bowel.  
The importance of bowel loops as an OAR for late toxicity was confirmed with data from 
this work, corroborating findings from two published studies. In their study of prostate and 
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pelvic node patients Guerrero-Urbano et al (112) suggested constraints of V40<124cc and 
V45<71cc. Use of their V45 constraint on toxicity data from this study successfully 
dichotomised patients with and without toxicity for three symptoms. Toxicity rates above 
and below this constraint were 32.6% and 14.6% (p=0.006), 24.5% and 13.2% (p=0.046), 
and 59.4% and 41.9% (p=0.015) for incontinence, diarrhoea and urgency respectively.  
Their V40 constraint was applicable for incontinence seen in our study, toxicity above their 
constraint being 34.2% and below being 15.2 % (p=0.03). A further similarity was that we 
also found the total volume of bowel loops to be predictive of urgency, though the 
constraints derived in our study were not clinically applicable, as below the constraint the 
rate of toxicity was 43.5%.  
McDonald et al (149) suggested bowel loops constraints in bladder cancer patients. 
Although most of their constraints could not be corroborated by data in this study, their 
V50<127cc (EQD2=45Gy) was applicable to our data and significantly dichotomised 
patients with faecal urgency and overall toxicity. Again however the “split” of toxicity still 
would mean that patients below the constraint 48.4% would still have faecal urgency, and 
41.5% high grade overall toxicity which would not be considered clinically acceptable. 
 
For bowel loops, the constraint derived within this study with some potential for clinical use 
was V50<80.9cc, which dichotomises patients with diarrhoea from 50% to 17.9%. Though 
having a high specificity of 99%, caution must be applied given its extremely low 
specificity, and AUC value of 0.5 (no discriminatory ability). The constraint could not be 
verified with the 24 month data. On balance therefore, this constraint is not recommended 
to be of value. 
 
For bowel bag parameters, although a correlation is reported with late toxicity there are no 
published constraints in the literature. Mouttett-Aldouard et al (150) in their study of 
cervical cancer patients found correlation with late “whole digestive toxicity” and V10-V30 
of the bowel bag.  
In this chapter though V5-V35 bowel bag were correlated with toxicity on UVA, on MVA 
only very low dose, V5 was associated with diarrhoea. A constraint of V5<1689cc 
dichotomised patients between 28.9% and 14.8% (p=0.03). This parameter was weakly 
correlated on ROC analysis (AUC 0.6). At 24 months toxicity above and below this 
constraint was 25.8% and 9% (p=0.029) adding to its strength. This would therefore be a 
recommended constraint from this study, and is a novel finding.  
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Though doses as small as 5Gy may be deemed insignificant, this finding may hold 
importance with the increased use of IMRT techniques where a highly conformal dose 
distribution to the target is balanced by large areas of low dose bath.  
For acute bowel toxicity QUANTEC recommend a bowel bag constraint of V45<195cc. In 
the sample of patients in this study the constraint was not corroborated.  
 
Small bowel dose-volume parameters had no predictive value for late toxicity, and 
constraints could not be derived, which concurred with results of four other published 
studies (135, 142, 143, 153). Neither of the small bowel constraints from two studies 
(V15<275cc, V40<340cc) (139, 145) were substantiated in the patients in this study. The 
QUANTEC acute toxicity parameter of V15<120cc could not be corroborated with late 
toxicity in our study.  
 
The sigmoid colon was identified as a key OAR for late bowel toxicity. Seven parameters 
remained positive on MVA for sigmoid, predictive for faecal urgency, faecal incontinence 
and overall toxicity, and statistically significant constraints could be derived from these. 
High-grade faecal urgency, seen in 41.3% of patients in this study was predicted by V10-
V25 of sigmoid. For example the V10<52.6% sigmoid constraint dichotomised patients 
with faecal urgency from 43.8% to 19%, which would be an important clinical benefit. The 
V10-V25 constraints had high sensitivities (89-95%), and validation was seen with 24 
month data, where toxicity was dichotomised from 30.9-31.9% to 11.4-15.4%, which 
despite not being statistically significant differences would be clinically desirable.  
Sigmoid Dmedian was also predictive of faecal urgency, with a constraint of 
Dmedian<13.8Gy dichotomising patients from 53.7% above the constraint to 22.7% below, 
with a high sensitivity of 95% and some concordance seen with 24 month data also.  
The sigmoid as a late toxicity OAR has been mentioned by Mouttet-Aldouard et al in 
cervical cancer patients and Fonteyne et al in prostate cancer patients (185).  Fonteyne et 
al suggest sigmoid constraints of V40<10% and V30<16%, though these constraints could 
not be corroborated with our data. Mouttet-Aldouard et al (150) also suggest that V10-V40 
of sigmoid were important for overall toxicity, showing some concordance with our 
findings, though no constraints were specified in their study.   
 
Large bowel V15 was predictive of diarrhoea on MVA, with ROC analysis showing a weak 
but statistically significant discriminatory ability. With a cut-off of 60.9cc rates of diarrhoea 
were dichotomised from 44.4% to 17.6% at 12 months, and 17.7% to 6.9% at 24 months. 
Specificity was 97% for this cut-off, and this may be a useful constraint clinically. Large 
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bowel V15 was also found to be significant in a study by Chopra et al (139), though their 
constraints were not substatiated in our study data, and this may be as their toxicity 
endpoint was grade 3 toxicity. 
 
For the rectum no additional constraints were derived in this study, and the majority of 
patients met the constraints recommended by QUANTEC (127)  and Gulliford et al.(133) . 
For the anal canal, 100% of patients met the suggested constraint from chapter II of this 
thesis, Dmean<40Gy. No additional constraints were derived.  
 
Therefore, from this work suggested constraints are: 
1. Bowel loops V38.6Gy<71cc for diarrhoea (any grade)  
2. Bowel bag V5Gy<1689cc for urgency, incontinence and diarrhoea (any grade) 
3.  Sigmoid V10Gy<52.6% for faecal urgency (high grade) 
4.   Sigmoid V25Gy<36.2% for faecal urgency (high grade) 
5.   Sigmoid Dmedian<13.7Gy for faecal urgency (any grade) 
6.   Large bowel V15Gy<60.8cc for diarrhoea (any grade) 
3.5.3. Strengths of Study 
This study had many strengths. The toxicity data was collected from an unselected group 
of non-trial patients, with the aim of assessing “real world” toxicity, and to examine dose 
parameters and constraints that can be widely applicable. The main analysis was 
performed on 203 patients, a sample size that was larger than most of the studies (19 of 
25) in the systematic review in chapter II. 
Patient-reported data, as opposed to clinician-reported data was used from a validated 
questionnaire with a good response rate (74%).(186) 
A symptom-based approach was largely adopted, as recommended by QUANTEC, 
focussing on those symptoms which are thought to affect quality of life, and important to 
improve for patients. Overall toxicity scores were also studied, though in this sample of 
patients the overall toxicity score was largely influenced by the score for faecal urgency, 
and added little to the study.  
Statistically, as many of the recommendations as possible of QUANTEC were followed, 
including stating the toxicity levels, goodness of fit statistics, discrimination and validation. 
Some findings from this study corroborated data from published literature suggesting the 
methods used were robust.  
Relatively novel findings were found highlighting the importance of less established OARs 
such as sigmoid, large bowel and bowel bag. Sigmoid dose parameters were particularly 
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associated with faecal urgency, a symptom recently highlighted as being important in the 
literature, with a case made for its inclusion in CTCAE (187).  
 
3.5.4. Limitations  
There were also limitations to this work. Time limitations on the study did not allow 
patient’s toxicity data to be collected at baseline, and the findings of this study are based 
on the presumption that the symptoms reported are toxicity, rather than being “normal” for 
an individual patient or due to other co-morbidity. An additional question to assess if 
patient’s symptoms are pre-existing was added to compensate for this, however this would 
be prone to recall bias and cannot completely be relied on.  
Previous bowel surgery (188) and the presence of inflammatory bowel disease (189) are 
important co-morbidities when considering late bowel toxicity. This data could not be 
collected retrospectively from the hospital records as it was not reliably recorded, and in 
hindsight should have been collected when the questionnaires were sent. 
 
The overall aim of this work in the context of this thesis is to derive constraints for use in 
gynaecological IMRT. The majority of patients included in this study were prostate cancer 
patients (given its higher incidence) and treated with conformal treatments rather than 
IMRT (given the time when the data was collected). On one hand this may not matter, as 
bowel constraints should be the same regardless of tumour diagnosis and type of 
radiotherapy planning. The influences of tumour diagnosis, brachytherapy, hormones and 
concurrent chemotherapy on toxicity were assessed statistically and had no apparent 
impact. On the other hand, gynaecological radiotherapy is different to prostate pelvic node 
radiotherapy in that treatment volumes can be as high as the bifurcation of the aorta, and 
therefore bowel volume is likely to be much higher. The inclusion of more gynaecological 
patients within the study may have given more conclusive results for dose-volume 
parameters of small bowel for example.     
For the OARs and dose-volume parameters studied there may be significant overlap, 
which may hinder the clarity of the results. For example sigmoid forms part of large bowel 
which forms part of bowel loops. Similarly with the use of cumulative dose-volume data, 
parameters V5, V10 etc will all have overlap. 
 
None of the constraints recommended had perfect attributes of high sensitivity, high 
specificity, and discriminatory value. Though some were highly specific others were highly 
sensitive and balance was not always achieved; although on review of the literature this is 
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not uncommon, and many authors do not report these statistics. Though an attempt to re-
explore and validate the constraints with 24 month data was made, these toxicity scores 
were not totally independent with 50% of patients having the same toxicity score at 24 
months that was found at 12 months. An independent data set to properly externally 
validate these findings would be important. 
 
Given the exploratory nature of the work done, a large number of dose-volume parameters 
from many OARs were tested for predicting toxicity. This would increase the risk of chance 
findings, and appropriate statistical testing was attempted to minimise this risk.  
The analyses performed in this thesis were regression analyses attempting to link dose 
parameters from the DVH to toxicity endpoints. DVH data does not take into account 
spatial information and thus this kind of analysis may have limitations. A superior method 
to analyse this data would be to use NTCP modelling, though this was beyond the scope 
of this current work due to time constraints. 
Finally, dose-volume data was taken from the “snapshot” planning CT scan. Pelvic organ 
motion is a known phenomenon not only for tumour sites but for OARs also. It is known 
that organs such as the rectum can move significantly during treatment and the dose to 
the rectum at the time of planning can be different to the accumulated dose on treatment 
(190). It is likely that other components of bowel also move significantly during the course 
of treatment, and toxicity may be better associated to the accumulated dose rather than 
the planning dose. This may be an important consideration for future work. 
3.6. Conclusions  
Patient-reported late bowel toxicity is a common occurrence, with faecal urgency being 
reported most frequently. Late bowel toxicity can be predicted by dose-volume parameters 
to bowel loops, bowel bag, sigmoid and large bowel. Constraints for these OARs to 
prophylactically reduce the toxicities studied are suggested in this study, for bowel loops 
confirming those within published literature, as well as novel constraints for bowel bag, 
sigmoid and large bowel. 
3.7. Future work 
The dose-volume constraints derived in this study will first need to be assessed to see if 
they are achievable practically when treatment planning for gynaecological patients, for 
example for many patients where the PTV encompasses the uterus for example lowering 
the dose to the sigmoid colon may be difficult to achieve without PTV compromise, or 
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increased dose to other OARs. If they can be achieved, external validation of these 
constraints with toxicity data from an independent sample of patients would be the next 
step. If validated these constraints can be used to model novel radiotherapeutic 
techniques to assess their likely benefit in limiting toxicity, and the true benefits of the 
constraints may be assessed in prospective study. 
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4. Chapter IV: A Systematic Review 
of Organ Motion and Image-guided 
Strategies in External Beam 
Radiotherapy for Cervical Cancer 
4.1. Introduction  
For cervical cancer survivors, toxicity from pelvic radiotherapy is a major problem, and 
IMRT is therefore desirable to reduce the risk of toxicity. The last 15 years have seen the 
emergence of IMRT techniques for cervical cancer and the evidence to support its use in 
definitive cervical cancer is summarized in chapter I. Planning studies comparing IMRT 
with conformal radiotherapy demonstrate reduced doses to bowel, rectum, bladder and 
bone marrow with IMRT (56, 83, 191). Arc therapies, such as volumetric arc therapy 
(VMAT) and RapidArc, improve OAR sparing further, with the added benefit of a shorter 
treatment delivery time (192). Clinical data suggest these dosimetric observations may 
translate to improved toxicity for patients, though clinical data are limited in terms of the 
quality of studies. Two prospective studies, one of which is randomised, suggest that IMRT 
can improve late GI toxicity (63, 64) over conformal radiotherapy.   
  
Despite this there has not been widespread uptake of IMRT for cervical cancer. One 
reason is the lack of clear dose-volume constraints to prevent late bowel toxicity, as 
discussed in the last two chapters of this thesis. Another major issue is the problem of 
organ motion and unclear guidance on its management. This issue is addressed in the 
work in this section of the thesis, with Chapters IV and V focusing on definitive cervical 
cancer and Chapter VI focusing on adjuvant radiotherapy for post-hysterectomy cervical 
and endometrial cancer. 
4.1.1. The problem of pelvic organ motion 
Pelvic organs are naturally prone to positional and volumetric changes over time. As a 
result the pelvic anatomy at the time of radiotherapy planning may differ from the pelvic 
anatomy during treatment. These individual organ changes may result in variations in CTV 
position and shape. 
When conventional ‘box’ radiotherapy techniques are used, the irradiated volume 
encompasses the whole pelvis from the sacral promontary to the obturator foramen. 
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Internal organ motion is thus less important because the CTV is more likely to remain 
within the irradiated volume.  
However with IMRT complex dose distributions are achieved with steep dose gradients 
around the target, meaning that organ motion needs to be considered to avoid 
geographical miss. The successful implementation of IMRT relies on accurate CTV 
delineation and selection of an appropriate margin around the CTV to form the PTV. The 
CTV-PTV margin has two components: the internal margin, which encompasses the 
internal target volume (ITV) and accounts for organ motion, and the set-up margin which 
accounts for patient set-up and delivery errors (193).  
In the case of definitive cervical cancer treatment, the CTV consists of cervix, uterus, 
upper vagina, parametrium, ovaries and pelvic lymph nodes. Each of these components 
may have their own organ motion pattern, and comprehension of these patterns is 
important. In close proximity to the CTV lies rectum, bladder and bowel which with their 
own positional and volumetric variation may influence the position of the CTV components. 
Knowledge also of the influences of adjacent organ filling is required to determine an 
appropriate ITV.  
 
Though consensus guidelines exist for delineation of CTV in definitive cervical cancer 
IMRT (95), there is a paucity of information on appropriate margins to be used. RTOG 
recommend a 1.5-2cm CTV-PTV margin, however no clear rationale for this is given. 
Margins should be evidenced based, ideally utilising data from individual treating 
institutions. They should be large enough to minimize geographical miss. However, if 
these margins are too large, they are likely to incorporate OARs within the PTV, and the 
clinical advantages of IMRT will be reduced (194).  
4.1.2. Image-guided radiotherapy  
Image-guided radiotherapy (IGRT) is the use of imaging initially to plan radiotherapy, and 
then to monitor, update and adjust the treatment process to improve its accuracy (115). 
IGRT is complementary to IMRT in achieving its goals to ensure target coverage and 
reduce OAR doses. It has many aspects, including patient set-up, patient preparation, 
margin use and on-treatment imaging. Patient set-up includes the patient’s position on 
treatment and the use of immobilisation devices to maintain patients in a consistent 
position for each treatment.  
Patient preparation involves the use of protocols to reduce internal organ motion, for 
example breathing techniques for lung cancer treatments, and the use of rectal enemas for 
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prostate cancer patients. There are no widely used preparation protocols in cervical 
cancer.     
On-treatment imaging or verification aims to ensure that the area treated is that as 
planned, reducing the risk of geographical miss. The type of imaging, frequency of imaging 
and choice of offline versus online protocols are important components of this. “Offline 
imaging” uses imaging before or after treatment to match to a reference image offline (ie 
without the patient on the couch). The aim of this is to correct ‘systematic errors’ which are 
reproducible errors occurring in the same direction and in a similar magnitude with each 
fraction of radiotherapy. “Online imaging” is acquired, checked and corrected prior to 
treatment with the aim of correcting both random and systematic errors. Random errors 
arise from changes in target position and shape between and during fractions of treatment. 
The type of matching is an additional consideration with bone-bone matching or soft tissue 
matching being potential options. 
A further concept is that of adaptive radiotherapy, whereby an individual’s organ motion, 
as determined by on-treatment imaging, is used to modify the treatment during its course. 
This has been studied in other pelvic tumour sites such as bladder cancer, and prostate 
cancer, though its use in cervical cancer is to be established.  
 
At a time when IMRT for cervical cancer is being adopted, the most reproducible and 
clinically practical IGRT methods must be determined.  
4.2. Aims  
To systematically review published studies to determine:  
- The patterns and extent of pelvic inter-fraction and intra-fraction organ motion in 
cervical cancer EBRT.  
- The correlation of these organ motion patterns with bladder and rectal filling  
- Appropriate image-guided solutions to manage pelvic organ motion in cervical 
radiotherapy   
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4.3. Methods 
4.3.1. Inclusion criteria 
The inclusion criteria were as follows: 
1. English language studies 
2. Human studies only 
3. Studies involving adults 
4. Studies with patients treated with external beam radiotherapy for cervical cancer 
5. Studies examining interfractional and intrafractional organ motion in cervical cancer 
radiotherapy 
6. Studies examining IGRT techniques in cervical cancer radiotherapy 
4.3.2. Exclusion criteria 
1. Review articles and letters 
2. Studies using brachytherapy only 
3. Studies with post-operative cervical and endometrial cancer rather than radical 
treatments 
4.3.3. Quality criteria 
With many of the studies around this subject being observational, Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (195) could not be 
followed, as these guidelines are applicable to mainly interventional and randomized trials. 
In view of this three quality criteria were defined for inclusion of studies into this review: 
a. Was the spectrum of patients included representative of those in clinical 
practice?  
b. Were the methods described in sufficient detail to permit replication of the study 
at a different institution?  
c. Were the outcomes measured appropriate to the aims of the study?  
Studies not meeting all three criteria were excluded from the review. 
4.3.4. Information sources and search strategy 
Searches were performed using Medline, preMedline, Embase, Cochrane Library, Web of 
Science and CINAHL, no date or language restrictions were applied. Update searches 
were performed in February 2013, and November 2015 and included an additional 
Pubmed search for e-publications ahead of print. The search strategy is in Appendix D. 
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All searches were performed by Ms Anne Cleves, Assistant manager, Cancer Research 
Wales Library, Cardiff. Peer-reviewed papers and conference abstracts were sought. 
Database appropriate strategies were developed around terms for Uterine Neoplasms, 
Image guided Radiotherapy, Organ motion and target volume using controlled vocabulary 
and text word terms.  
4.3.5. Study Selection 
Two reviewers (myself and Dr Catharine Pembroke, specialist registrar) independently 
screened the abstracts for inclusion in the review. For abstracts meeting the eligibility, full 
papers were acquired and assessed further for suitability against the eligibility criteria. 
Consensus between the two reviewers was gained for studies to be included. 
The reference lists of all included papers were hand-searched for any additional relevant 
references.  
4.3.6. Data Extraction and synthesis of results 
Data was extracted from each of the included papers and collected on Microsoft Excel. 
Included studies were subdivided by subject into the following categories: interfraction 
motion (cervix, uterus, lymph nodes, CTV motion); intrafraction motion; correlation with 
bladder and rectal filling; patient positioning and preparation; margins for organ motion; on-
treatment imaging modality and marker use; online and offline strategy; adaptive 
strategies. 
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4.4. Results  
Outcomes of the systematic search are illustrated in Figure 4.4-1.  
	
 
Figure 4.4-1: Results of systematic Search 
 
Overall, 53 relevant studies were used for analysis including 16 conference abstracts. 22 
studies were prospective studies, though the majority was retrospective analyses of 
previously acquired imaging. Aspects covered by the studies overlapped, as detailed in 
Table 4.4-1. 
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Figure 1: Systematic Search Outcomes 
 
Overall, 53 r levant studi s were used for analysis including 16 confer nce abstracts. 22 
studies were prospective studies, though the majority was retrospective analyses of 
previously acquired imaging. Aspects covered by the studies overlapped, as detailed in 
Table 4.4-1. 
1352	records	identified	through	
database	searching	
909	records	screened	
787	records	excluded	
122	full	text	articles	assessed	for	
eligibility	
69	excluded:		
post-op:	n=12	
abstracts	of	papers	
included	n=10	
reviews	n=2	
not	meeting	eligibility	n=45	
443	duplicates	
removed	
53	included	in	review:	37	papers,	
16	abstracts	
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Table 4.4-1: Summary of included studies 
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Adli (196) 2003 P 16 P     X    Assessment of prone positioning on small bowel dosimetry  
Ahmad(197) 2008 P 24 R   X      Studies bladder volumes variation using bladder ultrasound 
Ahmad (111) 2011 P 13 R X  X      Relation of bladder filling to cervix/uterine motion 
Ahmad (198) 2013 P 14 R        X Margin-of-the day modeling study   
Beadle (110) 2009 P 16 R X  X      Cervical motion, and in relation to bladder filling 
Bhaumik (199) 2014 A 20 P     X    Comparing small bowel coverage in prone and supine position 
Bhuva (200) 2015 A 11 R     X    Use of ITV formed by CTVs on full bladder & empty bladder scans  
Bloemers (201) 2010 A 16 R X  X   X   Coverage of uterine CTV in relation to bladder filling 
Bondar (202) 2011 P 13 R   X      Predictive models for cervix-uterine motion based on bladder filling 
Bondar(123) 2012 P 14 R        X Adaptive strategies for cervical cancer 
Bondar(203) 2014 P 13 R X  X      Motion of iliac vessels (nodal volume)  
Buchali (204) 1999 P 29 R X  X X     Uterine movement in relation to bladder & rectal filling 
Chan (108) 2008 P 20 R X X X X  X   Inter- and intra-fraction motion using MRI  
Collen (109) 2009 P 10 R X X X   X   Inter- and intrafraction motion study with CT  
De Pree (205) 2007 A 9 P X  X    X  Cervical motion measured using marker   
Georg (206) 2006 P 20 R   X      Association of bladder volume with small and large bowel sparing  
Gordon (207) 2011 P 10 R      X   Use of tapered margins with larger uterine and smaller cervix margin  
Haripotepornkul 
(105) 2011 P 10 R X X       
Inter- and intra-fraction cervical motion using KV imaging 
Heijkoop(124) 2014 P 64 P        X Clinical implementation of Plan of the Day  
Heijkoop (208) 2015 A 16 R  X X X  X   Intrafractional motion of cervix-uterus measured on CBCT 
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Hoogeman (209) 2012 A 21 P        X Implementation of plan of the day strategy  
Huh (210) 2004 P 66 R X        Interfraction motion study of the uterus  highlighting rotational motion 
Huh (211) 2004 P 10 P     X    Assessment of small bowel displacement system (SBDS) 
Kaatee (212) 2002 P 10 R X      X  Interfraction motion of the cervix with KV imaging and markers 
Kager (213) 2014 A 6 P        X Clinical implementation of plan-of-the-day  
Kerkhof  (214) 2008 P 11 R        X 
Modelling of adaptive replanning with 4mm margin compared 
with standard 15mm margin 
Kerkhof (215) 2009 P 22 R  X X      
Intrafraction motion measured with MRI over 16 minutes and 
correlation with bladder filling 
 
Khan (216) 2012 P 50 R        X Optimised individualized PTV margin modeling study 
Langerak (217) 2015 P 50 P X     X X  Interfraction cervical motion using polymeric markers  
Latifi (218) 2013 A 14 P X     X X  Cervical margin determined with gold fiducial markers and MVCT  
Lee (106) 2004 P 17 R X     X   Uterine sleeve used to determine cervical motion and margins 
Lee (219) 2007 P 13 R     X    Study of uterine position on treatment with SBDS 
Lim (220) 2009 P 20 R      X   Modelling of different margins considering interfraction motion using MRI  
Lim (221) 2014 P 30 P        X Comparison of automated replanning due to anatomy change with replanning only when dosimetric reductions occur 
Mahantshetty 
(222) 2014 A 40 R X     X   
Inter-fraction motion of the CTV nodes and uterus-cervix 
complex using daily CBCT 
Malyapa (223) 2001 A 16 P      X   Uterine margins to account for motion  
Mayr (224) 2006 A 12 P  X       Intrafractional motion measured by dynamic MRI 
Mens (225) 2011 A 12 P X      X  Submucosal placement of polymeric markers used to measure cervical motion 
Oh (226) 2013 P 15 P       X X Compared the use of bony matching and soft tissue matching using on-treatment MRI  
Park (227) 2005 P 10 P     X    Study of SBDS displacement small bowel  
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Abbreviations: SBDS: small bowel displacement system; MVCT: megavoltage computed tomography; 4D-CT: 4-dimensional computed tomography
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Pinkawa (228) 2003 P 20 P     X    Compares supine and prone positioning in terms of rectum and bowel sparing 
Raj (229) 2005 A 10 P  X X   X   Intrafractional motion of the cervix and its relation to bladder filling  
Schippers (230) 2014 P 17 R X     X   Motion study of lymph nodes on MRI 
Stewart (231) 2010 P 33 P        X Replanning of IMRT plans with 3mm margins based on weekly MRI imaging 
Stromberger 
(232) 2010 P 10 P     X    
Impact of prone position on small bowel dosimetry 
Taylor (233) 2008 P 33 P X  X X  X   Interfractional study of cervical, uterine and vaginal motion using MRI. Influence of bladder and rectal filling. 
Tyagi (234) 2011 P 10 R X  X X  X   CTV motion measured with daily CBCT 
Van de Bunt 
(235) 2006 P 14 R X  X X  X   
Use of weekly MRI to derive CTV-PTV margins  
Van den Bosch 
(236) 2014 A 10 R        X 
Development of criteria to determine which patients may 
benefit from plan of the day 
Van den Bosch 
(237) 
2015 A 5 R      X   Assessment of structure-specific margins for cervix, uterus 
and vagina 
Van der Heide 
(238) 
2007 A 20 R X  X X  X   Strategies to manage interfraction motion 
Yamamato (239) 2004 P 10 P  X     X  Intra-fractional cervical organ motion using gold markers  
Wang (240) 2012 A  P X X    X   Inter- and Intrafractional motion measured with 4D-CT 
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4.5. Interfractional Motion 
4.5.1. Cervix Motion 
Twelve studies, including a total of 209 patients, examined interfractional cervix motion. 
Details of these studies are shown in table 4.5-1.  
A variety of imaging modalities were used to assess motion. 5 studies used portal imaging 
with fiducial markers, either using seeds (105, 205, 212, 225) or a ring (106) as a marker. 
7 studies used volumetric imaging, including 5 using CT-based studies 
(CT/megavoltageCT (MVCT)/4-dimensional CT (4DCT) and cone beam CT (CBCT) (109, 
110, 218, 237, 240) and 2 MRI-based studies (108, 233). Motion was measured either at 
the cervix itself (centre of mass, cervical os, cervical boundaries) or by using fiducial 
markers as a surrogate for cervix position.  
Overall the predominant cervical motion was in the anteroposterior (AP) and 
superiorinferior (SI) directions, with relatively less seen laterally. Inter-fraction average 
cervical movements ranged from 0.4mm to 16mm in the AP, 0.5mm to 8mm in the SI and 
0.2 to 10mm in the lateral directions depending on the method used to measure it. Studies 
using fiducial markers reported smaller magnitude of motion than other methods compared 
with those measuring motion of the cervical boundary or perimeter.  
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Table 4.5-1: Interfraction Cervical Motion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations NR: not reported; AP: anterior-posterior; SI: superior-inferior; LR: left-right
Ref 
 
Pt 
no 
Modality Imaging Frequency 
Measurement 
Method 
Average Movement (mm) Maximal movement 
(mm) 
Statistic Used AP SI LR AP SI LR 
Kaatee 
(212) 
 
10 EPID & seeds Daily Seed motion Mean of means 
Systematic motion 
Random motion 
1.7 
3.5 
3.9 
3.0 
4.1 
3.7 
-1.3 
3.7 
2.2 
NR NR NR 
Haripotepo
rnkul (105) 
10 KV portal & seeds Daily Seed motion Mean (SD) 4.2 (3.5) 4.1 (3.2) 1.9 (1.9) 18 18 14 
DePree 
(205) 
9 KV portal & seeds Daily Seed motion Mean 
Systematic motion 
Random motion 
-1.2 
10.0 
6.8 
2.6 
5.1 
4.9 
-1.5 
4.1 
2.8 
   
Latifi (218) 14 MVCT &  seeds Daily Seed motion Mean (SD) 4.4 (2.1) 4.7 (2.5) 2.2 (1.9) Up to 34mm 
Mens 
(225) 
12 KV portal, CBCT & 
seeds 
Daily portal 
& biweekly 
CBCT 
Seed motion Systemic motion 
Random motion 7.9 6.2 
6.9 
4.9 
6.6 
2.2    
Langerak 
(237) 
50 CBCT & seeds Daily Marker centroid 
position 
Mean 
Systematic motion 
Random motion 
1.0 
5.5 
4.5 
-3.9 
5.1 
3.6 
0.4 
3.4 
2.2 
   
Lee (106) 17 Portal films Weekly Ring motion Median 16 8 10 23 36 23 
Chan 
(108) 
20 MRI Weekly Cervical os Grand mean 
Mean range 
2.4 
11.2 
1.5 
11.3 NR NR NR NR 
Taylor 
(233) 
33 MRI 2 days Post-inf cervix Median 
Mean (SD) 
3 
4.1(4.4) 
3 
2.7 (2.8) 
0 
0.3(0.8) 19 12 3 
Wang 
(240) 
8 4DCT Week 1, 3, 5 Post-inf cervix Mean (SD) 7.9 (6.8) 3.8 (4.0) 3.9 (3.8)    
Beadle 
(110) 
16 CT Weekly Centre of mass Mean max 21 16 8 25 33 14 
Perimeter Mean max A: 17 
P: 18 
S: 23 
I: 13 
L: 9 
R: 8 
A: 29 
P:63 
S:35 
I: 30 
L:18 
R:18 
Collen 
(109) 
10 MVCT Daily Boundary shifts Mean (SD) A:0.4 
(10.1) 
P: -3.0 
(6.9) 
S:2.2(8.0) 
I: 0.5 (5.0) 
L: -3.5 
(6.9) 
R: 0.2 
(4.5) 
NR NR NR 
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4.5.2. Uterine motion 
Five studies, including 84 patients, report interfraction uterine motion. Results of these are 
shown in table 4.5-2.  
Overall the uterus moves more than and independently of the cervix. Chan et al assessed 
the motion of the cervical os, uterine canal and uterine fundus in 23 patients using weekly 
cinematic-MRI and described. The uterine fundus was more mobile than the uterine canal, 
with the cervical os moving the least (108).  
Taylor et al (233) assessed uterine motion with MRI imaging on two consecutive days. As 
well as translational movements, rotational aspects were noted, with the uterus being able 
to rotate from anteversion to retroversion. Of note, one patient had a rotation in uterine 
angle of 91 degrees, with the fundus moving up to 48mm in the AP direction. Variation in 
uterine angle was also described by Huh et al (210) using MRI scans, finding that 18% of 
patients showed positional changes of 30 degrees or more. 11% of patients who had an 
anteverted uterus at planning became retroverted during treatment.   
 
4.5.3. Lymph node motion 
Interfraction nodal motion is assessed in 3 studies including 70 patients (see table 4.5-2). 
Schippers et al (230) examined the motion of 39 visible lymph nodes in 17 patients with 
weekly MRI. Inhomogenous margins of 5-9mm, as a surrogate measurement of movement 
(Table 4.5-4) appropriately covered 95% of the nodal volumes.  
Bondar et al (203) made an assessment of nodal motion by investigating motion of the iliac 
vessels, as a surrogate, as well as any visible enlarged nodes in 13 cervical cancer 
patients. They found the motion to be patient-specific, and after correction for set-up error 
with bony anatomy matching (translational and rotational) they found there was a large 
range of motion of the nodal vessels of 7.6-23.8mm. Mahanshetty et al (222) in their 
abstract found that in 40 patients with daily CBCT scans (767 scans) evaluated, that the 
pelvic nodal CTV had significant motion in all 6 directions (table 4.5-2).   
 
4.5.4. Overall CTV motion 
CTV motion (comprising pelvic nodes, cervix, uterus, parametrium and upper vagina) was 
assessed in one study, by Tyagi et al with the use of daily CBCT (234), measuring 
poisitional changes in CTV centre of mass (see table 4.5-2). They found an overall mean 
motion of 3mm (AP), -4.6mm (SI) and -0.28mm (LR).  
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Table 4.5-2: Interfraction motion of uterus, lymph node volumes and overall CTV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NR: Not reported; SD: standard deviation 
 
 
Target 
measured 
 
Ref Pt 
no 
Modality Imaging 
Frequen
cy 
Measurem
ent 
Method 
Average Movement (mm) Maximal movement 
(mm) 
Statistic  AP SI LR AP SI LR 
Uterine 
Motion 
Taylor 
(233) 
33 MRI 2 days Sup-ant 
fundus 
Median 
Mean (SD) 
5 
7(9)  
5 
7.1 (6.8)  
0 
0.8 (1.3)  
48 32 5 
Wang 
(240) 
8 4DCT Wk 1, 3, 5 Sup fundus Mean (SD) 14.2(10.5) 9.5 (6.6) 6.5 (4.8) NR NR NR 
Chan 
(108) 
20 MRI Weekly Uterine 
fundus 
Grand mean 
Mean range 
-4.6 
 
14.5 
7.8 
 
24.4  
NR NR NR NR 
Uterine 
canal 
Mean 
Mean range 
-4.8 
13.1  
5.7 
15.7 
NR NR NR NR 
Collen 
(109) 
10 MVCT Daily Boundary 
shifts 
Mean (SD) A: 3.3 (11.9) 
P: 0.3 (11.7) 
S: 6.1 (11.6)   
I: 5 (11.2)  
L: 0.7 (8.1) 
R: -0.6 (7.5)  
   
Lee2007 
(219) 
13 CT (using 
SBDS) 
Weekly Distance 
from 
isocentre 
Mean A: -1.1 
P: -.4.3 
S: -6.1 
I: NR 
R: -2.6 
L: -1.2 
A:20 
P:28 
S:45 
I: NR 
L: 28 
R:21 
Nodal 
Motion 
Schippers 
(230) 
17 MRI Weekly Margin from 
enlarged 
node 
Mean A: 7 
P: 8 
S: 7 
I: 9  
R:5 
L:8 
NR NR NR 
Bondar 
(203) 
13 CT Baseline 
and 40Gy 
Iliac vessel 
moton 
Mean A: 9.4 
P11.5 
S: 7.8 
I:10.1 
L: 8.5 
R: 9.1 
23.8mm (direction not 
specified) 
Mahantsh
etty (222) 
40 CBCT Daily Pelvic node 
shift after 
bony match 
Mean  A: 10.7 
P: 12.9 
S: 10.4 
I: 12 
L: 8.8 
R: 8.7 
A: 48 
P: 25 
S: 38 
I: 31 
L: 43 
R: 22 
CTV 
motion 
Tyagi 
(234) 
10 CBCT Daily CTV 
centroid 
position 
Mean (SD) 3 (5)  -4.6 (3.9) -0.28 (1.3) 18.9 -15.3 3.5 
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4.5.5. Organ motion: Intrafraction 
Eight studies examine intrafraction organ motion incorporating 108 patients (table 4.5-3), 
using cinematic-MRI, CT and portal imaging pre- and post- each fraction.  
Intrafraction motion of the uterus and cervix was small, with a mean range of 0.1mm-
4.2mm. Displacements greater than 5mm occurred less than 3% of the time (224), with 
displacements of >10mm 0.3% and 0.2% of the time with uterus and cervix respectively.  
As with interfraction motion, Chan et al noted the uterine fundus moved more than uterine 
canal and cervical os (108). There was no predominant direction of intrafraction movement 
identified. Kerkhof et al (215) measure intrafraction motion with 4 MRI scans over 16 
minutes, they noted the range of motion increased with time, 0.1mm in 4 minutes and 
0.6mm in 16 minutes.  
Table 4.5-3: Intrafraction Motion 
4.5.6. Impact of bladder filling on organ motion 
The correlation of bladder filling with interfraction cervix-uterine motion is examined by 12 
studies (108-111, 201, 203-205, 233-235, 238) including 230 patients.  
Ref Pt 
no 
Imaging 
modality 
Measured  
Point of 
interest 
Average Movement (mm) 
 
Maximal 
movement  
Statistic 
Used 
AP SI LR AP SI LR 
Chan 
(108) 
20 Cinematic 
MRI over 30 
mins 
Uterine fundus Grand mean 
Mean range 
-1.1  
12  
-3.1 
18.8  
 NR 
Uterine canal Grand mean 
Mean range 
0.3 
11.3 
-1.8 
12.8  
 NR 
Cervical os Grand mean 
Mean range 
-0.1 
10.6  
-0.5  
11.2  
 NR 
Haripot
epornku
nal 
(105) 
10 KV portal 
images pre 
and post RT 
Seed motion Mean (SD) 2.9(2.7) 2.6 
(2.4) 
1.6(2.0) 15 15 13 
Wang 
(240) 
8 4DCT  Cervix Mean (SD) 1.7(1.2) 1.6 
(1.4) 
1.4(1.1)    
Uterine body Mean (SD) 2.0(1.5) 2.0 
(1.7) 
1.8(1.4) 
Kerkhof 
(215) 
22 MRI scans: 4 
scans in 16 
min 
CTV motion Median 0.1 (in 4 minutes); 0.2 (in 9 
minutes); 0.6 (in 16 
minutes) 
Mayr 
(224) 
12 
 
MRI every 3 
secs over 2 
mins 
‘Tumour 
region’ 
Mean (SD) 0.9 (6.3) 6.2 (3.6) 
Uterus Mean (SD) 1.2 (0.5) 9.0 (4.1) 
Raj 
(229) 
10 MRI every 6 
secs for 20 
minutes 
Cervix Mean max A:1.4 
P: 5.1  
S: 3.9  
I: 2.9 
NR  
Yamam
ato 
(239) 
10 Orthogonal 
X-rays & 
markers 
Cervix 95% CI in 
motion 
1.4-3.4 2.4-
4.2 
1.9-2.5  
Heijkoo
p (208) 
16 CBCT pre 
and post 
fraction 
Cervix-uterus Mean (SD) 3.4 
(2.1) 
4.7 
(2.8) 
3.0 
(1.4) 
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Overall bladder volumes altered the position of the tip of uterus (ToU) in both AP and SI 
directions (111, 204, 233) and the effect was patient-specific. With variable bladder filling 
ranges of ToU motion of 5mm-40mm in the SI and 0mm-65mm in AP direction were 
observed among patients (111). Those with a more consistent bladder volume (variability < 
50mls) on consecutive days had an average superior ToU motion of 4.2mm compared with 
those with greater variability (> 50ml), who had superior motion of 11.2mm (233).  
Buchali et al (204) found the uterus to move 7mm superior and 4mm posterior from empty 
bladder (using a catheter) to full bladder (filling via catheter to a maximally tolerated 
volume) with less motion noted in cervical position. These results are difficult to fully 
interpret as both bladder and rectum were filled and emptied at once, and also the 
maximal bladder filling was only 175ml, which is considerably less than a typically full 
bladder volume. 
 
Bladder filling had less impact on cervix motion than uterine motion (233, 235) with a 
5.5mm inferior and 3.9mm anterior shift in cervical position demonstrated from empty to 
full bladder (110). Bladder volume also had a moderate correlation with nodal motion 
(203), though the clear pattern of this is not stated. 
 
One study examined the relationship of bladder filling on small bowel position. The small 
bowel sparing effect of IMRT correlated with bladder size (Pearson’s R=0.7). Larger 
bladder volumes appeared to displace the small bowel reducing the volume receiving 
>50Gy by 83cm3 (range 0-292cm3) (206). 
 
Over the course of radiotherapy treatment a systematic reduction in mean bladder volume 
was found in 3 studies (108, 109, 197). A decrease in mean bladder volumes from 156cc 
to 88cc between the first and last weeks of treatment is reported. Chan et al found that for 
every 10cc decrease in bladder volume the uterine fundus moved 18mm inferiorly, the 
uterine canal moving 8mm inferiorly and the cervical os 3mm anteriorly (108). Tyagi et al 
demonstrated a similar pattern, though with a smaller magnitude, such that a 10cc 
increase in bladder volume corresponds to superior shift in CTV centroid of 0.1mm (234). 
 
Retrospective analysis suggests pre-treatment bladder volumes may influence CTV-ITV 
margins (235). Larger (>115mls) baseline bladder volumes required a greater (12mm) 
inferior CTV-ITV margin than the 7mm required for those with smaller volumes (<115ml).  
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Three studies assessed the effect of bladder filling on intrafraction movement. Both 
Kerkhoff et al (215) and Heijkoop et al (208) demonstrated statistically significant 
correlations (R=0.46; R=0.6 respectively) between intra-fraction bladder filling and average 
intrafractional CTV motion. Chan et al found no significant influence of bladder volumes on 
intra-scan motion (108).  
 
4.5.7. Impact of rectal filling on organ motion 
Five studies including 103 patients report the impact of rectal filling on cervix-uterine 
motion, particularly AP and SI movements (108, 204, 233, 235, 238). A greater influence 
on cervical and upper vaginal motion compared to the uterus was noted (233). Significant 
correlations between rectal volume and AP shifts of the GTV, CTV and upper vagina were 
noted with correlation coefficients of 0.71, 0.79 and 0.66 respectively (238). In one 
individual, a 19mm AP shift of cervix position resulted from rectal diameter change from 71 
to 34mm (233). A 6cm3 decrease in rectosigmoid filling corresponded to inferior motion of 
uterine canal (3.6mm) and cervical os (2.6mm)(108).  
 
Retrospective analysis showed those with pre-treatment rectal volumes >70cc required 
greater posterior and inferior internal margins (20mm and 12mm respectively), than those 
with a smaller baseline rectal volume (<70cc) (10mm and 6mm)(235). Though daily 
variations in rectal volumes are reported (ranges between 21-150cc), no systematic 
change during the course of treatment was identified (233, 238).  No correlation was noted 
with iliac vessel motion (representing CTVnodes) and rectal filling (203).  
 
4.5.8. IGRT solutions  
Many studies relevant to IGRT solutions were identified and were categorized as below: 
4.5.9. Patient positioning 
Prone positioning with use of belly board device (allowing superior and anterior 
displacement of the small bowel) is compared with supine position in 4 studies including 
66 patients. Prone positioning using a ‘limited’ arc planning technique in 16 patients (9 
having definitive radiotherapy) reduced small bowel volumes receiving >45Gy (V45) from 
19% to 12.5% but increased large bowel volumes receiving >50Gy from 6.9% to 14.8% 
(196). Similarly using a 7-field IMRT technique small bowel V45 reduced from 20.3% to 
13.7%, though V40 rectum increased from 69.5% to 79.4% (232). Prone positioning did 
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not significantly reduce small bowel doses with conformal planning (228) in one study, 
however was found to reduce small bowel volumes significantly in another study (199).   
The use of the “small bowel displacement system” (SBDS), a Styrofoam compression 
device placed under the abdomen in the prone position in addition to a bellyboard was 
reported in three studies including 33 patients (219, 227, 241). With IMRT treatment SBDS 
use reduced the mean small bowel volume within the PTV from 67.9% to 16.8%.  
Patient Preparation 
With the noted patterns of bladder filling and uterine motion, early investigation into 
potential solutions has been described by Bhuva et al (200). The use of an ITV is 
investigated where the CTV is outlined on a “bladder full” planning scan and a “bladder 
empty” planning scan; these volumes are fused and a ITV-PTV margin is applied. In the 11 
patients studied they found that a 10mm ITV-PTV margin allowed CTV coverage in 37/40 
CBCTs studied and a 12mm margin allowed coverage in 39/40 CBCTs, compared with a 
standard isotropic 15mm margin which allowed coverage in only 16/40 scans. 
There were no studies that evaluated rectal preparation protocols as a means of reducing 
cervix-uterine motion or doses to OARs.  
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Margins for organ motion  
Fifteen studies including 271 patients proposed internal margins to allow for cervix-uterine 
motion (Table 4.5-4) based on organ motion studies. 
Table 4.5-4: Suggested Margins for Organ Motion  
 
Ref Pt 
No 
Imaging 
modality 
Imaging 
frequency 
Margin 
around: 
Margins suggested (mm) 
     AP SI LR 
Chan 
(108) 
20 MRI Weekly Cervical Os 10-15 (all directions) 
Latifi 
(218) 
14 MVCT with 
gold seeds 
Daily Fiducial 
marker COM 
12 11 8 
Collen 
(109) 
10 MVCT Daily Cervix A:17  
P:12  
S:15  
I: 9 
L:9  
R:8 
Wang 
(240) 
8 4DCT  Week 1, 3 
and 5 
Cervix 19 10 9 
Van de 
Bunt 
(235) 
20 MRI Weekly GTV A:12 
P:14 
S:4 
I:8 
L:11 
R:12 
Van den 
Bosch 
(237) 
5 CBCT Weekly Cervix Mean 7mm (max 10mm) 
Langera
k (237) 
50 CBCT with 
polymeric 
markers 
Daily Cervix 15.2 16.6 8.7 
        
Malyapa 
(223) 
16 CT  wk 2 & 4 Uterus 21.0 (10.1) (range 10.1-30.8) 
Chan 
(108) 
20 MRI Weekly Uterine fundus 10-40 (all directions) 
Uterine Canal 10-12.5 (all directions) 
Collen 
(109) 
10 MVCT Daily Uterus A:19 
P:19  
S:20  
I:19 
L:13  
R:13 
Wang 
(240) 
8 4DCT  Week 1, 3 
and 5 
Uterus 32 20 14 
Van den 
Bosch 
5 CBCT Weekly  Uterus Mean 10mm (max 18mm) 
      
Schipper
s (230) 
17 MRI  weekly Enlarged 
lymph nodes 
A: 7 
P: 8 
S: 7 
I: 9 
R:5 
L:8 
Mahants
hetty(22
2)  
40 CBCT Daily Pelvic nodal 
CTV 
10-15mm (all directions) 
        
Tyagi 
(234) 
10 CBCT Daily CTV 15.3 (grand mean) 
35 to encompass all volumes  
all fractions  
Kaatee 
(212) 
10 EPID with 
seeds 
Daily CTV 12  12.1 10.2 
Taylor 
(233) 
33 MRI  2 days CTV 15  15 7 
Lee 
(106) 
17 Portal films 
& metallic 
ring 
Weekly CTV 22.9  15.4 17.5 
Van de 
Bunt 
(235) 
20 MRI Weekly CTV A:24 
P:17  
S:11  
I:8  
L:16 
R:12 
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Suggested isotropic internal margins ranging from 10-21mm were suggested, though most 
studies suggested anisotropic margins. These ranged from 12-32 (AP); 8-20 (SI) and 7-
17.5 (LR).  
Structure-specific isotropic margins are proposed in two studies with different margins for 
different components of CTV. Chan et al suggested margins of up to 4cm around the 
uterine fundus and 1.25cm around the cervix (108), and Van den Bosch et al suggested 
maximal margins of 10mm and 18mm for cervix and uterus respectively based on weekly 
CBCT analysis. 
 A further study modelled 1cm, 2.4cm and ‘tapered margins’ (2.4cm around the fundus 
narrowing to 1cm around cervix) combined with different ‘motion’ models by Khan et al. A 
1cm margin led to insufficient fundal coverage of approximately 5Gy as an effect of motion 
(10% of the prescribed dose). Use of the tapered margin restored this loss of dose 
coverage, with slight increases in bowel and rectal doses (V50.5 from 17.8 to 19.0, and 
46.2 to 48.3 respectively)(216).  
 
Additionally three studies used pre-set margins to assess on-treatment CTV coverage. 
Tyagi et al (234) found the use of 15mm isotropic margin failed to encompass the entire 
CTV in 32% of fractions, studied however the mean volume “missed” was 4cc. Bloemers 
et al investigated the use of an anisotropic (20mm SI and AP margins, 10mm LR) and 
demonstrated insufficient CTV coverage in 13% of fractions (201). Conversely, dosimetric 
analysis in a study by Lim et al using 5mm and 20mm PTV margins with IMRT suggested 
a 5mm margin allowed for pelvic organ motion with adequate dose delivered to 98% of the 
CTV in 95% of patients, using weekly MRI scans. Of note, one of the twenty patients 
studied had significant underdosing due to unpredictable target motion (220).  
 
Regarding nodal internal margins, 9mm margins for visible nodes are suggested by one 
study (230), and 10-15mm margins suggested by another study (222) for the whole nodal 
CTV although maximal movements of up to 43mm of the CTV are noted. Consensus 
guidelines suggest a 7mm CTV-PTV margin for nodal volumes. (12).  
On-treatment imaging modality, matching and marker use 
Imaging modalities were not directly compared in any study, though 3 studies report inter-
observer variability as a measure of reproducibility. Using MRI inter-observer mean 
differences of -0.66 to 0.25mm were reported when determining uterine position (108). 
MVCT use was found to have inter-observer variability of -0.4 to 1.0mm at cervix and 0.2 
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to 0.9mm at uterus (109). Using CBCT mean inter-observer variability led to differences in 
margins required of 4.1mm (234). 
 
‘Fiducial’ markers (tantalum, gold and polymeric) were used in 6 studies. Good marker 
visualisation was reported with planar KV imaging (90% visualised) and CBCT (100%) 
(225). Initially high marker loss rates of 14%-50% were found (205, 212), though in the 
more recent study by Langerak et al (217) with the use of polymeric markers marker loss 
was only 6%. The authors used an alternative means of marker implantation by which the 
markers were implanted 5mm into the submucosal tissue of the vagina in four directions 
around the cervix. They also report significant less streaking artefact with the use of 
polymeric markers compared with gold markers.  
Lee et al used a metallic ring as a fiducial marker which was sutured in with the use of a 
uterine sleeve prior to treatment (106). Fixation was good with this approach though may 
be a practical challenge for routine clinical use.  
 
One study (Oh et al (226)) compared the use of soft tissue matching and bony matching 
for treatment verification in 15 patients. For soft-tissue matching on-treatment MRI was 
used, and found this to be increasingly enhancing of target coverage, as well as being 
cost-effective, as they postulated that increased replans would be required based on bony 
matching.  
3.8.1.2. Offline versus online IGRT solutions 
No studies directly compared offline versus online imaging strategies for management of 
organ motion. Most of the images acquired in the sections above were as part of an offline 
protocol with weekly imaging. 
4.5.10.  Individualised and adaptive strategies  
Eight studies discuss the use of individualised strategies, proposed around the concept of 
patient-specific uterine motion with variable bladder filling (123, 124, 198, 202, 207, 209, 
213, 236).  
 
Non-adaptive and adaptive strategies are compared in an important study by Bondar et al 
(123). Each strategy was tested against CT scans that had been acquired with variable 
bladder filling (VBF), with 9-10 scans acquired pre-treatment and after 40Gy of treatment.  
Initially a non-adaptive ITV approach (as described above) was modelled. The ITV 
required a PTV margin of 7-10mm to cover the CTVs on the VBF scans. With a 
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population-based approach, where no ITV was used, a PTV margin of 38mm was 
required. 
Compared with a population-based approach the ITV reduced average PTV volume by 
48%, reducing bladder and rectal volumes within the PTV by 5-45% and 26-74% 
respectively.  
The study went on to examine an adaptive strategy, ‘plan of the day’ (PotD). This concept 
uses formation of a library of plans per patient, and each day an appropriate plan based is 
chosen based on imaging that day. In this study plan libraries were generated using scans 
with VBF, either a 2-plan, 3-plan or daily plan library was generated. The PotD was chosen 
based on bladder volume on ultrasound. The authors concluded the adaptive approach 
increased OAR sparing compared to non-adaptive methods but the precise amounts were 
not quantified. No added benefits were seen with the use of a 3-plan library, or daily plan 
library over a 2-plan library. 
 
Heijkoop et al (124), took these concepts further with clinical implementation initially in 24 
patients where either an ITV-based IMRT plan was chosen, or a backup 3D conformal 
plan was chosen depending on the patients anatomy on daily CBCT.  The IMRT plan 
could be used in 17 of 24 patients for all treatments, though the benefits in terms of OAR 
sparing are not quantified.  
In their second phase of 40 patients, a backup 3D conformal plan, and either one or 2 
IMRT plans were produced. 2 IMRT plans were used for patients who were noted to have 
a cervix-uterus motion of >2.5cm at the time of planning (n=11). These were empty-to-half 
full, and half-full to full ITVs depending on bladder filling. For patients with <2.5cm motion a 
single IMRT plan was produced as in the first phase (n=29). IMRT could be used in 81% of 
treatment fractions. A potential bowel sparing effect was noted for 11 patients with 2 IMRT 
plans however this approach was not quantitatively compared with the other strategy or 
the use of a conformal plan throughout.  
Other authors have also suggested that plan of the day may be required only for certain 
patients (236), such as those where the uterus on empty bladder planning scan was 
outside a 1cm margin around the uterus on the full bladder scan. These concepts need 
further analysis before firm conclusions can be made. 
 
A further adaptive study, ‘Margin of the day’ (MotD), was modelled by the same research 
group (198). Again modelling took place on VBF scans acquired pre-treatment and after 
40Gy, 9-10 scans per patient. Incremental isotropic PTV margins of 5mm-45mm in steps 
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of 5mm around the CTV at planning were modelled for 14 patients. The number of plans 
per patient was determined based on the range of motion seen in the scans, with patients 
needing 3-8 plans in their library (median of 5). The maximum range in one patient was 
from 10mm to 45mm.  MotD was compared with a population-based margin of 15mm. 
They found that a population-based margin of 15mm around the cervix uterus resulted in 
underdosage in six patients out of the 14 studied. In these six patients, MotD improved 
CTV coverage but did not result in an increase in the average bowel V99, bladder and 
recum V90 parameters studied. For the 8 patients where the population-based margin was 
sufficient, MotD reduced the irradiated volume by 11%. 
  
Another individualised strategy proposed is the ‘optimised PTV margin’ where 758 
landmarks are placed over the planning CTV, and vectors from these landmarks to the on-
treatment CBCT CTVs are measured, forming an optimised PTV margin with high target 
coverage with reduced OAR volumes in the PTV, so far this has only been modelled 
retrospectively (216). 
4.5.11. Adaptive Replanning Studies 
Replanning was modelled with MRI by Kerkhof et al (214) in their study of 11 patients. 
With weekly MRI scans they created 4 IMRT plans per patient with a PTV margin of 4mm 
to model an “online IMRT” approach. They compared volumetric and dosimetric 
parameters with a fixed 15mm “pre-IMRT” approach.  A significant reduction in doses to 
OAR that overlaps within the primary PTV- bladder (53% to 11%), rectum (57% to 13%), 
bowel (12% to 1%), sigmoid (63% to 13%) were noted with the ‘online’ plan. The 
practicalities of how this could be implemented prospectively with daily adaptation were 
not considered, suggestions were either a library of plans or a new treatment plans based 
on daily anatomy. 
Work from Princess Margaret Cancer Centre, Toronto, has also addressed the issue of 
replanning (221, 226, 231). Initially Stewart et al (231) modelled the use of replanning to 
accommodate for organ motion with weekly MRI scans in 33 patients. They compared the 
use of a “no replan” strategy, where a plan based on the planning MRI was compared with 
a “replan” strategy. This involved an automated replan performed on the updated weekly 
MRI. Both strategies were modelled with a 3mm PTV margin.  With no-replan 27% of 
patients failed to meet the 95% prescription dose and this was improved in the “replan” 
strategy, though doses to rectum and bowel increased in 52%.  
Lim et al (221) modelled 2 adaptive strategies on the same patients, also using 3mm 
margins. Either an automated adaptive IMRT (A-IMRT) approach where a replan was 
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treatment based on anatomical change, or a dosimetric-triggered adaptive replan (D-
IMRT) which was performed only if anatomical change led to underdosing of the CTV or 
PTV. The D-IMRT approach reduced replanning frequency by 23%, and improved 
coverage from 90% of patients to 100% of patients compared with A-IMRT.  
Although this concept is promising it is important to note the CTV definition in these 
studies was limited superiorly to 2cm above GTV and did not encompass the whole uterus. 
Compared to the rest of the studies within this systematic review this CTV is likely to have 
significant less motion with the uterus being most prone to organ motion.  
4.6. Discussion 
This systematic review summarizes the results of 53 studies examining inter- and intra-
fraction organ motion during radiotherapy for cervical cancer and the potential IGRT 
solutions to account for this motion. The results could help inform future IMRT planning 
and verification protocols for definitive cervical cancer radiotherapy.  
4.6.1. Interfraction and intrafraction motion 
Multiple studies exist within the literature examining predominantly cervical and uterine 
motion. These studies highlight that cervical motion and uterine motion is an important 
consideration, and must be addressed when determining an IMRT protocol. The uterus 
was more mobile than the cervix; Taylor et al examined both uterine and cervical motion 
and demonstrated greater ToU motion in the AP (maximal 48mm) and SI (maximal 32mm) 
directions compared to cervical motion in the AP (maximal 19mm) and SI (maximal 12mm) 
directions (233). Cervical motion is translational, though the uterus is prone to both 
translational and rotational change, adding to its complexity. Direct comparison between 
studies of uterine-cervix movement is difficult as each study uses different methods to 
measure motion and report different statistics.   
Many studies report the impact of bladder filling on uterine motion. With bladder filling the 
tip of uterus can move in the anterior direction of 65mm (111), however this pattern is 
patient specific and cannot be predicted. Rectal filling was associated with anterior-
posterior motion of the cervix.   
 
Intra-fraction motion also exists, though is relatively much less pronounced than 
interfraction motion and both are likely be accounted for within internal margins. Studies 
looked at intrafraction motion over for example a timespan of 16 minutes (224), however 
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with the use of arc therapies such as VMAT, this issue may become much less important 
as delivery times shorten to 2-3 minutes. 
4.6.2. IGRT considerations 
3.8.1.3. Patient positioning and patient preparation 
Studies addressing patient positioning were not conclusive. Though prone positioning has 
been shown to reduce small bowel within the treatment field, it can be associated with 
considerable set-up errors (up to 15mm) caused by AP sacral rotations (-14º-11.5º) (242). 
Increasing PTV margins to account for these errors possibly negates the benefits of small 
bowel sparing. 
 
In terms of patient preparation, bladder filling is an important factor to manage uterine 
motion. The use of “strict” bladder filling protocols is likely to be insufficient. Studies in 
other pelvic tumour sites, such as post-hysterectomy endometrial, bladder and prostate 
cancer (114, 243, 244) show that despite strict drinking protocols a constant bladder 
volume is difficult to maintain. Bladder volume has been shown to systematically reduce 
during treatment, probably due to reduced bladder capacity and radiation cystitis (108, 
109, 111) adding to the problem of maintaining a consistent bladder volume. The concept 
of an ITV may be an important solution in this setting (123, 200) though needs more 
investigation to confirm its benefits and ITV-PTV margins that are appropriate. 
 
With regards to rectal filling, no guidance is derived from this literature review. 
Extrapolation from prostate cancer, where bowel preparation is commonly used to 
maintain an empty rectum, may suggest its potential use in cervical cancer. This 
hypothesis would need to be tested clinically to assess its value in gynaecological 
malignancies. 
3.8.1.4. Margins to account for motion 
RTOG consensus documents aim to aid delineation of target volume for cervical cancer 
IMRT, though there is minimal information with regards the CTV-PTV margins. They report 
that 15-20mm margins are commonly advocated (95). 
From the studies within this review a wide range of isotropic internal margins (from 10mm 
up to 21mm) and anisotropic margins (up to 32mm AP, 20mm SI and 17.5mm laterally) 
were suggested. This implies that commonly used CTV-PTV margins of 1.5-2cm may be 
insufficient. However a wide variety of methods were used to derive these proposed 
margins so it is unclear what the optimal margins should be.  
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Structure-specific margins, with a larger uterine margin (4cm) and a smaller cervical 
margin (1.25cm) potentially would allow for the differences in the movement observed 
(108). The concern with large margins such as 4cm around the uterus is that this will lead 
to significant inclusion of OARs within the PTV and negate the benefits of IMRT. Further 
there is ongoing debate as to whether the uterine fundus should be included within the 
CTV for all patients, as there is limited data suggesting the fundus to be a common site for 
microscopic spread in cervical cancer. This important issue needs addressing given that 
the fundus is the most mobile CTV component and therefore the margins required to 
account for its motion are so much greater.  
 
Lymph node motion is also an important consideration in cervical cancer where lymph 
nodes are a common site of disease recurrence, and geographical miss must be avoided. 
Schippers et al (230) provide some data regarding lymph nodes visible on MRI, suggesting 
a 9mm margin around these should be used. However for elective nodal CTV, Bondar et al 
(203) suggest that such a margin would be insufficient. Mahanshetty studied a large 
number of data (776 daily CBCTs in 40 patients) and suggest margins of 10-15mm 
margins. However the authors do not clearly state how their CTV was defined or how the  
margins were calculated, as they had patients with motion of up to 48mm anteriorly for 
example. 
  
As well as internal margins, consideration of set-up margins to create a PTV is also 
necessary when developing an IMRT/IGRT protocol, though is beyond the scope of this 
review. Studies using daily CBCT suggest set-up margins of up to 11.6mm (SI), 9.6mm 
(LR) and 8.2mm (AP), which would be a significant addition to internal margins (245). Set-
up margins should be centre-specific as they are dependent on patient positioning, 
immobilisation and imaging protocols.  
 
4.6.3. On-treatment verification 
Daily online imaging may reduce both internal and set-up margins, yet to date no studies 
directly compare online versus offline modalities in this setting. Many centres use imaging 
protocols such as day 1, 2, 3 and then weekly offline guidance as standard for conformal 
pelvic treatments. However both UK National Guidance (193), and international guidance 
(95) recommend an offline strategy is likely to be insufficient for cervical cancer IMRT, 
given the unpredictable nature of uterine movement, and this is confirmed by the 
significant random error noted in this review (108, 212, 225). The use of soft tissue 
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imaging to be used with IMRT techniques for both radical and post-operative IMRT is also 
recommended. This is due to the independence of pelvic organ motion to bony anatomy.  
 
However even with daily online volumetric imaging, simple translational shifts are likely to 
be insufficient to compensate for the complexity motion of this target volume. A 
translational shift to accommodate change in uterine position may lead to poor coverage of 
the more static pelvic node volumes. An IGRT solution is therefore required that can 
accomodate the complexity of differential CTV motion whilst taking into account the intra-
patient variation of organ motion.  
 
4.6.4. Adaptive and Individualised Strategies 
Individualised adaptive approaches are likely to be important avenues of research in 
cervical cancer given the complex, patient-specific nature of CTV organ movement. 
Adaptive planning has been studied in other tumour sites. In bladder cancer for example 
the plan of the day has been modelled, with each patient having a library of plans with 
“small”, “medium” or “large” margins used. This has shown some promise in single centre 
studies for significantly reducing the volume of normal tissue irradiated whilst maintaining 
CTV coverage (120, 121), and is now being tested in a UK Phase II multicentre trial (122).  
 
Within this review two concepts around plan of the day have been modelled. Plan of the 
day (PotD), has been modelled by Bondar et al with some clinical implementation by 
Heijkoop et al. This group compared PoTD against two other strategies, including the use 
of a non-adaptive ITV, taking into account organ motion on two scans only at the time of 
planning, and a population-based margin of 38mm. With the individualised strategies 
smaller PTVs are possible with sparing of OARs, however the sparing of OARs was not 
quantified which would be essential to know when deciding whether to implement a 
technique that is likely to be time- and labour-intensive.  
The other concept was margin of the day, but with patients needing up to 8 plans prior to 
commencing radiotherapy the labour-intensitivity of this strategy must be considered, 
unless a more automated planning process can be used.  
With regards to replanning strategies the studies described use very small margins (3-
4mm), and weekly imaging only. CTV definition is variable, with some studies not taking 
into the account the whole uterus which is included in RTOG defined cervical cancer 
guidelines. The true benefits of these methods need therefore to be investigated before 
they can be adopted.  
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4.6.5. Strengths and limitations 
The work in this chapter had strengths; the search strategy was comprehensive and a 
detailed assessment of all relevant aspect to this subject could be performed. Limitations 
were that some aspects, such as organ motion in brachytherapy were not covered, 
although external beam radiotherapy is the focus of this thesis and thus thought not as 
relevant. Some of the exclusion criteria such as studies limited to English may have 
excluded potential useful data.   
4.7. Conclusions and Future Work 
Interfractional organ motion for cervical cancer is a significant concern. Uterine motion is 
more predominant than cervical motion. Uterine motion is influenced by bladder filling and 
cervical motion more by rectal filling. Despite a number of studies on this subject findings 
are difficult to compare given the variety of methodologies used to derive them. This 
makes direct application of these results on prospective patients difficult.  
There are still many unexplored research avenues with regards to IGRT for cervical 
cancer, including protocols for bladder and rectal filling to limit organ motion. As for 
margins, a range of population-based margins are suggested in the literature, and optimal 
margins cannot be concluded from this work. Given that organ motion patterns are patient-
specific, adaptive individualized approaches may be of benefit to avoid unnecessary 
irradiation of OARs in patients where organ motion is minimal.  
Future work would aim to extend knowledge of adaptive strategies and to quantify their 
likely benefits of such strategies in terms of CTV coverage and OAR sparing. 
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5. Chapter V: Comparison of margin 
strategies for definitive cervix IMRT 
5.1. Introduction 
Although IMRT for cervical cancer is desirable, pelvic organ motion is an important barrier 
towards its widespread adoption. Published literature of cervical cancer organ motion and 
its possible solutions are reviewed in chapter IV of this thesis.  
A promising avenue of solutions highlighted in the systematic review is the use of different 
margin strategies. Although these have been proposed and assessed in the literature, the 
benefits and drawbacks of each solution are not quantified such that an overall best 
solution can be chosen. In this section of the thesis these margin strategies will be 
compared and analysed in detail.  
 
Margin strategies can be categorised into population-based margins, individualised non-
adaptive margins and individualised adaptive margins.  
5.1.1. Population-based margins 
Isotropic margins 
Traditionally standard radiotherapy treatments use isotropic PTV margins around a CTV 
which are large enough to account for organ motion and set-up error. However in cervical 
cancer IMRT the most appropriate isotropic margin to use is unclear.  
RTOG published guidelines (95) for IMRT outlining in cervical cancer and suggested 
isotropic CTV-PTV margins of 1.5 to 2cm may be suitable if “good quality daily soft tissue 
imaging” is available, however if bone matching is being used “larger” margins should be 
used. Trial protocols (113) suggest 2-3cm, and many centres use 2cm isotropic margins 
as a standard. Suggested isotropic margins from organ motion studies range widely from 
1-3.5cm (234, 237). There is little validation of these margins in independent samples of 
patients, and their success in clinical practice is unknown. 
Anisotropic Margins 
Anisotropic margin use is another solution with the knowledge that both the uterus and 
cervix move more in A-P direction compared with other directions. Tailoring margins in 
specific directions may be of value to spare neighbouring OARs whilst maintaining 
coverage. Population-based anisotropic margins from individual studies are suggested in 
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studies as summarised in the previous chapter. Again the variation between studies is 
significant, for example for anterior margins there is a range of margins from 7-32 mm 
(237, 240), and superior margins from 11mm to 20mm (109, 235). Comparisons of these 
margins with isotropic margins and validation of their use in clinical practice is not found. 
Structure-specific margins 
A key finding from the previous chapter was that different components of the primary CTV 
in cervical cancer have different motion patterns. A further solution therefore is that of 
structure-specific margins. Just as different margins are applied to pelvic nodal CTV and 
the primary CTV, further subdivision of the primary CTV into uterus, cervix, vagina etc. 
may avoid excessively large margins for components of the CTV where there is less 
motion. This concept was suggested in a key paper by Chan et al. (108), with 4cm and 
1.25cm margins for uterus and cervix proposed respectively. A further study suggested 
1.8cm around the uterus and 1cm around the cervix (237). The benefits of these margins 
over simple isotropic or anisotropic margins have not been quantified as yet.  
 
Benefits of all population-based margin solutions are their simplicity, whereby a margin is 
applied prior to treatment and little extra is required. Drawbacks are that for patients with 
limited organ motion population-based margins may well be excessive, with unnecessary 
inclusion of OARs within the PTV.  
5.1.2. Individualised non-adaptive margins: Internal target volume  
The internal target volume (ITV) solution in gynaecological cancers attempts to take into 
account CTV motion in relationship to bladder filling. This is ascertained by a patient 
having two planning scans, one with a full bladder and one with an empty bladder. The 
primary CTV on the full bladder scan is combined with the primary CTV on the empty 
bladder scan forming an ITV. Around this ITV a further margin is added to create a PTV, 
and those who have recommended this method in the literature have used margins of 7-
12mm (123, 200).  
 
RTOG guidance has recommended this method for post-operative gynaecological patients 
(98), though do not mention its use for radical cervical cancer patients. In radical cervical 
cancer there is a suggestion that this method is likely to improve coverage compared with 
15mm isotropic margins (200). Reported clinical outcomes with this method in 22 patients 
has found acceptable toxicity and locoregional control, though there is no comparison 
made with standard isotropic margins (246). 
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Although the ITV methods allows for individual patient organ motion based on bladder 
filling, it takes little account of rectal filling. It also requires the additional exposure from a 
second empty bladder planning CT scan. 
5.1.3. Individualised adaptive margins 
Further to the ITV concept is the use of adaptive margins where treatment is modified to 
adapt to the patient’s anatomy whilst on treatment using information from on-treatment 
imaging.  
5.1.3.1. Composite volumes 
One adaptive approach is the use of ‘composite volume’. For each patient this uses 
multiple images acquired at the start of treatment, for example from the first 3 or 5 days. 
The CTV is outlined on each image and a union of the CTVs forms a ‘composite’. To this a 
small margin is added for set-up error to form a PTV. 
This approach has been studied in bladder cancer and in prostate cancer (119, 247) 
though to date has not been addressed in cervical cancer. In prostate cancer, a composite 
from the first six fractions of treatment was generated with a 7mm PTV margin. Compared 
to a standard 10mm margin this reduced the irradiated volume and rectal doses. In 
bladder cancer, a composite using the first five fractions of treatment, reduced treatment 
volumes by 40% compared with a standard isotropic margin. 
This approach would require the patient to have a ‘standard’ margin for the first few 
fractions of treatment and then for the treatment to be replanned after the first few fractions 
once the composite has been created, which may add to the departmental workload.  
5.1.3.2. Plan of the Day 
An alternative approach is ‘Plan of the Day’ (PotD) where a patient has a library of plans 
(LoP) generated based on their pre-treatment imaging. The patient commences treatment 
with daily online imaging. Each day the most appropriate plan is chosen based on the 
patient’s anatomy that day.  
This has been used in bladder cancer, with each patient having a library with “small”, 
“medium” or “large” margins used. This has shown some promise in single centre studies 
(120, 121), and is now being tested in a UK Phase II multicentre trial (122). 
In cervical cancer rather than having different margins sizes applied the LoP is generated 
based on plans with different degrees of bladder filling, as this is likely to impact uterine 
position, and would take into account the rotational motion of the uterus.  
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In cervical cancer radiotherapy Bondar et al (123) modelled PotD. In their study they 
modelled the range of CTV position from full to empty bladder, and chose two or three 
mid-range CTVs, to which 7-10mm PTV margins were added. The library was then tested 
against 6-7 CT scans per patient, with plans chosen based on bladder volumes on bladder 
US scans. They found their method reduced bladder within the PTV by up to 10%, and 
rectum by up to 9% compared to an ITV, though this was not quantified dosimetrically. 
  
Heijkoop et al (124) clinically implemented some of these concepts from this study, with a 
two-plan library or three-plan library chosen depending on the range of uterine motion for 
that patient. Plans were chosen daily based on CTV position as seen on daily online 
CBCT. If the plan library did not offer an appropriate plan a 3D-conformal plan was used 
as a “back-up”, and this was needed in 17.5% of all fractions. Overall the authors found 
PotD to be clinically feasible, and plan selection was possible in a timely manner with a 
well-trained team. OAR sparing however was not fully detailed compared to a standard 
margin, making it difficult to quantify the achievable benefits.  
  
Although these initial PotD studies are promising, many questions remain unanswered 
about PotD methodology; for example – the appropriate number of plans; the requirement 
for a backup plan; the optimal bladder protocol to yield the largest variation between full 
and empty bladder scans; appropriate PTV margins for each plan.  
PotD techniques will increase departmental workload, potentially requiring additional 
planning scans, technology and manpower to “interpolate” volumes, generation of multiple 
plans and training of radiotherapy staff to choose the appropriate plan for the day. 
Therefore comparison of PotD techniques against other margin strategies is of vital 
importance to quantify its benefits in terms of CTV coverage, OAR sparing and 
subsequent clinical benefit and determine its cost-effectiveness.  
5.2. Aims 
The aims of this work were:  
- To compare the relative utility of different margin strategies for addressing the 
issue of internal organ motion in cervical cancer radiotherapy, in terms of CTV 
coverage and OAR sparing. 
- To determine the most promising strategy from the strategies modelled based on 
volumetric assessment  
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- To dosimetrically model the most promising strategy in comparison to standard 
treatment 
- To model dose escalation for the most promising strategy when sufficient bowel 
sparing is achieved 
5.3. General Methods 
Planning and treatment verification imaging from patients treated definitively for cervical 
cancer from April 2013 to September 2015 were analysed retrospectively.  
All patients meeting the inclusion criteria below were included consecutively: 
5.3.1. Inclusion: 
1. Patients treated for cervical cancer with definitive intent 
2. Patients who had two planning scans (full bladder and empty bladder) 
3. Patients who had at least 6 CBCT scans during treatment to allow sufficient 
analysis of organ motion. 
5.3.2. Exclusion: 
1. Post-hysterectomy patients 
2. Patients with hip replacements, which cause artefact on their CBCT 
3. Patients with long treatment volumes (sup-inf) where the CBCT scans did not 
include the lower pelvis, e.g. where para-aortic nodes were being treated 
 
5.3.3. Patient treatment 
All patients received treatment as part of routine care in our institution, and this is detailed 
in the following sections: 
Patients were treated with external beam radiotherapy (EBRT) with a prescribed dose of 
45Gy in 25 fractions. Concurrent chemotherapy (usually weekly cisplatin 40mg/m2) was 
administered unless clinically inappropriate. External beam radiation therapy was followed 
by intracavitary high-dose rate brachytherapy, delivering 21.3Gy in 3 fractions prescribed 
to point A in once weekly fractions. 
Simulation 
Patients were simulated in the supine position and immobilised with the OncologySystems 
Limited Combifix. Intravenous contrast was used to highlight vasculature where patients 
had sufficient renal function. Patients were scanned using Siemens Somatom Sensation 
CT scanners.  
Two planning scans, a “full bladder” and “empty bladder” scan were acquired for each 
patient, as was departmental policy in our institution since April 2013. For the full bladder 
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scan patients were scanned from T10 to below the perineum. Patients were asked to 
empty their bladder then drink 200-300mls of fluid 30 minutes prior to full bladder 
simulation. After acquisition of the full bladder scan patients were asked to void their 
bladder, and the empty bladder scan was acquired, from L4/5 to the perineum. 
No rectal preparation protocol was used for either scan. 
Target volume delineation 
Target volumes were outlined on the full bladder planning scan on Oncentra Masterplan 
(OMP) version 4.3. The full bladder and empty bladder scans were co-registered with the 
mutual information algorithm. 
The CTVnodes was delineated from a 7mm margin around pelvic vessels from the 
bifurcation of the aorta (for node positive patients) and from the L4/5 junction (for node 
negative patients). Further expansion of the CTV nodes included the presacral region from 
the sacral promontory to the pirifomis muscle, and to include the obturator nodes until the 
superior aspect of the obturator foramen. An 8mm margin was added to CTVnodes to form 
PTVnodes. 
The CTVprimary consisted of the GTV (determined by MRI and FDG-PET scans) plus a 
1cm margin. The CTV was further extended to include the rest of the cervix, uterus, 
parametrium and 2cm vagina below the GTV. Parametrial borders included the broad 
ligament superiorly, and pelvic diaphragm inferiorly. Laterally this was extended to the 
pelvic nodal CTV, anteriorly to posterior bladder and posteriorly to mid-rectum.  
A 1-2cm CTV-PTV margin was applied around the primary CTV (depending on clinician 
preference). The PTV was then checked against the empty bladder planning scan to check 
that all CTV components on the empty bladder scan were within the PTV outlined on the 
full bladder scan.  
Treatment planning and delivery 
Patients were treated using 3D-conformal planning with four-field technique to a 
prescription of 45Gy in 25 fractions on Elekta Synergy Precise units. On treatment patients 
followed the same drinking protocol as in planning.  
Each patient had an offline CBCT scan, acquired with use of the XVI software version 
4.5.1, on day 1,2,3 and then weekly scans over the remaining 4 weeks. An offline protocol 
was used to assess these scans. Online CBCTs were acquired when there were concerns 
about target volume coverage and the reasons for additional scans documented. 
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5.4. Modelling study methods 
5.4.1. Stages of Investigation 
This study was performed in 4 stages as illustrated in figure 5.4-1:  
 
 
Figure 5.4-1: Stages of investigation 
5.4.2. Fusion and target volume modification for modelling study 
Prior to the above stages each patient’s images were prepared with fusion, target volume 
modification and OAR outlining.  
Full bladder planning scans were co-registered with the empty bladder planning scans, 
and then to each CBCT for that patient using the mutual information algorithm on OMP. 
Fusion was checked for adequacy at three bony landmarks – femoral heads (on axial 
view), tip of sacrum (on sagittal view), and pubic symphysis (both on axial and sagittal 
views). If the fusion was not visually satisfactory then manual adjustments were made to 
correct it. 
CTVnodes was used as delineated for the patients original treatment on the full bladder 
scan, though was checked to ensure that protocol was adhered to. CTVnodes was not 
delineated on CBCT scans as nodal motion was not being measured in this study. 
 
CTVprimary was delineated on the full bladder scan (CTVfull), the empty bladder scan 
(CTVempty), and every CBCT scan (cbCTV1, cbCTV2, etc.). 
 
Stage	1:	
Exploratory	
study	of	9	
strategies	in	10	
patients
Stage	2:	Further	
examination	of	
2	most	
promising	
strategies	to	
determine	best	
strategy
Stage	3:	
Dosimetric	
analysis	of	"best	
strategy"	over	
standard
Stage	4:	Dose	
escalation	
potential	with	
best	strategy	
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CTVprimary had to be modified compared to the departmental standard protocol (as in 
5.3.3) for the purpose of this study. The reason for this was that the CTV needed to be 
consistently delineated on both planning CT and all CBCTs, and several structures were 
not clearly visible on CBCT.  
 
These modifications were as follows in table 5.4-1: 
Table 5.4-1: Modifications to CTVprimary for modelling study 
Issue Modification in this study 
GTV not visible on CBCT No GTV outlined, instead a CTV of whole cervix, 
uterus, upper vagina and parametrium used. 
Upper vagina usually is 2cm below visible GTV, 
instead the lower border of pubic symphysis was 
used as a landmark 
Anterior parametrial border: 
external iliac vessels not clear on 
CBCT 
Anterior border taken as the anterior most extent 
of the uterus/cervix and a straight horizontal line 
was extended from this point to reach the 
CTVnodes on either side (figure 5.4-2) 
Posterior parametrial border: 
mesorectum and internal iliac 
vessels not clear on CBCT 
Posterior border taken as a straight line across 
the posterior most aspect of the uterus/cervix to 
reach the CTVnodes (figure 5.4-2) 
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Figure 5.4-2: Anterior and posterior parametrial borders used in modelling study 
5.4.3. Organs at risk (OARs) 
OARs were outlined on the full bladder planning scan only. Four key OARs were used in 
this study, bowel loops, bowel bag, rectum and bladder for stages 1 and 2. For stages 3 
the small bowel, anal canal, sigmoid, and large bowel were also delineated given the 
dose-volume constraints discussed in Chapter II and III of this thesis. Definitions are 
detailed in table 5.4-2, justifications of these definitions can be found in chapter III section 
3.3.5. 
Table 5.4-2: Definitions of OARs 
Structure Definition 
Bowel 
loops 
Bowel loops (including contents) from the recto-sigmoid junction inferiorly 
to 4.2cm above the PTV superiorly.   
Bowel bag The entire abdominal/pelvic contents were initially outlined. The inferior 
slice was the most inferior small or large bowel loop (regardless of 
relation to rectum). The superior slice was 4.2cm above the PTV.  
Then all non-GI structures (muscle, bone, kidney, bladder, prostate, and 
uterus) were excluded. 
Rectum Defined inferiorly from the ischial tuberosities to the recto-sigmoid 
junction 
Bladder Whole bladder from apex to base 
Anal 
Canal 
Anal verge identified and 3cm of anal canal/distal rectum were outlined 
caudally, inclusive of contents 
Sigmoid Commenced inferiorly at the recto-sigmoid junction, followed to the most 
anterior-lateral point where it becomes descending colon 
Large 
Bowel 
Sigmoid and colon were combined 
Small 
Bowel 
All other bowel loops identified within 4.2cm above the PTV which were 
not large bowel. 
In figure 5.4-2 the yellow lines 
demonstrate the standard borders 
used with curving from the 
posterior bladder to the external 
iliac vessels anteriorly.  This was 
modified to the orange line shown, 
the anterior aspect of the 
cervix/uterus. 
Posteriorly instead of curving 
around mesorectum to the internal 
iliac vessels, as these structures 
are not seen consistently on 
CBCT, instead the blue line was 
used as posterior border, posterior 
aspect of the cervix/uterus. 
Laterally the CTV nodes are 
reached though not shown in this 
image 
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5.5. Stage 1 methods: volumetric strategy modelling 
Nine different margin strategies were modelled on the first 10 patients in the study. Each 
strategy was compared against a “standard margin”, which in this study was an isotropic 
2cm margin around the primary CTV.  
The strategies modelled are summarized in table 5.5-1, with further description of some 
below: 
Table 5.5-1: Summary of strategies used 
 
 Anisotropic margins: An anisotropic population-based margin was added around 
CTVfull derived from the CBCTs of the first 10 patients. For each CTVempty and cbCTV 
the margin around CTVfull required to fully cover the CTV in superior, anterior, posterior, 
left and right directions was determined. This was done by separately growing margins in 
   Strategy 
name 
Structures used/formed Margin Applied Reference 
Std Standard 
 
CTVfull 2cm isotropic margin to PTV RTOG 
(95) 
1 Iso_1.5 
 
CTVfull 1.5cm isotropic margin to PTV RTOG 
(95) 
2 Anisotropic CTVfull Population-based anisotropic 
margin (results in section 5.11.1) 
 
3 Structure-
specific 
Uterus, cervix, vagina and 
parametrium from CTVfull 
4cm margin around uterus (1cm 
inferiorly); 1.3cm margin around 
cervix, vagina & parametrium 
Chan et 
al.(108) 
4 ITV ITV = CTVfull + CTVempty 1cm margin to PTV Bhuva et 
al (200) 
5 Composite1 Composite = ITV + cbCTV1 
+ cbCTV2 + cbCTV3 
 
5mm margin to PTV  
6 Composite 
2 
Composite = ITV + cbCTV1 
+ cbCTV2 + cbCTV3 
 
10mm margin to PTV  
7 PotD1  CTVfull, CTVmid or CTV 
empty  
 
Library of 4 plans: 
- PTVfull= CTVfull + 7mm  
- PTVmid= CTVmid + 7mm  
- PTVempty=CTVempty +7mm  
- Backup plan =CTVfull+2cm  
 
8 PotD2 CTVfull, CTVmid or CTV 
empty  
 
Library of 4 plans: 
- PTVfull= CTVfull + 10mm  
- PTVmid= CTVmid + 10mm  
- PTVempty=CTVempty +10mm  
- Backup plan =CTVfull+2cm 
 
9 PotD3 CTVfull, CTVmid or CTV 
empty 
Library of 3 plans: 
- PTVfull= CTVfull + 10mm  
- PTVmid= CTVmid + 10mm  
- PTVempty=CTVempty +10mm  
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each direction at 2mm intervals from 0-70mm around CTVfull and choosing the tightest 
margin in each direction that will fully cover each CBCT being assessed. An example is 
shown in figure 5.5-1. 
  
Figure 5.5-1: Anisotropic Margin Derivation 
 
In each direction for all 10 patients the margin required to cover 95% of all cbCTVs studied  
was determined. As no inferior margin can be derived in this study as a bony landmark 
was used for inferior border of the CTV, a 1.5cm margin was applied inferiorly for the 
anisotropic margin. This was chosen to account for vaginal motion in a previous study 
performed at our institution. 
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in each direction that will fully cover each CBCT being assessed. An example is shown in 
figure 5.3.  
In each direction for all 10 patients the margin required to cover 95% of all cbCTVs studied 
was determined. As no inferior margin can be derived in this study as a bony landmark 
was used for inferior border of the CTV, a 1.5cm margin was pplied inferiorly for the 
anisotropic margin. This was chosen to account for vaginal motion in a previous study 
performed at our institution. 
Figure 5.3: Derivation of Anisotropic Margins 
5.5.1.1. Composite strategies 
	 	
	 	
The	figure	gives	an	example	of	anisotropic	margin	derivation.	The	first	image	shows	CTVfull		(in	blue)	
on	the	full	bladder	planning	scan.	The	second	image	shows	cbCTV1	(in	pink)	on	the	CBCT	from	day	1	
of	treatment,	which	shows	the	CTV	has	moved	anteriorly.	An	anterior	margin	of	32mm	(in	red)	
around	CTVfull	was	required	to	encompass	cbCTV1.	This	was	checked	on	the	sagittal	section	where	
the	need	for	the	32mm	margin	is	demonstrated	to	cover	cbCTV1	(in	pink).	
147 
 
Composite strategies 
 
Figure 5.5-2: Composite Margin Derivation 
CTVfull, CTVempty, cbCTV1, cbCTV2 and cbCTV3 were combined together to form a 
composite using the union function. A PTV margin of 5mm was added in composite 1 
strategy, and 10mm  in composite 2 strategy. These are illustrated in figure 5.5-2.  
 
For the composite strategy to be used practically patients need to be treated for the first 5 
days with a standard 2cm margin. Three days are needed to acquired cbCTV1, cbCTV2 
and cbCTV3 and two days are to replan the patients treatment plan based on the 
composite. In view of this the composite strategies were proportionately modelled with 5#s 
of standard margin treatment, and 20#s of composite use.   
Plan of the Day (PotD) 
Library of Plans (LoP) creation 
From the CTVfull and CTVempty a third CTV was created interpolating these two volumes 
to form ‘CTV mid’. This was performed by Professor Emiliano Spezi using structure-guided 
deformable image registration on the Velocity software (version 3.1, Varian Medical 
Systems) which maps the CTVempty onto CTVfull in relation to bladder filling.   
Custom software developed in the Matlab environment by Professor Spezi was then used 
with a scaling factor of 0.7 in order to give a CTVmid, with a bladder volume which is 70% 
between that on the full bladder scan and empty bladder scan. This scaling factor was 
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CTVfull, CTVempty, cbCTV1, cbCTV2 and cbCTV3 were combined together to form a 
composite using the union function. A PTV margin of 5mm was added in composite 1 
strategy, and 10mm  in composite 2 strategy. These are illustrated in figure 5.4.  
Figure 5.4: Composite Margins Strategies 
 
For the composite strategy to be used practically patients need to be treated for the first 5 
days with a standard 2cm margin. Three days are needed to acquired cbCTV1, cbCTV2 
and cbCTV3 and two days are to replan the patients treatment plan based on the 
composite. In view of this the composite strategies were proportionately modelled with 5#s 
of standard margin treatment, and 20#s of composite use.   
5.5.1.2. Plan of the Day (PotD) 
5.5.1.2.1. Library of Plans (LoP) creation 
From the CTVfull and CTVempty a third CTV was created interpolating these two volumes 
to form ‘CTV mid’. This was performed by Professor Emiliano Spezi using structure-guided 
deformable image registration on the Velocity software (version 3.1, Varian Medical 
Systems) which maps the CTVempty onto CTVfull in relation to bladder filling.   
Custom software developed in the Matlab environment by Professor Spezi was then used 
with a scaling factor of 0.7 in order to give a CTVmid, with a bladder volume which is 70% 
between that on the full bladder scan and empty bladder scan. This scaling factor was 
	
The	composite	of	CTVfull,	CTV	empty,	cbCTV1,	cbCTV2	and	cbCTV3	is	shown	in	green.	A	5mm	CTV-
PTV	margin	around	this	forms	Composite1	(orange)	and	a	10mm	CTV-PTV	margin	forms	Composite2	
(red).		
Composite1	
margin	
Composite2	
margin	Composite	
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chosen rather than 0.5 as with a bladder volume 50% that between full and empty bladder 
scans very little variation in CTV was noted.  
An example of a CTVmid volume is illustrated in figure 5.5-3. 
To each CTV (CTVfull, CTVmid, and CTVempty) a CTV-PTV margin was added, 7mm in 
PotD1 strategy and 10mm in PotD2 and PotD3 strategies. These PTVs were termed as 
‘plans’, forming a library of plans: full, mid and empty.   
For each CBCT the plan from the library was chosen based on which PTV covered >99% 
of the cbCTV. In addition, if two PTVs had equivalent levels of cbCTV coverage then the 
plan which maximally avoided critical OAR was selected (prioritised as bowel>bowel 
bag>rectum>bladder).  
In addition in PotD1 and PotD2 strategies, a standard PTV (“standard plan”) was used 
(defined as CTVfull with a 2cm isotropic margin) when >99% of the CTV was not being 
covered by any of the 3 plans. PotD3 had no backup plan use.  
Extrapolation of PotD data over the whole course of radiotherapy 
For each patient the number of each plan chosen (full, mid, empty or backup) was noted 
and the proportion of each determined in relation to the number of CBCTs for that patient. 
This was then proportionately increased to determine how many fractions (out of a total 
25) would use each plan.  
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Figure 5.5-3: Plan of the day library of plans: CTVfull, CTVempty and CTVmid 
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Figure 5.5: Creation of CTV mid in green (third image), from CTVfull in blue (first image) and CTVempty in red 
(second image) 
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5.5.1. Assessment of each strategy 
Each of the 9 margin strategies were assessed on each cbCTV for: 
1. PTV volume  
2. CTV coverage 
a. “Encompassed” or “missed”: if cbCTV is >99% covered this is “encompassed”, 
if <99% of the cbCTV is covered this is “missed”.  
b. % coverage: the % of the cbCTV included within the PTV 
c. Size of miss 
d. Direction of miss 
e. Site of miss: for each CTV miss the component(s) where the miss occurs is 
noted: tip of uterus (ToU), anterior uterus, posterior uterus, cervix, vagina or 
parametrium; see figure 5.5-4.   
 
 
Figure 5.5-4: Sites of CTV miss 
3. OAR within PTV 
For bladder and rectum the % volume of OAR within the PTV was noted. For bowel and 
bowel bag the volume of OAR in cc within the PTV was noted.  
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5.6. Assessment of each strategy 
Each of the 9 margin strategies were assessed on each CBCT for: 
1. PTV volume  
2. CTV coverage 
a. “Encompassed” or “missed”: if cbCTV is >99% covered this “encompassed”, if 
<99% of the cbCTV is covered this is “missed”.  
b. % coverage: the % of the cbCTV included within the PTV 
c. Size of miss 
d. Direction of miss 
e. Site of miss: for each CTV miss the component(s) where the miss occurs is 
noted: tip of uterus (ToU), anterior uterus, posterior uterus, cervix, vagina or 
parametrium; see figure 5.6  
 
3. OAR within PTV 
For bladder and rectum the % volume of OAR within the PTV was noted. For bowel and
bowel bag the volume of OAR in cc within the PTV was noted.  
 
 
Figure 5.6: Sites of CTV miss 
 
Anterior	Uterus	
Tip	of	uterus	(ToU),	
within	1cm	from	
furthermost	point	
Posterior	
Uterus	
Cervix	
Vagina	
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5.5.2. Statistical Analysis 
The mean values of each of the above assessments for each strategy were compared with 
the mean values when using a standard margin. Differences in these means were tested 
using Mann-Whitney U testing, given that the data was non-normally distributed 
(significance level of p<0.05 was used). All statistics were performed on SPSS version 20.  
Determination of “best” strategies 
The two “best” potential strategies were determined by assessing those with the overall 
ability to: improve CTV coverage, improve OAR sparing and reduce PTV volume. OAR 
sparing was prioritised in order of bowel, bowel bag, rectum and then bladder.  
5.6. Stage 2 Methods 
The two strategies that best performed with these criteria were further analysed in Stage 2 
with all additional patients meeting inclusion criteria. Methods were as described above 
(stage 1) and statistical analysis made with all patients including those in stage 1. Based 
on the same criteria as in 5.5.2 the single “best strategy” was determined from the results 
of Stage 2. 
5.7. Stage 3 Methods 
The best strategy from stage 2 was used to define volumes for VMAT planning. The 
resulting plan was compared dosimetrically to two other plans, a 3D-conformal plan with a 
standard margin, and a VMAT plan with a standard margin.  
3D-conformal planning was used as it is the current standard of planning of for cervical 
cancer radiotherapy within our institution. VMAT planning with a standard margin was 
performed for direct comparison of the margin strategy rather than differences being 
confounded by plan type. 
 
Each PTVprimary was combined with a PTVnodes to form a PTVfinal. Treatment plans 
were generated by experienced treatment planners/physicists (Kathryn Morgan, Christian 
McCracken, Aileen Lyons, Rhydian Maggs), using OncentraMasterplan (OMP) V4.3 
software. VMAT plans were created with the use of a class solution that had previously 
been developed for post-operative gynaecological patients.  
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Dummy volumes were automatically generated using a pre-determined “script” on 
Prosoma version 3.3, which relied on structure addition/subtraction/intersection and 
application of margins to produce patient-specific dummy volumes. These were then 
exported to OMP where the plan was produced using the inverse optimisation module. A 
dual arc technique was used with the use of 6MV photons.   
The primary aim was to obtain at least 95% of the prescribed dose to 99% of the PTV. The 
secondary aim was to reduce OAR doses as much as possible, without compromise to 
target coverage.  
Forward planned 3D-conformal plans were composed of 4 fields of 10MV photons, at 
orthogonal angles, with wedging as appropriate to improve coverage and uniformity. 
Where required additional ‘filler’ segments were added to shield regions of high dose 
and/or boost regions of low dose. 
5.7.1. Coverage assessment 
The prescription for each plan was 45Gy in 25#, 1.8Gy per fraction. Each plan was 
assessed according to the following with dosimetric criteria: 
1. 99% of the PTVfinal to receive at least 95% (42.7Gy) of the prescribed dose 
2. Dmedian of 99-101% 
3.  An ICRU maximum of 107% (48.15Gy) to 1.8cc 
5.7.2. OAR assessment 
DVH data for each patient was imported into Microsoft Excel by DVHImport software 
programmed by Phil Parsons (Physicist, Velindre Cancer Centre) 
For each OAR, the mean dose-volume histograms for all patients planned were compared 
to assess benefits of the strategy. Following this a range of dose-volume constraints as in 
table 5.7-1 were used (from published literature, chapter III of this thesis, and some 
departmental constraints) to compare strategies and determine whether the “best strategy” 
improved the chances of the constraints being met compared with the standard plans.  
No bladder constraints are found in the published literature for toxicity reduction at the 
doses used for cervical cancer patients (45Gy). In view of this planning-based constraints 
developed in Velindre Cancer Centre were used as a metric to test the strategies, 
acknowledging that they may not have any impact on bladder toxicity.   
DVH data was converted using the EQD2 formula so constraints defined for 2Gy fractions 
could be applied (α/β of 3).  
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Table 5.7-1: Constraints used for dosimetric analysis 
OAR Type of 
constraint 
Source of constraint Constraint EQD2 
Bowel  
 
Toxicity 
based 
Guerrero-Urbano et al 
(112)  
(validated in Chapter III 
thesis) 
V40<71cc V38.6<71cc 
Bowel bag Toxicity 
based 
QUANTEC (128) V45<195cc 
V5<1689cc 
V43.2<195cc 
V5<1689cc Chapter III thesis 
Rectum Toxicity 
based 
Gulliford et al (133) V30<80% 
V40<65% 
V30<80% 
V40<65% 
Bladder Planning 
based 
Departmental 
 
V35<70% 
V45<10% 
V45<20% 
V30.8<70% 
V43.2<10% 
(optimal) 
V43.2<20% 
(mandatory) 
     
Small bowel  Toxicity 
based 
QUANTEC (128) V15<120cc V10.8<120cc 
Anal canal Toxicity 
based 
Systematic review (ch 
II) 
Dmean<40Gy Dmean<40Gy 
Sigmoid Toxicity 
based 
Chapter III thesis  V10<52.6% 
V25<36.2%  
Dmedian<13.7Gy 
V10<52.6% 
V25<36.2% 
Dmedian<13.7Gy 
Large Bowel Toxicity 
based 
Chapter III thesis V15<60.8cc V15<60.8cc 
5.8. Stage 4 methods: Dose escalation 
In cases where bowel sparing was shown to be feasible in stage 3 of the study 
(determined by the bowel dose constraint V38.6<71cc being met), dose escalation was 
modelled.  
Increasing the dose to PTVnodes and PTVprimary fraction by fraction (by 1.8Gy at a time) 
was modelled until the bowel dose constraint V38.6<71cc, rectal constraints of 30Gy<80% 
and 40Gy<65%, and anal canal constraints of Dmean<40Gy were met. Once these 
constraints were being breached then the dose escalation modelling was stopped. 
An additional high dose constraint for bowel was added to ensure that bowel doses were 
not being pushed too high (bowel V56.6Gy>0.5cc, taken from Guerrero-Urbano et al (112)) 
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5.9. Results 
5.9.1. Patient characteristics 
Ten patients were included in stage 1 and a total of 111 scans were assessed (including 
10 full bladder, 10 empty bladder and 91 CBCT scans). For stage 2 10 additional patients 
were studied. For the total 20 patients 212 scans (including 20 full bladder, 20 empty 
bladder scans and 172 CBCT scans were assessed). 
 
Patient characteristics are outlined in table 5.9-1. The mean age was 60.4 years, and 
13/20 patients had concurrent chemotherapy.  
Each patient had between 7 and 13 CBCTs with a mean of 8.6 scans. 14 patients had 
additional scans to those specified in the departmental protocol and the reasons are noted 
were all due to changes in bladder, bowel or rectal position or filling compared with that at 
planning.  
 
Table 5.9-1: Patient characteristics 
Pt	no	 Age	
(yrs)	
Stage	 Radiotherapy	Regime	
(Gy/#)	
Concurrent	Chemotherapy		 No	of	CBCTs		
1 71 IIB 45/25 cisplatin weekly 9 
2 49 IIIB 45/25 cisplatin weekly 7 
3 51 IIA 45/25 No 13 
4 35 IIIB 45/25 cisplatin weekly 7 
5 54 IIB 45/25 cisplatin weekly 8 
6 74 IIB 45/25 No 12 
7 41 II 45/25 cisplatin weekly 7 
8 53 III 45/25 to pelvis, 18/10 
inguinal nodes 
cisplatin weekly 10 
9 55 IIB 45/25 cisplatin weekly 8 
10 29 IIB 45/25 cisplatin (2 cycles) then 
carboplatin 
10 
11 65 IIB 45/25 Cisplatin 7 
12 65 IIB 45/25 cisplatin weekly 9 
13 83 II 45/25 no chemo 7 
14 62 IIIB 45/25 no chemo 9 
15 68 IIB 45/25 cisplatin weekly 7 
16 82 IB2 45/25 no chemo 9 
17 29 IB2 45/25 Cisplatin weekly 8 
18 84 IVA 45/25 no chemo 8 
19 62 IB2 45/25 cisplatin weekly 6 
20 93 IIB 45/25 no chemo 11 
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5.9.2. CTV volumes over time 
CTV volumes ranged from 69.8cc to 443cc, with a mean volume of 175.4cc. 16 of the 20 
patients had a smaller CTV volume at the end of treatment compared with at planning 
which may reflect tumour regression. Mean CTV volumes over time are shown in Figure 
5.9-1. 
 
Figure 5.9-1: CTV volumes over time 
5.10. Stage 1 results 
5.10.1. Population-based anisotropic margins  
These were derived from the directional margins for the 101 CTVs from 10 patients. 
Statistics for these are shown in table 5.10-1. Margins encompassing the CTV in 95% of 
CBCTs assessed were taken as the population-based margins. These were significantly 
larger anteriorly compared with other directions. 
Table 5.10-1: Anisotropic margins derived from 10 patients 
  
 
0	
50	
100	
150	
200	
250	
Full	 Empty	 CBCT1	 CBCT2	 CBCT3	 CBCT4	 CBCT5	 CBCT6	 CBCT7	
	M
ea
n	
CT
V	
vo
lu
m
e	
(c
c)
	
Scan	number	
Mean	CTV	volume	over	Eme	
 Anterior 
(mm) 
Posterior 
(mm) 
Superior 
(mm) 
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(mm) 
Min  0 0 0 0 0 
25% quartile 10 4 0 8 8 
Median 22 10 0 22 20 
75% quartile 40 22 3 34 32 
90% 56 30 12 38 46 
95% 60 36 18 40 48 
Max 70 54 21 50 56 
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5.10.2. Plan-of-the day strategies (PotD1, PotD2 and PotD3) 
The overall use of the library plans for each strategy is shown in figure 5.10-1, With PotD1 
(7mm margins) the backup plan was required 70% of the time; and with PotD2 (10mm 
margins) a back-up plan was required 50% of the time. 
 
Figure 5.10-1: Plan library use 
Individual patient variation of plan use is noted in table 5.10-2. For some patients e.g. 
patient 3 and 6 the plan library was not suitable and a back-up plan was required most of 
the time. For others, such as patient 2, a single plan from the library was used throughout.  
Table 5.10-2: Plan-of-the-day modelling use 
 PotD 1 (7mm margins with Back-
up) 
PotD2 (10mm margin with 
Back-up) 
PotD3 (10mm margin 
with no Back-up) 
 Full Mid Empty Back-
up 
Full Mid Empty Back-
up 
Full Mid Empty 
Pt1 3 2 0 4 2 5 1 1 3 5 1 
Pt2 0 0 7 0 0 0 7 0 0 0 7 
Pt3 0 0 0 13 0 2 0 11 6 7 0 
Pt4 0 0 1 6 0 0 1 6 6 0 1 
Pt5 0 0 0 8 0 0 0 8 6 2 0 
Pt6 0 1 2 9 0 2 3 7 2 2 10 
Pt7 0 2 0 5 0 3 0 4 3 4 0 
Pt8 0 6 0 4 2 7 1 0 2 7 1 
Pt9 1 0 0 7 2 1 0 5 7 1 0 
Pt10 1 0 1 8 4 1 2 3 6 2 2 
Total 
(%) 
5  
(5.5%) 
11 
(12%) 
11 
(12%) 
64 
(70%) 
10 
(11%) 
21 
(23%) 
15 
(15%) 
45 
(50%) 
41 
(45%) 
30 
(33%) 
22 
(24%) 
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5.11. Comparison of strategies 
5.11.1. PTV volume 
PTV volumes are shown in figure 5.11-1. The PTV volumes when a standard margin is 
used is represented by the purple bar, with the line across the bar representing median 
volume. Srategies which increase median PTV volume compared with standard are in red, 
and those which reduce PTV volume are in green.  
Anisotropic margins doubled the PTV size and a structure-specific margin increased it by 
34% on average. All other strategies reduced PTV volume. These changes were all 
statistically significant (p<0.05) apart from the reduction from PotD1.  
 
 
Figure 5.11-1: PTV Volumes with different strategies 
5.11.2. CTV coverage and misses 
CTV coverage and misses CTV coverage is shown in table 5.11-1. The mean % coverage 
for the standard margin was 99.6% for all CBCTs studied. For all strategies studied the 
mean coverage was good ranging from 97.24% to 99.98%. 
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Table 5.11-1: CTV coverage compared with standard margin 
 
Looking at those with CTV “encompassed” and CTV “missed”, the standard 2cm margin 
resulted in misses in 13 scans studied, with a mean miss of 3% in those 13 scans.   
Five of the strategies increased the number of CTV misses (see figure 5.11-2). An 
isotropic 1.5cm margin increased misses to 34%, and an ITV to 45% Structure-specific, 
composite 1 and PotD3 stratgies all increased misses, with PotD3, where no back-up plan 
was used, increasing the rate of miss to 49%. This would therefore not be a clinically 
useful strategy. 
Four strategies reduced the rate of CTV misses. Anisotropic margins, as expected 
reduced the number of misses, down to 1%. With the adaptive strategies, the Composite2 
strategy best improved coverage by 6% (p=0.026). PotD1 and PotD2 also both improved 
CTV misses, though to a smaller degree. 
 
Figure 5.11-2: CTVs encompassed and missed by strategy 
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5.11.3. Details of CTV ‘Misses’  
Size of misses 
Of those misses that occurred with a standard margin, these were on average 3% of the 
CTV. The mean size of misses for other strategies (see table 5.11-2) ranged from 1.7% 
(with anisotropic) to 5.6% with PotD3. The largest miss for any patient was with ITV where 
19% of the CTV was missed.  
Table 5.11-2 Size of CTV Misses 
 
Direction of misses 
The most common directions of miss were anterior and posterior as in figure 5.11-3.  
 
 
Figure 5.11-3: Direction of misses 
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Iso_1.5 Aniso-
tropic 
Structure-
specific 
ITV Composite 
1 
Composite 
2 
PotD1 PotD2 PotD3 
Mean 
miss (cc) 
3.0 1.74 4.9 4.9 8.3 5.3 3.5 5.9 4.3 2.8 
Mean 
miss (%) 
 
3% 5% 1.7% 3.2% 4.5% 4% 2.3% 3% 2.5% 5.6% 
Maximum 
misses 
(%) 
6.6% 14.3% 1.72% 7.7% 19% 11% 4.5% 5.2% 5.2% 8.7% 
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Sites of Misses 
Figure 5.11-4 shows the most common sites of miss were ToU followed by parametrium. 
The cervix, the most important site to not be missed, had misses with PoTD3, isotropic 
1.5cm and ITV margins.  
 
Figure 5.11-4: Sites of CTV miss 
5.11.4. OARs within the PTV 
Figure 5.11-5 shows the OARs within the PTV for each strategy, with standard margin in 
purple, those with a median reduction in green, and increase in red. The use of anisotropic 
margin increased all four OARs within the PTV. Structure-specific margins increased 
bowel and bowel bag within the PTV. All other strategies reduced OARs within the PTV, in 
particular PotD3. 
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Figure 5.11-5: OARs within PTV by strategy
143	
	
	
	
	
	
162 
 
5.11.5. Stage 1 Overall results 
Table 5.11-3: Summary of strategies 
Strategy PTV 
volume 
CTVs 
encompassed 
Bowel in 
PTV 
Bowel 
bag in 
PTV 
Rectum 
in PTV 
Bladder 
in PTV 
Iso_1.5 Reduced Reduced Reduced Reduced Reduced Reduced 
Anisotropic Increased Increased Increased Increased Increased Increased 
Structure-
specific 
Increased Reduced Increased Increased Reduced Increased 
ITV Reduced Reduced Reduced Reduced Reduced Reduced 
Composite1 Reduced Reduced Reduced Reduced Reduced Reduced 
Composite2 Reduced Increased Reduced Reduced Reduced Reduced 
PotD1 Reduced Increased Reduced Reduced Reduced Reduced 
PotD2 Reduced Increased Reduced Reduced Reduced Reduced 
PotD3 Reduced Reduced Reduced Reduced Reduced Reduced 
 
A summary of the nine strategies is shown in table 5.11-3. Improvements are in green and 
worsening in red.  Statistically significant changes (p<0.05) from standard are highlighted 
in bold. 
Strategies that reduced the CTVs encompassed compared to standard margin were not 
assessed any further (Iso_1.5, structure-specific, ITV, composite1 and PotD3).  
The anisotropic margin although improved coverage resulted in a mean doubling of PTV 
volume, with resultant increases in all four OARs within the PTV. This was therefore not 
considered further. 
The remaining strategies, Composite2, PotD1 and PotD2, all improved coverage and 
reduced OAR sparing. Comparing the use of PotD1 and PotD2 in PotD1 a backup plan 
had to be used in 70% of scans assessed, compared with 50% with PotD2.  
 
In view of this Composite2 and PotD2 were taken into stage 2 for further analysis. 
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5.12. Stage 2 results 
In stage 2 a standard margin was compared with composite2 and PotD2 strategy for an 
additional 10 patients. Details of the use of PotD2 strategy are detailed below for all 20 
patients (including the first 10 from stage 1) in figure 5.12-1. Overall the plan library could 
be used in 62% of fractions studied, with the backup plan being used in 38% of fractions. 
 
 
Figure 5.12-1: Plan library use with 20 patients using PotD2 strategy 
 
The results for all 20 patients in terms of PTV volume, CTV coverage and OARs within the 
PTV are shown in table 5.12-1. PTV volume was significantly reduced with both strategies, 
though CTV coverage was similar. CTV misses were slightly improved (non-significant) 
with both adaptive strategies over a standard margin.  
 
PotD2 strategy reduced bowel, bowel bag, rectum and bladder within the PTV more than 
composite2 strategy (non-significant difference between the two strategies). Compared to 
a standard margin the reductions in all four OARs seen with PotD2 were statistically 
significant. In one patient for example, PotD strategy demonstrated the ability to reduce 
bowel in the PTV by 78.7%. 
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Table 5.12-1: Comparison of Composite2 and PotD2 against standard 
 
 The OARs within the PTV are shown in figure 5.12-2 and 5.12-3 below 
 
 
Figure 5.12-2: Bowel and Bowel bag in PTV 
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Bowel	and	Bowel	Bag	within	the	PTV	
Standard	
Composite2	
PotD2	
 Standard Composite2 PotD2 
Mean PTV vol (cc) 1053.1 779.8 733.4 
Mean change from standard 
(p-value) 
 Reduced 26% 
(p=0.001) 
Reduced 30.8% 
(p=0.000) 
   
Mean % CTV coverage 99.51 99.79 99.64 
Change from standard 
(p-value) 
  Increased 0.29 %  
(p=0.596) 
Increased 0.14% 
(p=0.113) 
    
No of CTVs encompassed (%) 176 (91.7%) 104 (92.9%) 160 (93.2%) 
Change from standard  Increased 1.2% Increased 1.5% 
No of CTVs missed (%) 16 (8.3%) 7 (6%) 12 (7%) 
    
Mean bowel in PTV (cc) 119.57 86.84 73.87 
Reduction from standard  27.7% (p=0.094)  39.4% (p=0.015) 
Mean bowel bag in PTV (cc) 356.79 277.78 221.76 
Reduction from standard 
 
 18.0% (p=0.004) 34.4% (p=0.000) 
Mean rectum in PTV (%) 73.53 62.16 50.29 
Reduction from standard 
 
 15.1% (p=0.000) 31.8% (p=0.000) 
Mean bladder in PTV (%) 55.32 48.93 38.62 
Reduction from standard 
 
 10.27% (p=0.33) 30.39% (p=0.009) 
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Figure 5.12-3: % rectum and bladder within PTV 
 
In view of the above trends PotD2 was considered the “best strategy”, and was taken 
forward for dosimetric modelling.  
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5.13. Stage 3 Results 
Dosimetric modelling was performed for the first 10 patients in this study. For each patient 
three planning techniques were compared; a 3D conformal plan with 2cm standard margin 
around PTVprimary (“conformal”), a VMAT plan with a 2cm standard margin 
(“VMAT_standard”), and a VMAT plan with PotD2 (“VMAT_PotD2”). 
5.13.1. PTV coverage 
All plans met the criteria of D99>95% though for most patients conformal plans had higher 
% coverage than VMAT plans. A Dmedian of 99-101% was met by the majority of plans, 
though 6 of the VMAT plans had Dmedian between 101.1 and 102.9. One of the plans had 
a ICRU maximum of 108.3% and on review was clinically acceptable. 
5.14. OAR analysis 
5.14.1. DVH analysis 
Bowel loops, bowel bag, large and small bowel 
The mean DVHs for each planning technique for bowel loops and bowel bag are illustrated 
in figure 5.14-1. A similar pattern was seen for small and large bowel. In doses higher than 
V15 an advantage is seen with VMAT planning over conformal planning. However 
comparing VMAT_standard and VMAT_PotD2 there is little difference in the mean DVHs.  
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Figure 5.14-1: Mean bowel and bowel bag DVHs 
Rectum 
 
Figure 5.14-2: Mean rectal DVH 
A different pattern is seen with the rectum. The mean rectal DVH for each strategy is 
shown in figure 5.14-2. As expected, overall VMAT planning improved the DVH compared 
with conformal planning. However in addition there is a clear separation of the curves with 
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the use of VMAT_PotD2 over VMAT_standard from dose levels 20-45Gy, which is 
statistically significant at multiple levels between V25 and V45.  
5.14.1.3. Anal Canal 
For the anal canal the DVH comparison is shown in figure 5.14-3. VMAT_standard 
improved dosimetry at all dose levels compared with conformal although these were not 
significant. VMAT_PotD2 however significantly improved dosimetry at V20, V30 and V40 
(p=0.015, p=0.043, and p=0.09) compared with conformal planning. Comparing 
VMAT_PotD2 with VMAT_standard there was improved dosimetry overall, with 
significance at the V40 level (p=0.035).  
 
Figure 5.14-3: Mean Anal Canal DVH 
5.14.1.4. Bladder 
The mean DVH for bladder is shown in figure 5.14-4 again demonstrating improved 
dosimetry of VMAT_PotD2 over VMAT_standard and conformal plans, albeit non-
statistically significant.  
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Figure 5.14-4: Mean Bladder DVH 
Sigmoid 
Figure 5.14-5 shows the mean sigmoid DVH. Marginal benefit was seen at V40 comparing 
VMAT_PotD2 with VMAT_standard, although this was not statistically significant.  
 
Figure 5.14-5: Mean Sigmoid DVH 
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5.14.2. Constraint Analysis 
The three planning techniques were assessed against dose-volume constraints as in table 
5.14-1.   
Table 5.14-1: Comparison of Conformal, VMAT_standard and VMAT_PotD2 with dose-volume constraints 
  No of patients meeting constraint (out of 10) 
OAR EQD2 of constraint Conformal VMAT_Standard VMAT_PotD2 
Bowel loops V38.6<71cc 0 1 1 
Bowel bag V43.2<195cc 
V5<1689cc 
1 0 1 
2 2 2 
Rectum V30<80% 
V40<65% 
0 
0 
0 
0 
3 
7 
Bladder V30.8<70% 
V43.2<10% (opt) 
V43.2<20% (mand) 
0 
0 
0 
2 
0 
7 
2 
1 
8 
     
Small bowel  V10.8<120cc 0 0 0 
Anal canal Dmean<40Gy 8 10 10 
Sigmoid V15<47.5% 
V25<36.2% 
Dmedian <13.7Gy 
0 
1 
0 
1 
1 
0 
1 
1 
0 
Large Bowel V15<60.8cc 0 1 1 
 
Dosimetric benefits were seen for rectum, anal canal and bladder. For the rectum in 
particular, dose-volume constraints for V30 and V40 that were not met with either 
conformal or VMAT_standard planning in any patients were met with VMAT_PotD2 in 3 
and 7 patients respectively. Figure 5.14-6 illustrates the V40 rectum across all 10 patients 
with clear benefits seen with VMAT_PotD2.  
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Figure 5.14-6: V40 Rectum 
At both dose levels studied there was a statistically significant improvement with the use of 
VMAT_PotD2 over VMAT_standard (table 5.14-2). 
Table 5.14-2: Comparison of V30 and V40 rectum between techniques 
Dose 
level 
Conformal 
(mean) 
VMAT_standard 
(mean) 
VMAT_PotD2 
(mean) 
Significance between VMAT_ 
standard and VMAT_PotD2 
V30 98.02% 90.9% 80.6% p=0.023 
V40 93.75% 81.5% 55.9% p=<0.001 
 
The constraint for anal canal (Dmean<40Gy) was met by all plans in all patients, however 
as seen in figure 5.14-7 the use of VMAT_PotD2 reduced Dmean anal canal in all patients 
more than VMAT_standard.   
 
Figure 5.14-7: Dmean Anal Canal 
 
With the lack of toxicity-based constraints for bladder, only two departmental constraints 
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seen with the use of VMAT over conformal planning (statistically significant,p=<0.001), 
with mean doses at V43.2 being 76.75% with conformal radiotherapy, 23.6% with 
VMAT_standard and 18.7% with VMAT_PotD2. Although improvements were seen for 7 
out of 10 patients with VMAT_PotD2 compared with VMAT_standard, the differences did 
not reach statistical significance. 
 
Figure 5.14-8: V43.2Gy Bladder 
The bowel loops constraint of V38.6<71cc, was only met by one patient (patient 1) with 
both types of VMAT planning (see figure 5.14-9). Although a lower V38.6 was seen in 9/10 
patients with VMAT_PotD2 compared with VMAT_standard, again statistical significance 
was not reached. 
 
Figure 5.14-9: V38.6 Bowel Loops 
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For small bowel, large bowel, sigmoid and bowel bag the use of VMAT_PotD2 did not 
increase the likelihood of the constraints studied being met compared with 
VMAT_standard.  
5.15. Stage 4: Dose escalation 
From the results of stage 3 only one patient (patient 1) met the dose-volume constraint for 
bowel, V38.6<71cc. Dose escalation was modelled for this patient, where the plan library 
had been used for 88% of fractions. For this patient at 45Gy/25#s the bowel loops V38.6 
was 48.9cc with VMAT_PotD2, compared with 53.4cc for VMAT_standard and 75.8cc for 
conformal plans 
Dose was escalated by a fraction at a time (steps of 1.8Gy). The constraints for bowel, 
rectum and anal canal were examined with each step of escalation. An additional high 
dose constraint for bowel was added to ensure that bowel doses were not being pushed 
too high (bowel V56.6Gy>0.5cc, taken from Guerrero-Urbano et al (112)) 
 
The table below (table 5.15-1) shows the details of dose escalation for patient 1: 
Table 5.15-1: Dose escalation for patient 1 
 OAR volume (cc) or % of OAR volume receiving dose of 
given constraint or higher 
Constraint 45Gy/25#s 48.6Gy/27#s 54Gy/30#s 57.6Gy/32#s 
Bowel 38.6Gy<71cc  48.93 56.14 64.96 71.04 
Bowel 56.6Gy<0.5cc 0 0 0 0.77 
Rectum 30Gy<80% 70% 72.7% 76.9% 79.11% 
Rectum 40Gy<65% 52.2% 60.8% 65.7% 68.16% 
Anal canal Dmean 
<40Gy 
12.58 13.53 14.98 15.8 
 
The number of fractions was increased to 27#s, 30#s and 32#s. This shows that for this 
patient with the use of VMAT_PotD2 strategy that dose escalation is feasible up to 
54Gy/30# with toxicity-based constraints being met for bowel, rectum and anal canal, an 
increase of total dose of 9Gy. Even at this dose level the V38.6 did not reach that of the 
conformal plan. 
A further increase to 57.6Gy/32#s started to breach constraints as shown in pink in the 
table.  
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5.16. Discussion  
Cervical cancer IMRT has the potential to improve late toxicity and disease outcomes. 
However due to the internal organ motion seen within the CTV, there are concerns 
regarding geographical miss and underdosage of the target.  
In this section of the thesis different margin strategies were compared to address organ 
motion in cervical cancer, contrasting their ability to maintain or improve target volume 
coverage, whilst reducing dose to OARs. 
Adaptive strategies were found to be most promising compared to population-based 
strategies balancing CTV coverage with OAR sparing. Both composite and PotD strategies 
showed potential, though PotD reduced the volume of OARs within the PTV the most. 
Dosimetric analysis confirmed benefits of PotD over conformal planning and 
VMAT_standard in terms of dose sparing to the rectum, anal canal and bladder, and to a 
minimal extent bowel and bowel bag.  
5.16.1. Stages 1 and 2: Volumetric comparison of margin strategies 
Stage 1 of this study compared 9 different margin strategies to a standard 2cm isotropic 
margin. As a standard, the 2cm isotropic margin was not faultless, as it led to CTV misses 
in 13 of 101 scans assessed. Misses ranged from 1.1-6.6% of CTV volumes, though in 
view of its common use in clinical practice and clinical trials, and as suggested by RTOG 
guidance this was thought to be representative of what many centres would use.  
 
The use of a smaller isotropic margin of 1.5cm, as a potential margin suggested by RTOG 
increased the CTV misses considerably and would not be acceptable.  
 
Anisotropic margins of 6cm anterior, 3.6cm posterior, 1.8cm superior, 4cm left and 4.5cm 
right were derived to account for motion in 95% of CBCTs. The pattern of these margins 
had some agreement with published studies, where larger AP margins are suggested. The 
size of the anterior margins however was much larger than in published studies. From the 
systematic review in chapter IV the largest comparable margins were 4cm around the 
uterus (Chan et al al (108)) and 3.2cm AP margins (Wang et al (240)).   
In this study with margins derived from data from only 10 patients, it is questionable 
whether these margins are influenced by outliers. Contrary to this idea however is that 
anterior margins above 3.2cm for example (as per Wang et al (240)) were needed in 6 of 
10 patients studied, and larger than 40mm were needed in 5 of 10 patients, suggesting 
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that large anterior margins were genuinely required in a significant proportion of patients 
within this study, not just one or two outliers. 
A potential reason for the large margins were because the margins were grown 2-
dimensionally rather than 3- dimensionally which is artificial in reality, as the effects of 
growing the margins separately in different planes may over-compensate what is required. 
For example part of an anterior margin may in fact be contributed to by superior margins 
from the slice above.  
The superior margins derived (18mm), were comparable to other studies where 20mm 
margins are suggested (109, 240). Posterior margins of 36mm were comparable to the 
32mm AP margins suggested. Lateral margins were large in our study, and this was 
mainly due to lateral positions of the parametrium, though in reality lateral motion of the 
CTVprimary would be absorbed by the PTVnodal volumes. 
Use of these large anisotropic margins improved CTV coverage, however this was at the 
cost of doubling the PTV size, and significantly increasing all the OARs studied within the 
PTV that would receive the treatment dose. In view of this the anisotropic margins were 
also discounted as the strategy of choice.  
 
Structure-specific margins, as described in the literature (108, 237), were studied with 
larger margins for the uterus and smaller margins for the cervix/vagina. In our patients this 
was not more successful than a standard margin, in fact there was a worsening of both 
CTVmisses and OAR volumes in the PTV. This may be improved by further refinements of 
the margins used for uterus and cervix, as the uterine margin especially superiorly was 
higher than required for most of our patients.  
 
The use of the ITV strategy was disappointing despite its early use in the literature being 
promising (200). The rate of CTVs missed was significantly increased compared with a 
standard margin.  A reason for this may be that the bladder filling protocol used within our 
institution was inadequate, such that bladder volumes on the “full bladder” scan and 
“empty bladder” scans were not significantly different.  Of the twenty patients studied 3 
patients actually had a larger bladder volume on the empty scan than on the full scan. The 
mean difference for all patients was only 150mls, which may not be a large enough 
difference between full and empty bladders. Improvement on the bladder filling protocol 
could be addressed in a prospective study.  
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The two margin concepts that yielded most promising results were the composite strategy 
and the Plan of the Day (PotD) strategies and these two strategies were modelled in all 20 
patients in stage 2. 
 
Composite strategy has not previously been studied in cervical cancer. Compared with a 
standard isotropic margin, the ‘composite2’ strategy with a 10mm margin to PTV was 
beneficial for all measures studied – CTV coverage was improved, whilst significantly 
reducing PTV volume (p=0.001), rectum (p=0.004) and bowel bag (p=0.00). Bowel loops 
and bladder were also reduced (non-significantly). This margin strategy showed much 
potential and would be a novel area to investigate.  
 
The PotD strategies were also promising. From stage 1 results, 2 methodological 
conclusions could be made from the first ten patients studied. Firstly that a back-up plan is 
required for a plan library, as PotD3, which did not use a back-up plan had CTV misses in 
49%. Secondly, as with PotD1 the use of 7mm CTV-PTV margins are likely to be too 
small, as with the use of 7mm margins the back-up plan had to be used 70% of the time.  
 
Of the PotD strategies, PotD2, which used 10mm CTV-PTV margins and a standard plan 
as a back-up, was most effective. Comparing Composite2 and PotD2 strategies 
volumetrically revealed virtually equivalent CTV covering potential in 20 patients. Despite 
the need for back-up plan use in 38% of fractions, use of PotD2 resulted in statistically 
significant reductions of all 4 OARs within the PTV, compared with only rectum and bowel 
bag with the use of Composite2.  
The use of Velocity for derivation of a “mid-volume” was useful, with the PTVmid being 
used in 18% of CBCTs studied. The software, once initial problems were resolved, was 
quick and efficient to use, and could be used in clinical practice by treatment planners. 
 
5.16.2. Stage 3 and Stage 4: Dosimetric analysis and escalation 
As can be expected the use of a VMAT_standard plan over a 3D-conformal plan resulted 
in considerably improved dosimetry for the OARs studied. Compared with 
VMAT_standard, VMAT_PotD2 was beneficial in terms of dose sparing to some of the 
OARs studied. 
Benefits to higher dose levels of bowel and bowel bag were seen with VMAT_PotD2 
compared with VMAT_standard, although these benefits were minimal and statistically 
non-significant. This contrasted the volumetric analysis, where highly significant results 
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were seen. This discrepancy in findings is because the volumetric analysis of stage 1 and 
2 was assessing OARs in relation to the PTVprimary only. 
In gynaecological cancers both PTVnodes and PTVprimary are treated. The volume of 
bowel and bowel bag within or close to the PTVnodes volume can be significant, 
especially when nodal volumes extend up to include the para-aortic nodes. In view of this 
the effect of the bowel/bowel bag sparing that is seen lower in the pelvis with the use of 
VMAT_PotD2 is minimised when compared with the large proportion of bowel/bowel bag 
that is seen with PTVnodes.  
In this work CTV-PTV margins of 8mm were used for PTVnodes, however as discussed in 
2 studies in the previous chapter (203, 230) these margins may actually be insufficient. 
Increasing the PTVnodal margins further is likely to include more bowel/bowel bag into the 
PTV.  
Even the most effective strategy to address pelvic organ motion of the CTVprimary will not 
be able to improve the dosimetric consequences of having large amounts of bowel within 
PTVnodes.  
 
On the other hand, rectum, anal canal and bladder, were clearly improved with 
VMAT_PotD2 over VMAT_standard, with statistically significant differences seen for 
rectum and anal canal between the two techniques.  
For the rectum the constraints used to compare techniques were V30<80% and V40<65%. 
Use of this constraint may prophylactically reduce toxicities such as bleeding, proctitis, 
sphincter control and urgency (133). VMAT_PotD2 significantly reduces rectum volumes 
treated at these levels, which may contribute to improved toxicity for patients.  
With the use of VMAT_PotD2 these constraints are met in 30% of patients for the V30 
constraint, and in 70% of patients for the V40 constraint, compared with 0% of the time 
with VMAT_standard planning.  
 
For the anal canal Dmean is the dosimetric parameter associated with faecal incontinence. 
Dmean was already low for all patients included, though VMAT_PotD2 further improved 
this. For bladder no reliable toxicity-related dose constraints are published at doses lower 
than 45Gy. With the use of departmental planning constraints PotD2 improves the 
likelihood of meeting these constraints. It cannot be predicted whether this level of 
dosimetric improvement will improve toxicity outcomes for patients.  
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The other OARs studied were sigmoid and large bowel, with constraints derived in chapter 
III of this thesis, and small bowel with use of QUANTEC recommended constraints (128). 
These constraints were met in very few plans of the 10 patients studied, the large bowel 
constraint V15<60.8cc for example was only met by one patient in both VMAT plans.  
It may be that these constraints are not always feasible in the use of cervical cancer 
radiotherapy, as the QUANTEC constraints were derived in rectal cancer patients, and the 
constraints derived in this thesis were a mixture of urological and gynaecological patients, 
with definitive cervical cancer patients being a small proportion of 17 of 203 patients 
studied. 
 
In terms of dose escalation, only 1 patient met the bowel loops constraint of V38.6<71cc 
with VMAT planning and consequently dose escalation was only modelled in that one 
patient. In this patient with the use of VMAT_PotD2 the patient would have been able to 
have an additional 5 fractions, increasing the dose used from 45Gy to 54Gy. For 9 of the 
10 patients, though not meeting the constraint some benefit was noted at the V38.6 dose 
level with the use of VMAT_PotD2 over VMAT_standard. If not for focus solely on this 
constraint, dose escalation could be modelled for other patients also.  
 
An alternative approach may have been to escalate the doses of VMAT_PotD2 to the level 
of the bowel doses achieved by conformal planning with 45Gy/25#s, given that these 
patients have already been treated with conformal radiotherapy with presumed acceptable 
toxicity. However for this approach the whole DVH would need to be considered, as given 
the shape of the DVH it is likely that at higher dose levels the limits of the conformal 
radiotherapy would be reached by small amounts of dose escalation. 
 
5.16.3. Limitations and Strengths 
This study was originally planned to be a prospective study with assessment of each 
strategy with daily CBCT. Due to resource constraints within the department, this was not 
possible and a retrospective study was performed on days 1,2,3 and then weekly scans. 
The use of daily CBCTs would give much more information regarding the success or 
failures of different techniques, rather than weekly scans that may not represent the whole 
treatment course.  
Performing a prospective study may have allowed for improved patient preparation, such 
as improved bladder filling protocol. As mentioned above the full and empty bladder scans 
were not always significantly varied. In the study by Heijkoop et al for example, with 
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different drinking protocols they aimed for a full bladder of 700mls and empty bladder of 
<50mls, which was achieved in our study of 0/20 of our full bladder scans and 3/20 of 
empty bladder scans. The authors do not comment on the success of their bladder 
protocol, however this protocol has allowed use of their plan library in 82.5%, compared 
with 61.6% in our study.  
The patient number was limited to 20 due to the exclusion criteria, and the main reason 
that many patients were excluded due to long PTV volumes. Many patients had involved 
pelvic nodal disease and were treated up to the aortic bifurcation if not higher. The longer 
PTV volumes exceeded the maximal length of the CBCT scan, the CBCT was centred 
higher up and did not fully encompass the lower pelvis, which was key to this study hence 
the need for exclusion. In view of this the results of this study may be biased towards 
node-negative patients or patients where for example smaller PTV volumes were used, 
possibly due to age or co-morbidity. The impact of these factors on organ motion is 
unknown. 
 
The use of on-treatment CBCT as a modality for analysis did have some drawbacks as not 
all structures, including GTV could be seen. As a result modifications had to be made to 
the studied CTV and for example inferior motion could not be studied as a bony landmark 
was as the inferior most border of the CTV. The use of on-treatment MRI for example may 
have been a better solution, albeit less readily available in the clinical setting. With MRI 
tumour regression and its impact on organ motion may also have been studied.   
 
Much of the focus of stage 1 was around “CTV misses”, with CTV misses commonly 
involving the tip of uterus (ToU). The importance of ToU misses is questionable. Though 
RTOG consensus guidelines (95) suggest that the whole uterus should be included in the 
CTV, this was a debated topic when the consensus guidelines were drawn up, with 42% of 
panel members not believing the whole uterus needs to be included.  
There is little published literature to highlight the importance of the uterus as a common 
site of recurrence, though part of the reason for this may be that the whole uterus is 
always included in conformal treatments, and not treating the whole uterus is somewhat 
against convention. Some of the strategies were rejected as a consequence of ToU 
misses, and in fact may have been promising. 
Many of the CTV misses were small, and resulted again in strategies appearing less 
favourable even though they may not have had any impact on dosimetry and when 
planned may have been inside the 95% isodose. 
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In stage 3 dosimetric analysis of PotD was only performed in the first ten patients, though 
the next ten patients are in progress and may add further to the results.  
 
Despite the limitations, many strengths were also noted. Included patients were selected 
consecutively over time regardless of the number of on-treatment images. A large 
proportion (14 of 20) had more on-treatment imaging than the protocol reflecting the fact 
that pelvic organ motion is an issue in these patients even with conformal planning, and 
making the results more applicable to “real world” patients.  
 
A wide variety of strategies were compared, ranging from simple isotropic margins to more 
complex adaptive strategies and an in-depth analysis was performed. All CTV outlining 
was performed by a single operator (myself) reducing inconsistency. All strategies were 
compared volumetrically and dosimetrically on the same patients allowing for direct 
comparison which is lacking in many of the published studies so far making conclusions on 
which strategy is best very difficult. 
As far as possible an attempt was made to quantify any benefits seen in terms of toxicity-
based dose-volume constraints, with the aim of predicting if any noted dosimetric benefits 
may improve patient outcomes.    
The use of simple strategies such as 15mm isotropic margin, as suggested by RTOG (95), 
were discounted, which is a useful finding, unpublished in the literature. Composite 
strategy has not been assessed previously in this setting, and its potential was a novel 
finding.  
5.17. Conclusions 
Organ motion is a barrier to implementation of definitive cervical cancer IMRT. Margin 
strategies offer a solution though the use of adaptive individualised strategies holds more 
promise than population-based margins. In particular, plan of the day best balances CTV 
coverage with OAR sparing. Significant dosimetric improvements with this technique were 
found to the rectum and anal canal, and with the rectum this may translate into clinical 
benefits.  
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5.18. Future work 
Although PotD was promising in this study, further work is required in the form of a 
prospective study to refine the methods used. Bladder filling forms the basis of the plan 
library for plan of the day and methods to maximise the difference between empty and full 
bladder on planning CT would be crucial. If this is achieved then PotD techniques should 
be validated in a larger number of patients.   
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6. Chapter VI: Organ motion and 
margins required for post-hysterectomy 
gynaecological IMRT 
6.1. Introduction 
Post-hysterectomy pelvic radiotherapy is recommended for endometrial and cervical 
cancer patients with high-risk pathological features following hysterectomy.  For those with 
cervical cancer this can improve survival (248, 249), and for those with endometrial cancer 
improve local control (48). However, as with definitive cervical cancer radiotherapy, these 
benefits can come at a cost of significant late toxicity from radiation to rectum, bladder and 
bowel. Furthermore in the absence of a uterus an increased amount of bowel can be 
displaced into the pelvis, with irradiation of this bowel further increasing the risk of toxicity.  
 
IMRT is therefore highly desirable in the post-hysterectomy radiotherapy setting, aiming 
primarily to reduce toxicity. In this scenario, the CTV comprises the paravagina and the 
pelvic nodes. The paravaginal CTV is formed of the vagina that remains post-
hysterectomy and paravaginal tissue. The vagina is the most common site of disease 
recurrence post-hysterectomy and its coverage therefore of paramount importance. 
Anatomically it lies between the bladder and the rectum, which are both prone to volume 
and positional changes, potentially impacting on the position of the vagina. 
 
As previously described, an important concern with gynaecological IMRT is pelvic organ 
motion, and the risk of geographic miss and underdosage of the target given the high level 
of conformity in IMRT planning. This has been described in the definitive cervical cancer 
radiotherapy setting in the last two chapters of this thesis. In the post-hysterectomy setting, 
it is paravaginal CTV motion that is of concern, and quantifying this motion is key to 
developing safe, evidence-based internal margins.  
 
However, compared with definitive cervical cancer treatment there have been far fewer 
studies to quantify organ motion in the post-hysterectomy setting, despite the fact that 
many more women are treated with post-hysterectomy RT than with definitive 
radiotherapy. Six studies (114, 250-254), 5 using vaginal fiducial markers, have been 
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published with some assessment of vaginal motion in this setting. The results are 
summarised in table 6.1-1.  
 
Table 6.1-1: Summary of post-hysterectomy organ motion studies 
 
 
Pt 
no 
Modality Mean motion (mm) Maximum  motion (mm) Suggested 
margins 
   AP SI LR AP SI LR  
Harris et al 
(250) 
22 MVCT + 
fiducials 
4.0 
(2.8) 
4.0 (3.7) 1.2 
(1.0) 
19.3 15 8.1 16mm 
isotropic 
Ma et al 
(251) 
11 MVCT+ 
Fiducials 
12.9 
(6.7) 
10.3 
(7.6) 
- 30.7 27 - - 
Rash et al 
(252) 
5 MVCT+ 
Fiducials 
7 2.9 3 28 12 7 - 
Chopra et 
al (253) 
16 MVCT+ 
Fiducials 
2.8 
(3.3) 
4.0 (3.5) 1.2 
(1.3) 
   10.6mm AP, 
10.3mm SI, 
4.1mm LR 
Jhingran 
et al (114) 
16 CT+fiducial
s 
7.3 
(3.6) 
7.0 (3.8) 2.5 
(1.4) 
27.9 21 9 - 
Jurgenliem
k-schulz et 
al (254) 
15 MRI - - - - - - 23mm AP, 
15mm SI 
and 18mm 
LR 
 
Motion in the anterior-posterior (AP) direction was predominant, with the average 
magnitude of this varying between studies from 2.8mm to 12.9mm making conclusions 
difficult.  
Problems with vaginal marker use include loss of markers on treatment (114), and the fact 
that they are only a point representation of an organ that can deform in shape on 
treatment.  Ma et al (251) used vaginal fiducial markers and daily MVCT however their 
findings are difficult to interpret as at simulation they used a 2.5cm vaginal dilator which 
was not used on treatment.  
 
Jurgenliemk-Schulz et al (254) adopted a different approach to measure motion, which 
was to look at margins required to encompass the boundaries of the vagina as it moves on 
treatment. In their study of 15 patients with weekly MRI scans, they also found that AP 
motion predominated. They suggested margins of 23mm anterior-posterior (AP), 15mm 
superior-inferior (SI) and 18mm lateral margins would cover vaginal motion in 95% of 
cases. Their findings have not been validated in other studies. 
Unlike in definitive cervical cancer treatment where the influence of bladder and rectal 
filling on CTV motion is well researched, there is limited and conflicting information on their 
influence in the post-hysterectomy setting. Jhingran et al (114) found a relationship with 
bladder filling and vaginal motion in 6 of 16 patients in AP and SI directions, whereas 
Jurgenliemk-Schulz et al found no correlation. Jhingran et al also found a correlation with 
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AP motion and rectal filling in 6/16 patients, though Jurgenliemk-Schulz found a weak 
correlation only.  
Suggested CTV-PTV margins included isotropic 16mm margins (250), or anisotropic 
margins: 10.6mm AP, 10.3mm SI, and 4.1mm LR (253) and 23mm AP, 15mm SI and 
18mm LR (254). The RTOG consensus guidelines (98) do not give any definitive guidance 
on CTV-PTV margins, though suggest that an isoptropic 1.0-1.5cm margin is “commonly 
advocated.” For bladder filling, RTOG suggest that an ITV formed by combining the CTV 
on a full bladder scan, with the CTV on an empty bladder scan may be useful. One study 
that used this as part of their protocol (114) has suggested “this approach must be used 
with caution”, as bladder volumes at planning were not representative of those on 
treatment. Chopra et al (253) compared this approach with their population-based margin, 
and reported on the impact on PTV size and dose coverage, however did not specifically 
address the geographical miss with either approach. 
 
It has been suggested that organ motion in this scenario is patient-specific (114), as it is 
known to be for definitive radiotherapy for cervical cancer, and thus adaptive and/or 
individualised strategies may be of value. Conceptually as in other pelvic tumours, 
strategies such as composite strategy, plan of the day, or margin of the day may be useful 
However there is no modelling of any of these strategies in the post-hysterectomy pelvis in 
the published literature. 
 
In summary, although attempts to measure vaginal motion have been made in the 
literature, findings of these studies are varied and cannot be used to make definitive 
conclusions. Unlike in definitive cervical cancer radiotherapy, the influence of bladder and 
rectal filling on vaginal motion is unclear. Furthermore, management of organ motion in 
this scenario, either through the use of margins, patient preparation protocols or adaptive 
strategies are under-examined avenues of research, despite the increasing use of IMRT.  
6.2. Aims  
The aims of this work were to: 
- Examine organ motion patterns of the paravaginal CTV in the post-hysterectomy setting  
- Correlate paravaginal CTV motion with rectal and bladder filling 
- Assess the use of potential margin solutions for paravaginal CTV motion, including 10mm 
and 15mm isotropic margins (as suggested by RTOG), suitable anisotropic margins and 
adaptive solutions.  
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6.3. Methods  
A retrospective analysis was carried out on on-treatment CBCT imaging data from 20 
patients treated with adjuvant pelvic radiotherapy between January 2011 and August 2013 
in Velindre Cancer Centre. The following criteria inclusion and exclusion criteria were 
used: 
6.3.1. Inclusion: 
1. Patients with cervical or endometrial cancer who had undergone hysterectomy and 
required adjuvant radiotherapy.  
2. Patients who had at least 5 CBCT scans during treatment to allow sufficient 
analysis of organ motion 
6.3.2. Exclusion: 
1. Patients with hip replacements, which cause artefact on CT scanning  
2. Patients with long treatment volumes (superior-inferior) where the CBCT scans did 
not include the lower pelvis, e.g. where para-aortic nodes were being treated 
 
6.3.3. Patient treatment overview 
Patients were treated as standard in our institution, and details of this standard treatment 
are described in the following few sections:  
All cervical cancer patients were treated adjuvantly with 45Gy in 25 fractions with 
concurrent chemotherapy, unless clinically inappropriate. All endometrial cancer patients 
were treated adjuvantly with 40Gy in 20 fractions as standard, with higher-risk patients 
(defined on pathological findings) being treated with 45Gy in 25 fractions and concurrent 
chemotherapy. Following EBRT certain patients had intra-vaginal brachytherapy at a dose 
of 15Gy in 5 fractions over one week. 
Simulation 
For simulation and treatment, patients were positioned supine and immobilised using the 
Oncology Systems Limited Combifix. Using a standard Siemens Somatom Sensation CT 
scanner, patients were scanned from L3 to below the perineum. Patients were asked to 
empty their bladders and then drink 200-300mls of water 30 minutes prior to their planning 
CT as standard protocol in our institution. No specific rectal emptying instructions were 
given.  
Target volume delineation 
Target volumes were outlined on Oncentra Masterplan (OMP) version 4.3. For the CTV 
nodal volume the pelvic vessels were outlined from the bifurcation of the aorta (for node 
positive patients) and from the L4/5 junction (for node negative patients), a 7mm margin 
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was added to form CTVnodes (102). The CTVnodes was further expanded to include the 
presacral region from the sacral promontory to the pirifomis muscle, and to include the 
obturator nodes to the superior aspect of the obturator foramen. An 8mm margin was 
added to CTVnodes to form PTVnodes. 
 
For the paravaginal CTV, the vagina was outlined superiorly from where it becomes visible 
(including ‘dog ears’) to 1cm above the inferior aspect of the obturator foramen. 
Paravaginal CTV was formed according to RTOG guidance (98) by adding a 5mm margin 
anteriorly and posteriorly to the vagina, and then manually extending the volume laterally 
to the reach the pelvic nodal volume. Rectum and bladder were excluded from the CTV, 
whilst maintaining of a minimum CTV dimension of 15mm anterior-posteriorly in the 
midline of the vagina. At times this meant the CTV was only marginally wider than the 
vagina. Inferiorly where there was no pelvic node volume laterally, the volume was 
extended laterally to the medial aspect of the pelvic floor muscles.  
 
CTV-PTV margins used for the paravaginal CTV within the patient group varied with 
clinician preference and type of radiotherapy planning used.  
Treatment planning and delivery 
This study was performed at a time of transition in the way gynaecological oncology 
radiotherapy was planned at Velindre Cancer Centre. As a result, 10 patients were treated 
with conformal radiotherapy and 10 patients using volumetric modulated arc therapy 
(VMAT).  
Conformal radiotherapy was delivered using a ‘four field brick’ technique. VMAT was 
delivered using a fully optimized, single iteration VMAT plan created using a class solution 
planning approach developed in-house. All patients were treated using Elekta Synergy 
linear accelerators, and CBCT scans acquired during treatment on “XVI release 4.5.1”.  
Each patient had a CBCT scans on days 1, 2, 3 of their treatment followed by weekly 
imaging. Images were assessed using an offline strategy.  
6.3.4. Fusion and outlining for modeling study 
For the purpose of this study all CBCT scans were co-registered with their respective 
planning scans on OMP using a mutual information algorithm, excluding set-up error. 
Fusion was checked for adequacy at three bony landmarks – femoral heads (on axial 
view), tip of sacrum (on sagittal view), and pubic symphysis (both on axial and sagittal 
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views). If the fusion was not visually satisfactory then manual adjustments were made to 
correct it. 
 
The paravaginal CTV was already present on the planning scan and this was checked for 
adequacy, modifying it if necessary, and labelled as pCTV. On each CBCT scan the 
vagina and paravaginal CTV were retrospectively outlined as specified in 6.3.3, and 
labelled as cbCTV1, cbCTV2 etc. The length of vagina included on each CBCT was equal 
to the length of the vagina used on the planning scan for that patient to give a realistic 
estimate of inferior CTV motion, rather than to follow a bony landmark. pCTV volumes 
were noted and assessed for changes over time, which would be unlikely given that this is 
adjuvant treatment. 
 
To study the relationship of rectal and bladder filling with paravaginal motion, the rectum 
and bladder were retrospectively outlined on each planning scan and every CBCT scan in 
the study. The rectum was outlined from the sigmoid flexure to ischial tuberosities to 
determine its volume. Furthermore rectal diameter was measured at two predefined points: 
the maximal diameter at any point (‘RDmax’) and the tip of the coccyx (‘RDcoccyx’). These 
levels were chosen, as they are easily identifiable and therefore likely to be reproducible. 
The entire bladder was outlined to determine its volume. 
Each of these measures/diameters was also recorded to assess changes over time. It has 
been suggested in the literature that bladder volumes decrease over the course of 
radiotherapy treatment (108, 109).  
Rectal and bladder “variability” were determined for all measurements, defined as the 
difference between the volume/diameter on each CBCT scan compared with the planning 
scan. 
6.3.5. Analysis strategy 
Analysis was carried out in three stages: 
Step 1. Organ motion of the paravaginal CTV was quantified 
Step 2. Paravaginal CTV motion was correlated to rectal and bladder filling 
Step 3. Margin strategies to account for organ motion were compared 
Step 1: Organ motion 
Motion of the paravaginal CTV was quantified by defining a range of margins separately in 
anterior, posterior, left, right, superior and inferior directions in 1mm increments (from 1mm 
to 49mm) around pCTV for each patient. Each cbCTV was analysed to determine the 
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smallest margin to fully encompass the cbCTV in each of the six directions. This margin 
was taken as a surrogate for motion the cbCTV on each image studied. An example of this 
process is shown in figure 6.3-1.  
 
Figure 6.3-1: Determination of CTV motion 
 
This methodology has been used both in definitive cervical cancer and post-hysterectomy 
gynaecological studies (235, 254). This method was chosen over the use of fiducial 
markers given the potential limitations of markers in terms of marker loss, and concern 
over the use of a point measurement for a structure such as the vagina which may deform 
on treatment. 
The margins required in each direction to cover 95% of all cbCTVs for all patients studied 
was then determined. These margins were taken forward as the anisotropic margins for 
the next analysis.  
Step 2: Correlation of organ motion with rectal and bladder filling 
Patterns of rectal filling and bladder filling measures over time were sought. Correlations 
between rectal and bladder variability and CTV motion was determined using Pearson’s 
Correlation Coefficient (‘R’). All statistical analyses performed on SPSS version 20. 
Correlations were considered statistically significant with a p-value of <0.05.  
Step 3: Comparison of margin strategies 
The following margin strategies were compared: 
1) 10mm isotropic margins 
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was taken as a surrogate for motion the cbCTV on each image studied. An example of this 
process is shown in figure 6.3-1.  
 
 
This methodology has been used both in definitive cervical cancer and post-hysterectomy 
gynaecological studie  (239, 259). This method was chosen over the use f fiducial 
markers given the potential limitations of markers in terms of marker loss, and concern 
over the use of a point measurement for a structure such as the vagina which may deform 
on treatment. 
The margins required in each direction to cover 95% of all cbCTVs for all patients studied 
was then determined. These margins were taken forward as the anisotropic margins for 
the next analysis.  
6.3.5.2. Step 2: Correlation of organ motion with rectal and bladder filling 
Patterns of rectal filling and bladder filling measures over time were sought. Correlations 
between rectal and bladder variability and CTV motion was determined using Pearson’s 
Correlation Coefficient (‘R’). All statistical analyses performed on SPSS version 20. 
Correlations were considered statistically significant with a p-value of <0.05.  
6.3.5.3. Step 3: Comparison of margin strategies 
The following margin strategies were compared: 
1) 10mm isotropic margins 
	
Figure	6.3-1:	Determination	of	CTV	motion:	pCTV	in	yellow	on	the	planning	scan	(top	left),	and	the		
cbCTV	in	blue	on	the	CBCT	scan	(top	right).	The	red	volume	shows	pCTV	with		an	18mm	anterior	margin,		
fully	encompassing	the	cbCTV	anteriorly,	on	an	axial	(bottom	left)	and	sagittal	view	(bottom	right).	
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2) 15mm isotropic margins  
3) Population-based anisotropic margins as determined in stage 1 
4) Margin of the day strategy  
 
Margin of the day (MotD) strategy was chosen to assess whether an adaptive strategy 
would demonstrate any additional value to either isotropic or anisotropic margins.  
Plan of the day, as modelled in definitive cervical cancer patients in Chapter V, would be 
difficult in these patients given the less clear correlation with bladder filling and vaginal 
motion, and the lack of full and empty bladder planning scans available in this 
retrospective study. 
The use of composite strategy was also promising in chapter V, however in the current 
study would be difficult, as some patients had only 5 CBCTs, and with a composite of 3 or 
5 scans, this would leave only 0-2 CBCTs to assess the adequacy of the strategy, which 
would be insufficient.  
 
MotD concept has been described in the definitive cervical cancer setting by Ahmad et al 
(255) and involves a “margin library” whereby multiple plans are made per patient with 
different isotropic margins around the planning CTV. In this case margins from 10mm up to 
35mm margins at 5mm intervals were used. For each CBCT the smallest margin to 
encompass the CTV that day from the library of 6 margins was chosen.  
 
For each strategy the following were compared:  
1. PTV volume  
2. CTV coverage 
a. “Encompassed” or “missed”, with the cbCTV considered encompassed if >99% 
was covered  
b. % coverage  
c. Mean and overall range of misses  
3. OAR within PTV: The % bladder volume, % rectal volume and bowel volume (in cc) 
within the PTV  
 
Differences between the mean of the above measures for each strategy were compared 
using Mann-Whitney testing (as non-parametric data). A p-value of <0.05 was considered 
statistically significant.   
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6.4. Results 
6.4.1. Patient and scan details 
Twenty post-hysterectomy patients were included in the study, including 14 patients with 
endometrial cancer and 6 with cervical cancer. Details of their characteristics are shown in 
table 6.4-1. The median age was 65 (range 33-81). Patient 1 had high-risk endometrial 
cancer so was treated with 45Gy in 25 fractions with concurrent weekly cisplatin 
chemotherapy. Patient 7 was treated for a recurrence of her disease after hysterectomy, 
however as this was sub-centimeter disease, she was still included as it was thought her 
organ motion should be similar to the other patients within the study. 
 
Each patient studied had 5-7 offline CBCTs. In total, 20 planning scans and 116 CBCT 
scans were examined. 1 of the CBCT scans was unusable (patient 14 CT5) as no 
structures were visible, therefore 115 scans were analysed in total. 
 
Table 6.4-1: Patient and Treatment characteristics 
Pt 
no 
Age 
(yrs) 
Diagnosis Stage Radiothera
py Regime 
(Gy/#) 
Radiotherapy 
Planning 
Concurrent 
Chemotherapy  
No of 
CBCTs 
available 
1 45 Endometrial III  45/25 Conformal Cisplatin 6 
2 67 Endometrial IB 40/20 Conformal None 5 
3 81 Endometrial II 40/20 Conformal None 6 
4 73 Endometrial IB 40/20 Conformal None 6 
5 52 Endometrial III 40/20 Conformal None 6 
6 73 Endometrial II 40/20 Conformal None 5 
7 63 Cervical  Recurrence 45/25 Conformal Cisplatin (1 cycle), then carboplatin 6 
8 42 Cervical IB1 45/25 Conformal Cisplatin 6 
9 68 Endometrial IB 40/20 Conformal No 5 
10 79 Cervical IIB 45/25 Conformal No  6 
11 78 Endometrial IIIA 40/20 VMAT No 5 
12 73 Endometrial IB 40/20 VMAT No 6 
13 46 Endometrial IIIC 40/20 VMAT No 6 
14 63 Endometrial II 40/20 VMAT No 6 
15 57 Cervical IIIB 45/25 VMAT Cisplatin 7 
 16 33 Cervical IB1 45/25 VMAT Cisplatin 6 
17 69 Endometrial II 40/20 VMAT No 5 
18 81 Endometrial IB 40/20 VMAT No 6 
19 35 Cervical III 45/25 VMAT Cisplatin 6 
20 63 Endometrial IB 40/20 VMAT No 5 
 
6.4.2. CTV, rectal and bladder volumes and measures 
The minimum, maximum, and mean statistics are tabulated for CTV, rectum and bladder 
for all scans of all patients (table 6.4-2).  
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Table: 6.4-2: Descriptive statistics for CTV, rectum and bladder 
 CTV volume 
(cc) 
Bladder 
volume (cc) 
Rectal 
volume (cc) 
RDMax  
(cm) 
RDCoccyx 
(cm) 
Min 44.1 32.2 32.8 2.5 1.6 
Max 127.6 980.5 242.7 7.1 6.4 
Mean 86.4 308.4 96.00 4.7 3.4 
Std dev 17.4 182.8 38.7 0.9 0.8 
 
6.4.3. Trends over Time 
 
Figure 6.4-1: CTV, rectal and bladder volumes over time 
Figure 6.4-1 shows the mean volumes of CTV paravagina, bladder and rectum over the 
time studied. No definitive trends were noted over the course of radiotherapy.  
6.4.4. Rectal and Bladder variability 
Rectal variability differed greatly between patients, with the largest increase from baseline 
being 156.6cc and the largest decrease being 121.5cc. The mean variability of the CBCTs 
studied was 29.8cc in rectal volume and 1.04cm in RDMax. 
Figure 6.4-2 shows examples of rectal variability in three patients, with the 0cc on the 
vertical axis representing the rectal volume on the planning CT. Patient 4 had a relatively 
minimal rectal variability with a maximal change of 38cc, in contrast to patient 3 where the 
largest variability was seen. Patient 7 had a large rectal volume at planning, though 
throughout treatment rectal volume was much smaller. 
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Figure 6.4-2: Rectal Variability Examples 
 
Mean bladder variability for all CBCT was 146.6cc, with a maximal bladder variability of 
606.8cc noted in one patient.  
Seven CBCT scans were taken on the day of concurrent cisplatin chemotherapy, but there 
was no evidence of increased bladder volume on these days which may be expected with 
the intravenous fluids given with cisplatin.  
 
6.4.5. Stage 1 results: Paravaginal CTV motion  
Table 6.4-3 shows the maximal paravaginal CTV motion for each patient in each direction, 
and then summarises the data for all 115 CBCTs analysed. This suggests the predominant 
direction of margins is in the AP directions, with anterior movement occurring more 
prominently. To completely cover 95% of cbCTVs (n=109) the margins required were 
25mm anterior, 29mm posterior, 6mm superior, 12mm inferior, 14mm left and 10mm right.  
To completely cover 100% of cbCTVs margins of 31mm anterior, 49mm posterior, 21mm 
superior, 24mm inferior, 16mm left and 14mm right would be needed. 
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Min 44.1 32.2 32.8 2.5 1.6 
Max 127.6 980.5 242.7 7.1 6.4 
Mean 86.4 308.4 96.00 4.7 3.4 
Std dev 17.4 182.8 38.7 0.9 0.8 
 
6.4.3. Trends over Time 
 
Figure 6.4-1: CTV, rect l and bladder volumes over time 
Figure 6.4-1 shows the mean volumes of CTV paravagina, bladder and rectum over the 
tim  studie . No definitive trends were noted over the course of radiotherapy. 
6.4.4. Rectal and Bladder variability 
Rectal variability differed greatly between patients, with the largest increase from baseline 
being 156.6cc and the largest decrease being 121.5cc. The mean variability of the CBCTs 
studied was 29.8cc in rectal volume and 1.04cm in RDMax. 
Figure 6.4-2 shows examples of rectal variability in three patients, with the 0cc on the 
vertical axis representing the rectal volu e on the planning CT. Patient 4 had a relatively 
minimal rectal variability with  m ximal change of 38cc, in contrast to patie t 3 where the 
largest variability was seen. Patient 7 had a large rectal volume at pl ning, though 
throughout treatment rectal volume was much smaller. 
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Table 6.4-3: Maximal Paravaginal CTV motion per patient (mm) 
  Ant Post Sup Inf Left Right 
Pt 1 16 18 9 6 4 4 
Pt 2 18 10 3 9 6 6 
Pt 3 16 18 0 15 12 8 
Pt 4 25 6 6 3 6 8 
Pt 5 24 10 21 12 6 4 
Pt 6 24 8 6 9 6 4 
Pt 7 0 49 3 6 6 2 
Pt 8 14 12 0 6 6 2 
Pt 9  12 13 0 6 6 4 
Pt 10 19 29 9 9 14 14 
Pt 11 12 17 6 0 16 14 
Pt 12 31 1 15 9 6 10 
Pt 13 25 12 6 6 11 10 
Pt 14 17	 8	 0	 12	 10	 6	
Pt 15 15	 10	 0	 6	 8	 8	
Pt 16 13	 15	 6	 21	 10	 8	
Pt 17 22	 7	 3	 12	 11	 6	
Pt 18 8	 21	 0	 3	 8	 8	
Pt 19 19	 20	 0	 24	 15	 12	
Pt 20 21	 16	 0	 6	 15	 7	
       
Min 0 1 0 0 4 2 
Max 31 49 21 24 16 14 
Median 17.5 12.5 3 7.5 8 8 
Minimum 
margin 
required 
to cover 
90% of 
CBCTs 22 18 6 9 11 10 
95% of 
CBCTs 25 29 6 12 14 10 
 
6.4.6. Stage 2: The influence of rectal and bladder variability on motion 
Rectal volumes/diameters at planning had no correlation with the margins required on 
treatment. However rectal variability had a significant influence on anterior and posterior 
margins needed.  
In particular the size of posterior margins was correlated with variability in RDcoccyx (R=-
0.75), RDmax (R=-0.73) and rectal volume (-0.7) (all p<0.0001). Patients with a large 
rectum at planning and then smaller rectum on treatment needed larger posterior margins. 
Anterior margins were also correlated with changes in rectal variability, RDcoccyx (R=0.6), 
RDmax (0.53), and for rectal volume (R=0.44) (all p<0.05). No correlation was noted in 
other directions. RDcoccyx data is illustrated in figure 6.4-3. 
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Figure 6.4-3: Correlations of RDcoccyx with anterior and posterior margins 
  
Specific bladder volumes at the time of planning had no correlation with the margins 
required. However bladder variability was correlated with anterior margins (R=0.44, 
p<0.0001). Weaker yet significant correlations with posterior and superior margins, 
(R=0.37, R=0.33, p<0.05) were also found. A weak correlation between initial bladder 
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volume change, large bladder volume changes and the need for larger margins was noted 
(R=0.59, p<0.01). 
 
Two patients (patient 7 and 12) in particular had a significantly large AP motion, one 
(patient 7) with a maximum posterior motion of 49mm. Patients 7’s planning and on-
treatment CBCTs are illustrated in figure 6.4-4. This patient’s organ motion was associated 
with rectal filling, as she had a maximum rectal diameter of 7.09 cm at planning (top 
image) which reduced by 3.14cm to 3.95cm on treatment (lower image).  
 
Figure 6.4-4: Patient 7 organ motion 
 
This patient was treated now 4 years ago, and since then there is increased awareness of  
organ motion, this patient is likely to have been rescanned at planning after evacuation of 
her rectum in attempt to reduce rectal distension. As her posterior margins fell into the 
highest 5% of CBCTs, posterior margin data from her scans was not included when 
determining anisotropic margins.  
 
Patient 12 had significant anterior motion (31mm) on treatment, which may have been in 
relation to variable bladder filling, with her bladder volume at planning being 531cc, 
reducing to 125cc during treatment. However, this was not consistent with all patients, as 
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volume change, large bladder volume changes and the need for larger margins was noted 
(R=0.59, p<0.01). 
 
Two patients (patient 7 and 12) in particular had a significantly large AP motion, one 
(patient 7) with a maximum posterior motion of 49mm. Patients 7’s planning and on-
treatment CBCTs are illustrated in figure xx.xx-x. This patient’s organ motion was 
associated with rectal filling, as she had a maximum rectal diameter of 7.09 cm at planning 
(top image) which reduced by 3.14cm to 3.95cm on treatment (lower image), as seen in 
figure x x.xx 
 
 
This patient was treated now 4 years ago, and since then there is increased awareness of  
organ motion, this patient is likely to have been rescanned at planning after evacuation of 
her rectum in attempt to reduce rectal distension. As her posterior margins fell into the 
highest 5% of CBCTs, posterior margin data from her scans was not included when 
determining anisotropic margins.  
 
Patient 12 had significant anterior motion (31mm) on treatment, which may have been in 
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even those with bladder filling changes of 600mls did not have as much anterior motion. 
The strength of the influences of bladder and rectal filling appear to be patient-specific.  
 
6.4.7. Stage 3: Margin strategy assessments 
Margin of the day usage 
The frequency of the margins chosen within the margin library is shown in table 6.4-4. The 
35mm margin did not need to be used for any patient. 15 of 20 patients used only 10mm 
and 15mm margins.  
Table 6.4-4: Margin of the day use 
 10mm	 15mm	 20mm	 25mm	 30mm	 35mm	
Pt	1	 5	 1	 0	 0	 0	 0	
Pt	2	 5	 0	 0	 0	 0	 0	
Pt	3	 5	 1	 0	 0	 0	 0	
Pt	4	 3	 3	 0	 0	 0	 0	
Pt	5		 3	 3	 0	 0	 0	 0	
Pt	6	 4	 1	 0	 0	 0	 0	
Pt	7		 0	 0	 1	 4	 1	 0	
Pt	8		 6	 0	 0	 0	 0	 0	
Pt	9		 5	 0	 0	 0	 0	 0	
Pt	10		 3	 2	 1	 0	 0	 0	
Pt	11	 4	 1	 0	 0	 0	 0	
Pt	12	 0	 0	 3	 3	 0	 0	
Pt	13	 0	 6	 0	 0	 0	 0	
Pt	14	 6	 0	 0	 0	 0	 0	
Pt	15	 7	 0	 0	 0	 0	 0	
Pt	16	 0	 2	 3	 1	 0	 0	
Pt	17	 2	 3	 0	 0	 0	 0	
Pt	18	 1	 4	 0	 0	 0	 0	
Pt	19	 4	 0	 0	 2	 0	 0	
Pt	20	 5	 1	 0	 0	 0	 0	
total	 68	 28	 8	 10	 1	 0	
%	of	total	 59.13	 24.35	 6.96	 8.70	 0.87	 0	
  
6.4.8. Comparison of CTV coverage, PTV volume and OARs included 
The PTV volume, CTV coverage and OARs within the PTV is shown in table 6.4-5 for the 
four different margin strategies, and individual patient data for each strategy in figure 6.4-5. 
CTV coverage was insufficient (only 62.5% of cbCTVs studied) with an isotropic 10mm 
margin. Coverage was significantly improved by use of a 15mm margin (p=0.004), 
anisotropic margin (p=0.013) and margin of the day (p=0.00), which encompassed 100% 
of cbCTVs. 
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In the patients with more organ motion (patients 7 and 12), isotropic 10mm and 15mm 
margins were not sufficient for any of the CBCTs assessed. The anisotropic margin was 
sufficient for one of these patients but the MotD was for both.  
Table 6.4-5: Comparison of margin strategies 
 Isotropic 
10mm 
Isotropic  
15mm 
Anisotropic MotD 
Mean PTV vol (cc)  314.56 478.57 531.01 430.90 
Mean % CTV coverage 96.14 98.51 99.34 99.88 
     
No of CTVs encompassed 
(%) 
75 (65.2%) 99 (86.1%)  105 (91.3%) 115 (100%) 
Mean proportion of CTV 
missed (%) (range) 
11.3% 
(1.03-40.8%) 
10.9% 
(3.3-26.6%) 
6.6% 
(1.8-17.3%) 
0 
     
Mean % bladder in PTV 21.64 33.63 43.83 26.61 
Mean % rectum in PTV 30.88 44.40 63.65 39.15 
Mean bowel volume in PTV 
(cc) 
9.99 21.63 11.54 18.09 
 
Individual patient data for CTVs encompassed is illustrated in figure 6.4-5. 
 
Figure 6.4-5: Comparison of margins for CTVs encompassed 
 
As expected PTV volume was smallest with an isotropic 10mm margin, yet this was at the 
expense of CTV coverage. The mean data regarding OAR sparing according to strategy is 
illustrated in figures 6.4-6 and 6.4-7. 
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Figure 6.4-6: Rectum and bladder within PTV 
 
 
Figure 6.4-7: Bowel within the PTV 
	
As	 10mm margins inadequately encompassed cbCTVs studied, with 34.8% of CTVs 
missed, this was not considered further. The remaining three strategies were examined 
further. Considering rectum within the PTV, use of anisotropic margin (with its large 
posterior component, 29mm) lead to an increased mean volume of rectum from 44.4% 
with a 15mm margin to 63.65% with an anisotropic margin (p=0.02)). Comparing MotD and 
15mm margins, MotD had a reduced amount of rectum within the PTV, though this was 
non-significant (p=0.27). 
Again with bladder, MotD had the least amount of bladder in the PTV, though the 
difference between this strategy and use of a 15mm margin was non-significant (p=0.19).  
For bowel, it was the use of anisotropic margin that led to the lowest volume of bowel 
being irradiated, presumably due to the smaller superior margin (6mm). 
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6.5. Discussion 
Safe delivery of IMRT in the post-hysterectomy gynaecological patients requires 
knowledge of paravaginal CTV motion and determination of margins to account for this 
motion. In this section of the thesis key findings were that paravaginal CTV motion is a 
significant issue, with AP motion being most predominant. AP CTV motion is correlated 
with rectal variability between planning and on-treatment, with some impact of bladder 
variability also. In these patients 10mm isotropic margins are inadequate. Coverage can 
be improved with anisotropic margins, 15mm isotropic margins and margin of the day 
strategy. Overall MotD best improved CTV coverage with relative sparing of rectum and 
bladder within the PTV, and is therefore the preferred margin strategy. 
 
As in the limited published literature regarding organ motion in this setting, CTV motion in 
this study was found to be an important consideration. In this study population-based 
anisotropic margins of 25mm anterior, 29mm posterior, 6mm superior, 12mm inferior, 
14mm left and 10mm right were found to account for the motion in 95% of CBCTs studied.  
These findings, in part, agree with Jurgenliemk-Schulz et al (254) who used similar 
methodology, and suggested margins of 23mm AP, 15mm SI, and 18mm LR. Compared 
with the other published studies (114, 250-253), the motion detected in our study was 
much greater in magnitude. These differences are likely to be due to methodological 
differences, as in the other studies vaginal motion was determined using a point 
representation (fiducial marker within the vagina). The vagina is a deformable and non-
uniform organ, and motion of a fiducial marker may not represent its entire motion, 
therefore I believed this to be a more realistic method of assessing motion. 
 
Rectal variability was significantly correlated with the magnitude of posterior margins 
(R=0.74, p<0.001) and, to a lesser extent, with anterior margins. These findings have 
some agreement with other studies, where Jhingran et al (114) found rectal filling was 
associated with vaginal motion in the AP direction in 6 of 16 patients. Rash et al (252) in 
their small study of 5 patients also found a correlation with AP motion and rectal diameter 
(R=0.53). One can conclude that rectal filling does influence paravaginal CTV motion; 
however this pattern is not seen to the same degree in all patients.  
Despite the significant influence of rectal variability on CTV motion, no guidance is 
available for rectal management in gynaecological radiotherapy. In the case of prostate 
cancer a distended rectum at planning has been associated with poorer CTV coverage 
and consequentially poorer clinical outcomes (256, 257). Many institutions follow a 
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protocol to ensure a rectum of <4cm in diameter at the time of planning and whilst on 
treatment for prostate patients.  In post-hysterectomy patients, as noted in this work, this 
would not be a useful measure in the population of patients studied, as a rectal diameter of 
>4cm was found in 77% of scans examined. Rather than the absolute value of rectal 
diameter, it would be maintenance of the same rectal diameter on treatment as that at 
planning that would be of importance. 
 
Bladder variability had a moderate correlation with paravaginal CTV motion in the anterior 
direction, R=0.44 (p<0.001). Jhingran et al (114) found an influence of bladder filling in 6 of 
16 of their patients, though Jurgenliemk-Schulz et al (254) found no correlation at all. 
Again all that can be concluded is that bladder variability may influence motion, though this 
pattern is not as robust as rectal variability. 
Within the RTOG consensus guidelines (98) the influence of bladder filling is considered 
important and the use of an ITV is advocated, based on CTV position on a ‘full’ bladder 
planning scan combined with CTV position on an empty bladder planning scan. To date 
this approach has not been proven to be successful. One study using this method found 
(114) that on treatment patients often had a “fuller” or “emptier” bladder than their ‘full’ and 
“empty” bladder volumes at the time of planning. Others (253) demonstrated that the use 
of an ITV generated by the full and empty bladder approach had decreased target 
coverage compared to a population-based ITV. Findings in this chapter suggest the ITV 
approach may be of benefit in some patients where bladder filling is influential on CTV 
position, although a more pressing issue would be rectal filling management.  
 
An important finding of this work was that isotropic 10mm margins were insufficient to 
cover 95% of the CTV in 38% of cbCTVs studied, and this finding concurred with that of 
one other study. The potential advocated margin by RTOG of 10mm is therefore 
inappropriate.  
15mm margins improved coverage, though were still insufficient in 14% of cbCTVs 
studied.  Anisotropic margins improved coverage to 91% of CBCTs, but at the expense of 
significant increases in dose to rectum and bladder. In comparison MotD to anisotropic 
margins improved CTV coverage to 100% and reduced PTV volume, resulting in reduced 
doses to rectum and bladder, although not to bowel. 
Overall MotD may offer a balanced solution to account for organ motion in the post-
hysterectomy setting. The drawback of MotD would be that for each patient 5 IMRT plans 
would need to be produced, and daily online IGRT would be required. This would have 
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practical and workforce implications, and it would need to be assessed in more detail in a 
dosimetric study, and potentially a prospective study to assess its clinical feasibility and 
cost effectiveness.  
 
An intermediate solution may be to have a margin library of 10mm and 15mm (which was 
sufficient for 75% of all CBCT in this work), and then a large margin plan as a back-up, 
such as 30mm, for the remaining treatment days. A further concept that may be worth 
addressing is a margin of the day with anisotropic margins, larger in AP directions, this 
method is already in use in the ongoing bladder cancer trial, Hybrid (122).  
 
6.5.1. Strengths and Limitations 
This is the first study to use kV CBCT as a means for evaluating CTV margins in the post-
hysterectomy setting, which may be more accurate than previous studies using MV 
imaging of fiducial markers and more clinically applicable than studies using on-treatment 
MRI.  CBCT is available in most clinical departments, and in this study the vagina, bladder 
and rectum were all visible in all CBCT scans used, especially when using axial imaging in 
conjunction with coronal and sagittal views.  
This work also is novel as adaptive strategy for post-hysterectomy patients has not 
previously been examined in published literature, and margin-of-the-day is demonstrated 
to have significant promise. Adaptive strategy may be an important area of research in 
future, enabling more effective IMRT in this setting. 
 
The study does have some limitations; firstly all assessments are based on retrospective 
assessment of weekly CBCT scans, whereas daily CBCT scans may be a more realistic 
representation of daily anatomical variations. With the nature of a retrospective study 
bladder and rectal protocols could not be adapted. Secondly, this study did not assess the 
other significant component of PTV – PTVnodes. Measuring of pelvic node motion on 
CBCT is difficult, and appropriate CTV-PTV margins remain unclear within the literature 
(203, 230). Although anisotropic margins were derived, as was the case in chapter 5, 
these were derived 2-dimensionally, and it may be that the addition of separate margins in 
all 6 directions result in an overly large margin, as for example a component of the anterior 
margin could be contributed from superior margins.  
 
203 
 
6.6. Conclusions 
This work has demonstrated that paravaginal CTV motion is a significant consideration for 
post-hysterectomy IMRT. Rectal filling variation contributes significantly to this motion in 
AP directions in some patients. 10mm isotropic margins are inadequate for IMRT in these 
patients and although 15mm margins are better, the use of population-based anisotropic 
margins can further improve CTV coverage. A margin of the day adaptive strategy, 
appeared more effective than anisotropic margins and even though this strategy may have 
workload implications, it is most suitable to IMRT use in terms of balancing CTV coverage 
and OAR sparing.  
 
6.7. Future Work 
Although a volumetric assessment of MotD and other strategies was performed, a 
dosimetric analysis of MotD is required to further model its benefits. If found to be 
advantageous dosimetrically compared with non-adaptive approaches MotD could be 
further investigated in prospective study.  
   
Aside from margin based solutions, the use of rectal measures in the post-hysterectomy 
setting is an important avenue of investigation. The use of measures such as dietary 
modification, oral laxatives and enemas should be investigated in prospective study to 
potentially reduce rectal variability and consequently margin size.  
 
6.7.1. Acknowledgements 
Guidance on fusion of CBCT scans was provided by Dr Nachi Palaniappan (Consultant 
Clinical oncologist, Velindre Cancer Centre) and Mr Arek Mazurek (Physicist, Velindre 
Cancer Centre). All work for this study was conducted by myself.  
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7. Thesis summary and conclusions 
7.1. Introduction 
Implementation of pelvic IMRT for gynaecological cancers is a desirable goal to reduce 
toxicity for patients. Though theoretically beneficial, there are several practical barriers to 
its widespread adoption. Concerns include the lack of consensus on target volume 
definition, lack of appropriate dose-volume constraints for quantifying toxicity reduction, 
and lack of optimal management strategies for organ motion and tumour regression.  
 
This thesis focused on two of these concerns; Section A (chapters II and III) investigated 
dose-volume predictors and constraints for late bowel toxicity; Section B (chapters IV, V 
and VI) examined organ motion in both the definitive and post-hysterectomy settings, with 
an assessment of strategies to manage this motion. Key findings, conclusions and 
proposed future work for these sections are summarised below.  
7.2. Section A: Dose-volume constraints for late bowel toxicity 
Bowel toxicity is the key concern with pelvic radiotherapy, and unfortunately occurs 
commonly with an impact on quality of life for pelvic cancer survivors. When implementing 
new radiotherapy techniques that may reduce toxicity it is important to know the 
appropriate dose-volume constraints to assess the likely genuine benefits of the new 
technique. 
A systematic review was performed in chapter II to examine and appraise the published 
literature on dose-volume constraints for late bowel toxicity. Within the 25 studies included, 
seven papers addressed the whole bowel (either as peritoneal cavity or bowel loops), ten 
papers looked at small bowel and duodenum, and fifteen studies at components of large 
bowel.  
This review highlighted the anal canal as an important OAR, and its dose-volume 
parameters, particularly Dmean was associated with late toxicities such as faecal urgency 
and faecal incontinence. Given that a number of studies were found with similar findings it 
was concluded that a Dmean of <40Gy is associated with reduced toxicity from the anal 
canal.   
Regarding other definitions or components of bowel, dose-volume parameters of small 
bowel, bowel loops, large bowel and sigmoid colon were all suggested to have an 
association with late bowel toxicity, and constraints were derived for some of these organs. 
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However, none of these individual findings or constraints were corroborated in other 
studies, and firm conclusions on these components of bowel could not be made based on 
the published literature.  
Chapter III aimed to further the information gathered from chapter II. In this chapter a 
dose-volume toxicity study, based on late bowel toxicity data collected prospectively at 
Velindre Cancer Centre was performed. High rates of patient-reported late bowel toxicity 
were found in the 203 patients who returned questionnaires 12 months after completion of 
their pelvic radiotherapy. Symptoms of late toxicity were reported by 79% of patients, with 
the most common symptom being faecal urgency, which was severe (grade 3-4) in 41.3% 
of patients (defined as “daily” or “continuously”).  
Dose-volume parameters of different bowel OARs were studied to assess their predictive 
value for faecal urgency, faecal incontinence, diarrhoea, and rectal bleeding. Constraints 
for these parameters were derived which dichotomised patients into groups with higher 
and lower rates of toxicity, and their “goodness-of-fit” was determined.  
From this work the four OARs that were found to be relevant were bowel loops, bowel bag, 
sigmoid and large bowel and statistically significant constraints were derived for each of 
these. The sigmoid was highlighted as a particularly important OAR for the development of 
faecal urgency, which is a novel finding. 
Furthermore the toxicity data collected in chapter III was used to corroborate constraints 
from the systematic review in chapter II. In particular, the constraint for bowel loops 
described by Guerrero-Urbano et al (112) (V38.6<71cc) successfully dichotomised 
patients with faecal urgency, faecal incontinence, and diarrhoea (all p<0.05), validating 
their findings in our study patients. 
 
7.2.1. Recommendations from this section 
Based on combined analysis of chapters II and III, the following dose constraints for late 
bowel toxicity are recommended: 
- Bowel loops V38.6<71cc for faecal urgency, diarrhea and incontinence (any grade) 
- Bowel bag V5<1689cc for diarrhoea (any grade) 
- Sigmoid V10<52.6% for faecal urgency (high grade) 
- Sigmoid V25<36.2% for faecal urgency (high grade) 
- Sigmoid Dmedian<13.7Gy for faecal urgency (any grade) 
- Large bowel V15<60.8cc for diarrhoea (any grade) 
- Anal Canal Dmean<40Gy for incontinence 
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7.3. Section B: Assessment and management of pelvic organ 
motion 
The second issue addressed within this thesis was pelvic organ motion, which was 
investigated for both definitive cervical cancer and post-hysterectomy cervical and 
endometrial cancer. 
7.3.1. Definitive cervical cancer 
For definitive cervical cancer radiotherapy patterns of organ motion and solutions to 
account for this motion were initially sought in a systematic review and secondly in a 
retrospective modeling study. 
The systematic review included 53 papers, and detailed studies looking at the motion of 
the cervix, uterus, whole CTV, and lymph nodes. Key findings were that organ motion was 
significant and cannot be ignored when considering IMRT. Uterine motion had a greater 
magnitude than cervical motion, with the added complexity of translational and rotational 
movement. Uterine motion was related to bladder filling, whereas rectal filling was more 
associated with cervix motion. These patterns were patient-specific, and not applicable in 
all patients to the same degree.  
With this in mind the concept of individualized and adaptive strategies in this group of 
patients emerged. Preliminary planning studies and early clinical studies have been 
performed assessing strategies such as plan of the day (PotD) and margin of the day 
(MotD). From the published literature however the benefits of these methods compared 
with standard techniques in terms of coverage and OAR sparing have not been quantified.  
The exploratory study performed in Chapter V built on the findings of the systematic 
review. Using retrospective data from patients treated with definitive radiotherapy for 
cervical cancer at our centre, a comparison of nine different margin strategies was made.  
Key findings were that adaptive margin strategies were better than population-based 
margins in terms of balancing CTV coverage and sparing of OARs. Isotropic margins of 
15mm, as proposed by RTOG were insufficient. Anisotropic margins (6cm anterior, 3.6cm 
posterior, 1.8cm superior, 4.0cm left and 4.8cm right) improved CTV coverage but 
significantly increased, at times doubling, the volumes of OARs within the PTV.  
The most promising strategies volumetrically were composite strategies and PotD, both in 
terms of CTV coverage whilst sparing OARs.  
Dosimetrically PotD significantly reduced dose to the rectum, bladder and anal canal 
compared with a standard VMAT plan. The dose-volume constraints for rectum were 
statistically significantly improved, which could correlate with a reduction in toxicity (133).  
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However when considering bowel loops, bowel bag, sigmoid and large bowel (the OARs 
determined as important in chapter III), there was no statistically significant dosimetric 
improvement when comparing PotD with a standard VMAT plan.  
With an important theme of this thesis being bowel sparing and late bowel toxicity 
reduction, this study identified that even with the best technique for pelvic organ motion 
management, although sparing of the rectum and anal canal is possible, bowel dosimetry 
is unlikely to majorly improve over that of a standard VMAT plan. 
Of note, the bowel loops constraints could not be met by either standard VMAT plans or 
PotD VMAT plans in 9 out of 10 patients. The reason for this is likely to be the large 
volumes of bowel that are irradiated higher up in the abdomen, rather than lower in the 
pelvis. With adaptive strategies, although the volume of bowel within the primary PTV 
being significantly reduced, this cannot compensate for the large amount of bowel within 
the nodal PTV which remains high regardless of whether an adaptive technique is used or 
not. 
For the one patient where bowel dose-volume constraints were met with PotD, dose 
escalation modeling was carried out. An additional 9Gy in 5 fractions could be added 
before the bowel dose constraints were met. With the use of PotD and a dose of 54Gy, the 
doses to bowel were still lower than use of a conformal plan with a dose of 45Gy. Although 
in only one patient, this does highlight the potential that for individual patients who do have 
favourable bowel dosimetry that dose escalation may be possible, and an individualized 
approach to dose escalation may therefore be worth investigating.   
7.3.2. Post-hysterectomy cervical and endometrial cancer 
In the post-hysterectomy setting, given the limited published data on paravaginal motion, 
in chapter VI a retrospective study was performed to assess organ motion of the 
paravaginal CTV, and its relation to bladder and rectal filling. The paravaginal CTV moved 
significantly on treatment, predominantly in the anterior-posterior direction, although the 
magnitude of motion varied from patient to patient. Posterior motion was correlated 
(R=0.7, p<0.0001) with change in rectal filling between planning and treatment, and 
bladder filling had a weaker correlation with anterior motion, which did concur with some of 
the previous published findings (114, 254).  
Margin strategies to allow for this motion were volumetrically assessed in twenty patients. 
10mm isotropic margins (as suggested by RTOG) were found to be insufficient resulting in 
geographic miss in 34.8% of CBCTs studied. The use of either 15mm isotropic margins or 
population-based anisotropic margins (25mm anterior, 29mm posterior, 6mm superior, 
12mm inferior, 10mm left and 14mm right) improved CTV coverage. However anisotropic 
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margins doubled the % volume of rectum and % volume of bladder found within the PTV 
compared with a 10mm margin, making it a less appealing strategy. 
An adaptive strategy, margin of the day (MotD), was modelled. This strategy demonstrated 
most promise in terms of CTV coverage allowing 100% of coverage. It also allowed 
increased sparing of rectum and bladder compared with 15mm isotropic margins (by 7% 
and 5.3% respectively), with a more substantial sparing compared with anisotropic 
margins (by 24.5%, p=<0.001 and 17.2%, p=0.004).  
 
7.3.3. Recommendations from this section 
From this section of work the key recommendations are: 
-If IMRT is to be delivered safely and effectively for gynaecological malignancies 
appropriate strategies to monitor and manage organ motion is required. Given the 
magnitude of organ motion in certain patients daily on-treatment imaging is required to 
ensure target coverage if IMRT is to be used. 
- Given the relation of rectal and bladder filling to organ motion in both of the radiotherapy 
scenarios studied maintenance of consistent rectal and bladder filling from the time of 
planning and whilst on treatment is important 
- For both definitive and post-operative radiotherapy adaptive strategies such as plan of 
the day or margin of the day would optimise CTV coverage whilst reducing dose to some 
OARs when compared to population-based margins. 
7.4. Future Work 
The work in Section A led to derivation of dose-volume constraints for four OARs. Future 
work would aim to validate these constraints and to determine their value in the different 
pelvic tumour sites. In chapter III dose-volume constraints were derived from a mixed case 
selection of prostate, cervical, endometrial and bladder patients with the aim of being 
inclusive, however the majority of patients (63%) studied ended up being prostate cancer 
patients, given its high incidence. Although theoretically these dose constraints should be 
applicable to all pelvic radiotherapy patients, it is unclear whether in practice this will be 
the case, and certainly in the ten patients with cervical cancer that were planned in chapter 
V these constraints were largely unachievable with either conformal or VMAT planning that 
was used.  
With the focus of this work being gynaecological malignancies I would first want to assess 
the dose constraints derived in an independent group of patients with cervical and 
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endometrial cancer. The collection of late toxicity data is ongoing within Velindre Cancer 
Centre for gynaecological patients. I would choose a sample of these patients for which 
late toxicity data is available and determine whether the dose-volume constraints from 
chapter III successfully dichotomise patients with and without toxicity.  
If the constraints are validated in an independent group of gynaecological patients this 
would confirm their potential value for future patients. These constraints could be tested in 
a prospective study to assess their ability to reduce the risk of toxicity. 
Similar work could be performed to validate the dose-volume constraints for patients 
treated with prostate and pelvic node radiotherapy, bladder cancer and rectal cancer, with 
either the use of toxicity data collected for clinical practice, or from clinical trials.  
 
If the constraints are found to be valid in independent groups of patients, but are difficult to 
achieve with current planning techniques, especially for gynaecological patients where 
there are large volumes of bowel close to PTV, then alternative planning techniques could 
be sought. Proton techniques are being developed and their potential in cervical cancer 
radiotherapy has been studied in planning studies (258, 259), and have been found to be 
beneficial compared with IMRT and VMAT techniques in terms of bowel sparing. Future 
studies would then compare the use of IMRT/VMAT with proton therapy to enable these 
bowel dose constraints to be met. 
 
The toxicity data and dosimetric data collected in this thesis could also be used for normal 
tissue complication probability (NTCP) modelling, which is considered a superior method 
to predict toxicity rather than dose-volume metrics alone. In chapter III dose-volume 
relationships were sought from DVH parameters, which are not ideal as they disregard 
spatial information (126). NTCP modeling uses both dosimetric and anatomical information 
and may allow for improved modeling of toxicity. These models could potentially be used 
in combination with other factors, such as clinical factors, in nomograms, such that an 
individual patient’s risk of toxicity can be calculated prior to commencing treatment based 
on both dosimetric and clinical factors (260).  
. 
The work from Section B highlighted the importance of adaptive strategies in 
gynaecological malignancies to manage organ motion whilst reducing dose to pelvic 
organs such as rectum, bladder and anal canal. In particular in definitive cervical cancer 
PotD appeared most promising and I would aim to take this concept further in future.  
210 
 
I would plan to first perform a prospective single-centre feasibility study of PotD in a small 
number of patients, for example 20 patients. Patients would be treated with PotD as 
modelled in chapter V, with a library of three plans (full, mid and empty bladder) and a 
back-up plan. They would have daily online CBCT prior to treatment and each day the 
most appropriate plan would be chosen based on the patients anatomy that day. 
The prime aims of this work would be to assess the feasibility of this technique in clinical 
practice given the increased workload for all teams involved. For physics teams this would 
require streamlining of the process for plan library generation, as this would involve 4 
plans rather than a single plan. For the radiographer team this would involve training staff 
to be able to choose between plans in the plan library based on information from the online 
CBCT that day.  
One of the main concerns highlighted in chapter V was that the back-up plan had to be 
used in a large proportion of patients, as the full and empty bladder planning scans were 
not sufficiently different from each other and the extent of the range of CTV motion 
between these scans did not represent that on treatment. Use and assessment of a 
refined bladder protocol to allow greater variation between a full bladder planning CT and 
an empty bladder planning CT and an improved plan library would be a further aim of this 
study. 
Dosimetric benefits of the method would again be assessed by comparing the use of PotD 
against a conformal plan with a standard margin for these patients.  
 
If this study confirmed the dosimetric benefits and feasibility of PotD in cervical cancer 
then the next step would be a randomised study comparing PotD with standard treatment, 
with clinical outcomes of acute toxicity, local control and late toxicity being the endpoints 
measured. 
 
For post-hysterectomy gynaecological malignancies one of the key findings from the work 
in chapter VI was that rectal variation was related to CTV motion and subsequently larger 
margins. The use of rectal measures such as rectal enemas are used commonly in 
prostate cancer and I would propose to use these in a prospective study in post-
hysterectomy gynaecological patients to determine if their use can reduce variation in 
rectal filling and CTV motion. Patients would be asked to use enemas at planning and prior 
to each treatment, and their organ motion would be assessed on daily CBCT. Their organ 
motion would be compared against a group of patients treated with standard practice 
(without rectal measures).  
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Margin of the day for post-hysterectomy patients have been demonstrated to be beneficial 
on volumetric analysis in chapter VI. I would plan to assess this benefit dosimetrically with 
a planning study of these patients. If this was found to be significantly beneficial then 
clinical implementation of these methods could be considered.  
7.5. Final conclusions  
This thesis aimed to address practical issues which hamper the implementation of 
gynaecological IMRT. The work presented in this thesis has furthered knowledge of dose-
volume constraints for late bowel toxicity symptoms. If validated in future groups of 
patients these may be helpful in preventing late bowel toxicity, improving outcomes for 
survivors of pelvic radiotherapy. 
 
For management of pelvic organ motion both in the definitive cervical cancer radiotherapy 
and post-hysterectomy settings, adaptive margin strategies rather than population-based 
margins are most beneficial in terms of balancing improved CTV coverage and reduced 
OARs within the PTV. The knowledge acquired from these studies would hopefully form a 
basis for further research addressing clinical feasibility of these methods. This may in turn 
lead to a change of clinical practice and allow for safer and more efficient IMRT techniques 
for gynaecological patients. 
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Appendix B: Bowel toxicity questionnaire (chapter III) 
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Have you had any bleeding when you 
have opened you bowels recently? 
No Rarely Occasionally 
>2/week 
Persistent/ 
Daily 
Regular 
heavy 
bleeding 
If you had bleeding, was any of the 
following required?  
Laxative, 
iron 
tablets 
Occasional 
transfusion 
Frequent 
transfusion 
Needed 
operation 
Have you had any tests or investigations 
to do with bowel symptoms? No Yes 
If so do you know what and when? 
 
 
 
Have you had any operations to help with 
bowel symptoms or problems? No Yes 
If so do you know what and when? 
 
 
 
 
Comments: 
Are any of the above symptoms you describe longstanding? (ie. started before radiotherapy). If so 
please mention these here with any details you feel relevant. 
 
 
 
 
 
Any other comments: 
 
 
 
 
 
 
      Thank you for completing this questionnaire. 
 
 
How often have you had any difficulty 
controlling you bowels? (eg. any accidents) 
Never 
 
Monthly Weekly Daily Constantly 
If so, have you had to use pads? 
 
 
No Occasionally Intermittently Persistently Needed operation 
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Materials/Methods: Fourteen pairs of brachytherapy planning CT scans
derived from 11 patients were re-segmented and re-planned using the same
parameters. All patients underwent brachytherapy with vaginal cylinders.
Gas pocket removal was carried out with a rectal tube. A CT-set before and
after gas removal, with a rectal tube, were acquired without any other
modification. A CT-based plan was computed for each image set. Metrics
derived from bladder and rectum dose-volume histograms (DVH) and
dose-surface histograms (DSH) were extracted. The area under the curve
(AUC) was calculated to describe the integral absorbed dose. Non-para-
metric paired non-parametrical tests were performed (Kruskal-Wallis and
Wilcoxon signed-rank test).
Results: Rectum volume decreased significantly from 77.8 ! 45 cc to
55.43 ! 17.6 cc (pZ 0.0052) after gas removal. Such volume diminution
represented a significant reduction on all rectal DVH parameters analyzed
but D25% and D50%. Rectum DSH parameters results were similar to DVH.
A significant increase on DVH metrics was observed despite a non-
significant increase of the bladder volume.
Conclusions: Gas pocket removal is a simple and inexpensive maneuver
that decreases the rectal dose thus it could improve the therapeutic ratio.
Changes on bladder are deemed to be linked with the increase on urine
volume due to the interval between scans.
Author Disclosure: S. Sabater: None. I. Andres: None. M. Sevillano: None.
R. Berenguer: None. S. Machin-Hamalainen: None. M. Arenas: None.
2558
The Impact of Rectal and Bladder Filling on Internal Target Volume
Margins in Postoperative Endometrial and Cervical Cancer Patients
R. Jadon,1 C.L. Hanna,1 N. Palaniappan,1 E. Hudson,1 M. Evans,1
H. Maloney,1 A. Mazurek,2 and J. Staffurth3; 1Department of Clinical
Oncology, Velindre Cancer Centre, Cardiff, United Kingdom, 2Department
of Medical Physics, Velindre Cancer Centre, Cardiff, United Kingdom,
3School of Medicine, Cardiff University, Cardiff, United Kingdom
Purpose/Objective(s): Vaginal vault motion poses an important challenge
during IMRT for post-operative endometrial and cervical cancer (post-op)
patients. Large PTV margins, of which internal target volume (ITV)
margins are the major component, are required to allow for this motion,
especially in the anterior-posterior (AP) direction. This study assesses
patterns of rectal and bladder filling in this setting to determine their
correlation with required ITV margins and identify future interventional
strategies.
Materials/Methods: Image sets, comprising a pre-treatment CT (pre-CT)
and 5-6 CBCT scans, for 10 post-op patients were retrospectively
analyzed. No specific bladder or rectal filling protocols had been used.
Each CBCT was co-registered with the respective pre-CT using a mutual
information algorithm. On each scan the vaginal CTV, rectum and bladder
were outlined. For each CBCT an anisotropic margin was generated around
the pre-CT CTV such that the CBCT CTV was fully encompassed in 6
directions (ant, post, sup, inf, left and right). Rectal filling was assessed by
4 measures: rectal volume (RV); AP rectal diameter (RD) at S4/S5 border;
RD at the tip of coccyx and maximum RD at any point. Rectal distension
was defined as RD " 4 cm at any point. Patterns of bladder and rectal
filling were observed and correlated with the generated ITV margins.
Results: Large interfractional bladder variations were observed (median
247 cc [range, 197-528 cc]), though did not correlate with margin size.
Rectal distension was noted at least once in all patients, and in 5/10 pre-
CTs and 45/57 CBCTs. No trend was found towards decreasing RD over
time and 6 patients had a larger RD in week 4 than in week 1. Variations in
rectal filling between pre-CT and CBCT scans strongly correlated with
margin size. There were statistically significant correlations (all p < 0.001)
between posterior margins and variations in RV (R Z #0.80), maximal
RD (R Z #0.74), and RD at the coccyx (R Z #0.86). Anterior margin
correlated with RD changes at coccyx (R Z 0.65).
Conclusions: AP margins required to allow for vaginal motion are sizeable
and limit the benefits of IMRT in this setting. Required margins are
associated with inconsistent rectal filling between pre- and on-treatment
imaging. Maintenance of consistent rectal filling using dietary advice,
laxatives or enemas should be investigated to reduce these margins.
Author Disclosure: R. Jadon: None. C.L. Hanna: None. N. Palaniappan:
None. E. Hudson: None. M. Evans: None. H. Maloney: None. A. Mazurek:
None. J. Staffurth: None.
2559
Outcomes of Patients With Carcinosarcoma Treated With Combined
External Beam Radiation, Brachytherapy, and Chemotherapy
D. Guttmann,1 H. Li,2 S. Grover,1 S. Bhatia,2 G. Jacobson,2 and L. Lin1;
1University of Pennsylvania, Philadelphia, PA, 2University of Iowa, Iowa
City, IA
Purpose/Objective(s): Carcinosarcoma represents a rare, aggressive
subtype of endometrial cancer and the optimal adjuvant treatment is
unclear. We sought to characterize outcomes of patients treated for this
Poster Viewing Abstract 2557; Table Dose percentage related to the prescribed dose (5 Gy)
A)
D0.1 cc D1 cc D2 cc D5 cc D10 cc V5 Gy AUC
Bladder Basal 100.9 ! 27 79.4 ! 18.6 70.7 ! 18.1 52 ! 26.6 38.4 ! 26.7 0.4 ! 0.5 56 ! 35.5
Post 116.6 ! 48.3 88.6 ! 23.6 79.5 ! 19.9 65.6 ! 17.9 48.5 ! 25.2 1.1 !2.4 84.3 ! 81
P .3003 .0413 .0186 .0157 .0235 .1707 .0157
Rectum Basal 141.1 ! 23.4 112.7 ! 15 101.2 ! 14.5 82.1 ! 13.6 65.7 ! 12.2 2.51 ! 2.1 93.8 ! 49.5
Post 125.2 ! 11.9 101.4 ! 12.6 90.3 ! 12.1 72.2 ! 10.6 56.2 ! 10.1 1.32 ! 0.8 63.1 !23.4
P .011 .0052 .0035 .0023 .0019 .0035 .0029
B)
D2 cm2 D5 cm2 D10 cm2 D15 cm2 D20 cm2 A5 Gy AUC
R. surface Basal 133.5 ! 14.3 115 ! 16.3 91 ! 18.9 70.9 ! 15.1 57.2 ! 12 8.2 ! 3.4 124 ! 29
Post 120 ! 15.5 103.4 ! 16.3 78.8 ! 13.1 62.9 !11.8 50.1 ! 16.5 5.7 ! 2.5 102 ! 26.6
P .0052 .0063 .0029 .0035 .0063 .0035 .0029
Poster Viewing Abstract 2558; Table Margins required
Margin Size (mm)
Day 1
Median (min-max)
Day 2
Median (min-max)
Day 3
Median (min-max)
Week 2
Median (min-max)
Week 3
Median (min-max)
Week 4
Median (min-max)
Overall margin to cover
95% of CBCT CTVs
Ant 8 (1-22) 10 (1-20) 13.5 (4-19) 10 (1-18) 11 (1-19) 10 (1-15) 19 mm
Post 7.5 (4-28) 8 (4-29) 8 (2-23) 10 (4-29) 8 (4-31) 9 (6-29) 29 mm
Sup 1.5 (1-8) 4 (1-24) 1.5 (1-8) 2 (1-8) 1.5 (1-4) 4 (1-10) 10 mm
Inf 5 (1-10) 4 (1-10) 6 (1-12) 2 (1-15) 7 (1-17) 2 (1-15) 15 mm
Left 2 (1-4) 2 (1-8) 2 (2-6) 2 (1-4) 2 (2-6) 2 (2-6) 6 mm
Right 2 (1-4) 2 (1-6) 2 (2-8) 2 (2-6) 2 (2-8) 2 (2-2) 6 mm
Volume 87 $ Number 2S $ Supplement 2013 Poster Viewing Abstracts S417
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illustrates a small disparity from the reference whereas the 
fourth category show strong differences. Our hypothesis is 
that these categories can be used to identify patients in need 
of treatment adaptation. The Figure 1 shows the V95(%) 
parameter extracted from either the planning CT or the daily 
CBCT plan, as function of the average γ value for all beams. 
This average γ value is evaluated on the whole EPID image 
(Figure 1a) or the projected PTV1 image (Figure 1b). The 
horizontal dash line represent the dose tolerance for PTV1 
(99%). There is a correlation between the average γ and the 
PTV1 V95(%) but the projected PTV1 on the EPID image does 
provide additional information regarding the degree of error. 
However, the V95(%) variation from the original and 
deformed contours is related to the degree of error as 
indicated in Table 1. 
 
 
 
 
 
Conclusion: In summary, we demonstrated that PTV1 
projection on the EPID plan does not provide new information 
on the plan deterioration. However, this method was more 
sensitive to anatomical changes and could be used as an 
indicator instead of the mean γ on the whole EPID image. In 
the following steps, the organs at risk projections will be 
evaluated to verify if they do provide new information. This 
approach is valuable for the treatment quality, but does not 
increase the dose to the patient or the time required for 
treating a fraction. Image acquisition and analysis can be 
easily automatized to further minimize the impact on the 
clinical workload. 
 
EP-1819  
Plan of the Day is the optimal approach to address organ 
motion for cervical cancer IMRT 
R. Jadon1, E. Spezi
1Velindre Cancer Centre, Clinical Oncology, Cardiff, United 
Kingdom 
1,2, L. Hanna1, N. Palaniappan1, M. Evans1, 
E. Hudson1, J. Staffurth1,3 
2Cardiff University, Medical Physics, Cardiff, United Kingdom 
3Cardiff University, School of Medicine, Cardiff, United 
Kingdom 
 
Purpose or Objective: Intensity modulated radiotherapy 
(IMRT) for cervical cancer is challenging due to organ motion 
within the CTV, comprising cervix, uterus, vagina, 
parametrium and pelvic nodes. Large CTV-PTV margins to 
compensate for this motion result in large volumes of organs 
at risk (OARs) within the PTV, negating the benefits of IMRT. 
Furthemore, there is significant intra-patient variation in 
organ motion therefore individualised adaptive strategies 
may be appropriate. 
One option is Composite Strategy (CS) where a composite is 
formed from CTVs using planning scans and initial on-
treatment cone beam CT (CBCT) scans. A second is Plan of 
the Day (PotD), where a plan library is created and the most 
appropriate plan chosen each day based on CTV position. 
Material and Methods: Retrospective analysis of planning 
scans (full bladder (FB) and empty bladder (EB)) and on-
treatment CBCTs for patients treated with radical 
radiotherapy for cervical cancer was performed.  
CBCT scans were rigidly co-registered with FB scans on 
Oncentra Masterplan. On each scan the primary CTV (pCTV) 
comprising cervix, uterus, vagina, parametrium was outlined. 
On the FB scan bowel bag, bowel loops, rectum and bladder 
were outlined as OARs. 
We modelled: 
1) Standard margin: a 2cm isotropic CTV-PTV margin around 
the pCTV 
2) CS: a composite was formed from pCTVs from FB, EB, and 
day 1-3 CBCTs, with a 1cm margin to PTV 
3) PotD: a 3-plan library was created using pCTVs from FB 
and EB scans. A third mid-volume CTV was generated using 
deformable image registration on Velocity (v3.1, Varian 
Medical Systems) and custom software developed in Matlab. 
A 1cm margin was added to each CTV to generate PTVfull, 
PTVmid and PTVempty. If none of the 3 plans covered the 
CTV then a 'back-up' standard 2cm margin was chosen. 
The remaining CBCT scans for each patient were used to 
compare PTV volumes, CTV coverage, and OARs within PTV. 
Statistical differences were tested using Mann Whitney-U. 
 
Results: 141 scans were assessed for 14 patients (FB, EB and 
7-13 CBCTs each). The table below shows mean measures of 
the 3 strategies. The 3-library PotD could only be used in 58% 
of scans assessed, and the back-up plan was used for the 
remainder. Despite this PotD significantly reduced mean 
bowel, bowel bag, rectum and bladder in the PTV, whilst 
maintaining CTV coverage. 
 
 
 
Conclusion: Adaptive strategies show promise. PotD, even 
when the plan library was only used in 58% of scans, 
increased OAR sparing compared with CS. Dosimetric analysis 
of these strategies with IMRT planning is ongoing. 
 
EP-1820  
On the use of deformable image registration to evaluate 
the need to perform ART in head and neck cancer 
P. Delgado-Tapia
1Hospital de la Santa Creu i Sant Pau, Servei de Radiofísica i 
Radioteràpia, Barcelona, Spain 
1, M. Lizondo1, A. Latorre-Musoll1, N. 
Jornet1, T. Eudaldo1, P. Carrasco1, A. Ruiz-Martinez1, C. 
Cases1, M. Ribas1 
 
Purpose or Objective: ART is a time-consuming process and 
the question “do we need to replan?” is not always easy to 
answer. In this work, we investigate: (i) if Deformable Image 
Registration (DIR) software can provide reliable criteria to 
decide if we need to replan; (ii) if we can use DIR to replan 
the treatment without performing a new planning CT. 
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Appendix D: Search Strategies for systematic reviews 
 
  
  31/12/2016 
 Page 1 
Systematic Review Searching Record 
Question title:   
  Bowel toxicity following radiotherapy 
 
Literature search details    
Date Restriction & Why:  none  
Language Restriction & Why  :none 
 
Database name Dates covered No. of References  Date of search 
 
Medline 1946-2013 2107 15.10.13 
Premedline 15.10.13 69 15.10.13 
Embase 1974- 2013 2597 16.10.13 
Pubmed  188  
ISI Web of Science 
(Includes Science 
Citation Index & ISI 
Index to Conference 
proceedings)  
1900- 2013 1753 18.10.13 
    
    
    
    
    
    
Total refs    
 
Total References retrieved (after de-duplication):     
 
 
 
 
 
 
 
 
 
MEDLINE[OVID] 
 
1 exp radiotherapy/ 137329  Advanced 
2 exp radiation injuries/ 57035  Advanced 
3 (radiotherap* or radiat* or irradiat*).tw. 431482  Advanced 
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  31/12/2016 
 Page 2 
4 radiation effects/ 27553  Advanced 
5 or/1-4 498983  Advanced 
6 (ae or to or po or co).fs. 3161332  Advanced 
7 (safe or safety).ti,ab. 420402  Advanced 
8 side effect$.ti,ab. 171180  Advanced 
9 
((adverse or undesirable or harms$ or serious or toxic) adj3 (effect$ or reaction$ 
or event$ or outcome$)).ti,ab. 
291512  Advanced 
10 (toxicity or complication$ or noxious or tolerability).ti,ab. 836950  Advanced 
11 or/6-10 3940352  Advanced 
12 5 and 11 134114  Advanced 
13 exp Intestines/re [Radiation Effects] 4036  Advanced 
14 
((bowel* or intestin* or gastrointestin* or colon* or colorectal or rectal or rectum 
or gut*) adj3 (toxic* or morbidit* or injur* or dysfunction*)).tw. 
16662  Advanced 
15 13 or 14 20037  Advanced 
16 12 and 15 3204  Advanced 
17 exp Radiotherapy Dosage/ 49002  Advanced 
18 exp Dose Fractionation/ 6190  Advanced 
19 dose-response relationship, radiation/ 34319  Advanced 
20 (dose or dosage or dosimetric or fraction* or gray*).tw. 1294070  Advanced 
21 or/17-20 1329367  Advanced 
22 16 and 21 2107  Advanced 
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CANCER RESEARCH WALES LIBRARY 
Systematic Review Searching Record 
Question title:  Organ Motion in Cervical/Endometrial Cancer 
 
 
1. Literature search details  
Date Restriction: None 
Language Restriction: All 
Database name Dates 
Covered 
No of references 
found 
No of references 
retrieved 
Finish date of 
search 
Medline 1946 - present  166 166 08/10/2012 
Premedline present 2 2 16/10/2012 
Embase 1947 - present 294 294 10/10/2012 
Cochrane Library Issue 10 6 6 18/10/2012 
Web of Science 1899 - present 109 109 18/10/2012 
CINAHL 1981 - present 28 28 16/10/2012 
 
Total References retrieved (after de-duplication): 408 
Medline search strategy (This search strategy is adapted to each database.) 
1. exp Uterine Neoplasms/ 
2. (cervi* adj3 (cancer* or neoplas* or carcinom* or tumo?r* or malignan*)).tw. 
3. (endometr* adj3 (cancer* or neoplas* or carcinom* or tumo?r* or malignan*)).tw. 
4. (uter* adj3 (cancer* or neoplas* or carcinom* or tumo?r* or malignan*)).tw. 
5. or/1-4 
6. exp Radiotherapy/ 
7. ((radiat* or radio*) adj3 (therap* or treat*)).tw. 
8. ((image guid* or intensity modulated) adj3 (radiat* or radio*)).tw. 
9. (igrt or imrt).tw. 
10. exp Tomography, X-Ray Computed/ 
11. (CT or CAT).tw. 
12. (comput* adj3 tomograph*).tw. 
13. exp Magnetic Resonance Imaging/ 
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14. ((magnetic resonance or MR or NMR or diffusion weighted) adj2 imag*).tw. 
15. (MRI or DWI).tw. 
16. or/6-15 
17. exp Organ Size/ 
18. exp Organs at Risk/ 
19. exp Movement/ 
20. exp motion/ 
21. ((vagin* or uter* or organ*) adj3 (mov* or motion* or mobil* or displace*)).tw. 
22. (interfract* adj3 (motion* or mov* or displace*)).tw. 
23. (internal adj3 (margin* or boundar*)).tw. 
24. ((target or shape or volume or margin* or boundar*) adj2 (var* or change*)).tw. 
25. or/17-24 
26. 5 and 16 and 25 
 
 
2. Any further comments: 
Sifting Criteria: 
 
 
 
 
 
